



National
Kidney
Foundation™

2014
SPRING
CLINICAL
MEETINGS

April 22-26, 2014
MGM Grand
Las Vegas, Nevada

PROGRAM



Take a break from the crowded Exhibit Hall floor!

VISIT OUR

Exhibitor Showcase!

BOOTH
#136

Enjoy a comfortable, small-group setting and an interactive learning format at an Exhibitor Showcase.

THURSDAY, APRIL 24

7:15am – 7:50am

**Focal Segmental Glomerulosclerosis (FSGS):
A Common Phenotype with Multi-Variant Pathophysiology**
Supported by Questcor Pharmaceuticals, Inc.

12:15pm – 12:50pm

**Rituxan® (rituximab) for the Treatment of Granulomatosis
with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA)
with Updated Data for GPA/MPA**
*Supported by Genentech, A Member of the Roche Group and
Biogen Idec*

1:15pm – 1:50pm

**Advancing Paradigm Changes in Type 2 Diabetes
Management**
Supported by Janssen

FRIDAY, APRIL 25

8:15am – 8:50am

**Velphoro Chewable Tablets: A New Non-Calcium,
Iron-Based Phosphate Binder**
Supported by Fresenius Medical Care



National
Kidney
Foundation™

INTRODUCING NKF'S SCM14 APP!

Get 24-hour access to unique, on-the-go meeting information, maps, and networking. Get ready for a completely interactive meeting experience!

- Interactive program schedules and maps
- Customizable calendar and itinerary builder
- Abstract/Poster listings
- Exhibitor listings
- Meeting alerts
- Session evaluations

To download the app, go to:

[m.core-apps.com/
tristar_nkf_scm14](http://m.core-apps.com/tristar_nkf_scm14)



**NOW
AVAILABLE!**

NKF's SCM14 App is sponsored by Amgen. It is compatible with iPhone, BlackBerry, and Android smartphones, as well as iPads and most tablets.

Clinical Aspects of Fibroblast Growth Factor 23 in Chronic Kidney Disease

A Breakfast Symposium during the National Kidney Foundation 2014 Spring Clinical Meetings

Wednesday, April 23, 2014
6:00 A.M. - 7:45 A.M.
MGM Grand, Las Vegas
Premier Ballroom 318/319
Las Vegas, Nevada

Program Purpose

A proliferation of studies linking increased levels of the fibroblast growth factor 23 (FGF23) to adverse renal and cardiovascular outcomes in patients with chronic kidney disease (CKD) is setting the stage for new clinical trials that could lead to FGF23 becoming an important marker and/or therapeutic target in the management of CKD. Increased FGF23 is strongly associated with CKD progression, cardiovascular disease, and death even when serum phosphate is normal, suggesting that increased FGF23 may represent an earlier and more sensitive biomarker of disordered phosphorus metabolism than concomitant serum phosphate levels. Apart from its relationship to phosphate, FGF23 itself may mediate direct cardiac toxicity and thus represents a novel mechanism of adverse outcomes in CKD. While awareness of FGF23 within nephrology is high, uncertainty remains about its actual and anticipated roles in clinical practice. This symposium will provide current information about the emerging clinical significance of FGF23, a major modifier of bone mineral metabolism.

Program Objectives

- Identify the primary actions of FGF23 and their potential clinical significance.
- Develop knowledge of the epidemiology and possible mechanisms of changes in FGF23 levels and CKD progression and mortality.
- Develop awareness of dietary and pharmacologic modifiers of FGF23 levels, and their potential significance.
- Formulate an appreciation of FGF23 assays and their current clinical utility.

Agenda and Faculty

6:00 A.M. Breakfast

6:30 A.M. Introduction by Program Moderator

Csaba P. Kovesdy, MD, FASN

Fred Hatch Professor of Medicine in Nephrology
Director, Clinical Outcomes and Clinical Trials Program
Division of Nephrology, University of Tennessee
Health Science Center
Chief of Nephrology, Division of Nephrology
Memphis Veterans Administration Medical Center
Memphis, Tennessee

6:40 A.M. A Clinician's Perspective on Fibroblast Growth Factor 23

Csaba P. Kovesdy, MD, FASN

6:55 A.M. FGF23 and Clinical Outcomes in Chronic Kidney Disease

Myles S. Wolf, MD, MMSc

Margaret Gray Morton Professor of Medicine
Feinberg School of Medicine, Northwestern University
Director, Center for Translational Metabolism and Health
Institute for Public Health and Medicine
Chicago, Illinois

7:10 A.M. Dietary and Pharmacologic Modifiers of FGF23

Orlando M. Gutierrez, MD, MMSc

Associate Professor of Medicine
Division of Nephrology
University of Alabama School of Medicine
Birmingham, Alabama

7:25 A.M. Question and Answers / Panel Discussion

7:45 A.M. Closing Remarks by Moderator

Target Audience: Nephrology professionals

How You Will Learn: This CME/CE activity will be a live symposium consisting of lectures with panel discussion and audience participation.

Accreditation: The National Kidney Foundation is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The National Kidney Foundation is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.



The National Kidney Foundation is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR).

Designation Statements: The National Kidney Foundation designates this live activity for a maximum of 1.5 *AMA PRA Category 1 Credits*SM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Awarded 1.5 contact hours of continuing nursing education (includes 0.33 contact hours in the area of pharmacology).

Registered dietitians (RDs) and Dietetic Technicians, Registered (DTRs) will receive 1.5 continuing professional education units (CPEUs) for completion of this program/material.

This program is pending approval with the American Association of Nurse Practitioners.

Pharmacy continuing education is being sought for this program through the University of Illinois at Chicago, College of Pharmacy, an accredited provider by the Accreditation Council for Pharmacy Education (ACPE).

Declaration of Disclosure: It is the policy of the National Kidney Foundation (NKF) to ensure balance, independence, objectivity, and scientific rigor in all CME/CE activities. Any individual who has control

over CME/CE content is required to disclose to learners prior to the activity any relevant financial relationship(s) they may have with commercial supporters of this activity or whose products or devices are discussed in this activity. If, on the basis of information disclosed, a perceived conflict exists, resolution will be achieved based on NKF's Disclosure and Conflict of Interest policy. Accredited status does not imply endorsement by the NKF or ANCC of any commercial products displayed in conjunction with this activity.

Unlabeled/Investigational Use Declaration: During their presentations, faculty may discuss an unlabeled use or an investigational use not approved for a commercial product. Each faculty member is required to disclose this information to the audience when referring to an unlabeled or investigational use.

Disclaimer: The faculty, National Kidney Foundation, Amgen, and The Med Ed Group, do not recommend the use of any pharmaceutical, diagnostic test, or device outside of the labeled indications as approved by the FDA. Please refer to the official prescribing information for each product for approved indications, contraindications, and warnings. Information contained in this National Kidney Foundation (NKF) educational resource is based upon current data available at the time of presentation. Information is intended to help clinicians become aware of new scientific findings and developments. This NKF educational resource is not intended to set out a preferred standard of care and should not be construed as one. Neither should the information be interpreted as prescribing an exclusive course of management. Variations in practice will inevitably and appropriately occur when clinicians take into account the needs of individual patients, available resources, and limitations unique to an institution or type of practice. Every health care professional making use of information in this NKF educational resource is responsible for interpreting the data as it pertains to clinical decision making in each individual patient.

- Pre-registration for this symposium is not required. Seating is limited and will be available on a first come, first serve basis.
- You must be registered for the NKF 2014 Spring Clinical Meetings to attend this symposium and receive CME/CE credit.



National Kidney FoundationTM

AMGEN
Nephrology

Supported by an educational donation provided by Amgen

High-Dose Iron: TAKING TREATMENT OF Iron Deficiency Anemia TO A NEW LEVEL

WEDNESDAY
APRIL 23 2014

BREAKFAST PROGRAM

6:00-7:45 AM

PREMIER BALLROOM

310-311

MGM Grand, Las Vegas

AGENDA

Iron Deficiency Anemia in ND-CKD: Mechanisms and Treatment Implications

Jay B. Wish, MD (Program Chair)

Professor of Clinical Medicine, Indiana University •

Medical Director, Outpatient Dialysis Unit, IU Health University Hospital • Indianapolis, Indiana

Iron Therapy in ND-CKD Patients: Oral or Intravenous?

Wajeh Y. Qunibi, MD, FACP

Professor of Medicine, University of Texas School of Medicine •

Medical Director, Nephrology Outpatient Clinics and University Hospital System Dialysis Services, University of Texas Health Science Center • San Antonio, Texas

The Role of IV Iron Therapy in ND-CKD: Newest Evidence

Daniel W. Coyne, MD

Professor of Medicine, Division of Renal Diseases, Washington University School of Medicine •

Director, Hemodialysis, Chromalloy American Kidney Center •

Director, Outpatient Renal Clinics, Washington University Physicians • St. Louis, Missouri

Case Study: Applying Clinical Evidence to Practice

ACCREDITATION STATEMENTS

The National Kidney Foundation is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The NKF is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.



The NKF is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR).

DESIGNATION STATEMENTS

The National Kidney Foundation designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Awarded 1.5 contact hours of continuing nursing education (includes 0.8 contact hours in the area of pharmacology).

Registered dietitians (RDs) and Dietetic Technicians, Registered (DTRs) will receive 1.5

continuing professional education units (CPEUs) for completion of this program/material.

This program is pending approval with the American Academy of Nurse Practitioners.

Pharmacy continuing education is being sought for this program through the University of Illinois at Chicago, College of Pharmacy, an accredited provider by the Accreditation Council for Pharmacy Education (ACPE).

DECLARATION OF DISCLOSURE

It is the policy of the National Kidney Foundation (NKF) to ensure balance, independence, objectivity, and scientific rigor in all CME/CE activities. Any individual who has control over CME/CE content is required to disclose to learners prior to the activity any relevant financial relationship(s) they may have with commercial supporters of this activity or whose products or devices are discussed in this activity. If, on the basis of information disclosed, a perceived conflict exists, resolution will be achieved based on NKF's Disclosure and Conflict of Interest policy. Accredited status does not imply endorsement by the NKF or ANCC of any commercial products displayed in conjunction with this activity.

UNLABELED/INVESTIGATIONAL USE DECLARATION

During their presentations, faculty may discuss an unlabeled use or an investigational use not approved for a commercial product. Each faculty member is required to disclose this information to the audience when referring to an unlabeled or investigational use.

DISCLAIMER

The faculty, National Kidney Foundation, AMAG Pharmaceuticals, Inc., and American Regent, Inc. do not recommend the use of any pharmaceutical, diagnostic test, or device outside of the labeled indications as approved by the FDA. Please refer to the official prescribing information for each product for approved indications, contraindications, and warnings. Information contained in this National Kidney Foundation (NKF) educational resource is based upon current data available at the time of presentation. Information is intended to help clinicians become aware of new scientific findings and developments. This NKF educational resource is not intended to set out a preferred standard of care and should not be construed as one. Neither should the information be interpreted as prescribing an exclusive course of management. Variations in practice will inevitably and appropriately occur when clinicians take into account the needs of individual patients, available resources, and limitations unique to an institution or type of practice. Every health care professional making use of information in this NKF educational resource is responsible for interpreting the data as it pertains to clinical decision making in each individual patient.

ACTIVITY PURPOSE

This symposium addresses the medical challenge of iron deficiency anemia (IDA), and its clinical management in nondialysis-dependent patients. Content will examine the role of chronic inflammation and reduced kidney function in the pathogenesis of iron deficiency, and the utility of iron status tests and iron indices for differential diagnosis and management of IDA. Expert faculty will examine the clinical benefits and limitations of available iron therapy, and will provide insight to the role of novel high-dose IV iron for the treatment of anemia in CKD.

EDUCATIONAL OBJECTIVES

Upon successful completion of this activity, participants will be able to:

1. Identify iron deficiency as a common cause of anemia in kidney disease, and describe the role of chronic inflammation and reduced kidney function in the pathogenesis of IDA in nondialysis-dependent patients with chronic kidney disease (ND-CKD).
2. Cite clinical guidelines for evaluation of IDA in ND-CKD patients, and describe the utility of iron status tests in differential diagnosis and the application of iron indices to guide treatment.
3. Compare and contrast clinical evidence for the safety and efficacy of oral and IV iron preparations, including recent studies supporting novel high-dose IV iron therapy for treatment of IDA in ND-CKD, and identify the advantages and limitations of therapeutic options.

TARGET AUDIENCE

This activity is designed to meet the educational needs of physicians, fellows and residents, pharmacists, physician assistants, nurse practitioners, nephrology nurses and technicians, nephrology social workers, and renal and clinical dietitians.

LEARNING DESIGN

This CME/CE activity is a live interactive symposium incorporating a case study, didactic lectures and audience participation using the audience response system (ARS).



Revisiting Phosphate Management in Chronic Kidney Disease

A Lunch Symposium during the National Kidney Foundation 2014 Spring Clinical Meetings

Wednesday, April 23, 2014

12:00 P.M. – 2:00 P.M.

MGM Grand, Las Vegas

Premier Ballroom 318/319

Las Vegas, Nevada

Program Purpose

Hyperphosphatemia is a common, well-recognized complication in patients with chronic kidney disease (CKD), especially those on dialysis. The high cardiovascular mortality associated with CKD is related in part to disturbances in mineral metabolism. Hyperphosphatemia in patients with CKD is considered an independent risk factor for cardiovascular mortality and is a major factor in CKD mineral bone disease (CKD-MBD). Efforts to reduce morbidity and mortality associated with CKD-MBD are therefore primarily directed at controlling hyperphosphatemia via diet, phosphate binders, and dialysis. This requires a multidisciplinary approach based on an understanding of the differences in dietary sources of phosphorus and designing an individualized plan in combination with phosphate binders. Members of the renal health team, including nephrologists, nurses, dietitians, pharmacists, social workers, occupational therapists and physiotherapists can work together to provide patients with the education and comprehensive team-based care required to manage hyperphosphatemia. This educational program will address the issues at the center of the challenge, and present recent clinical results that provide further insight and opportunities for phosphate management.

Program Objectives

- Describe the differences between inorganic and organic dietary phosphates and their sources.
- Emphasize the centrality of phosphate control and the need for an informed and pragmatic approach to traditional phosphate binders.
- Compare and contrast individualized phosphate control based on blending dietary restrictions, traditional and newer phosphate binders, acceptable pill counts and balanced PTH modifiers.

Target Audience: Nephrology professionals

How you will learn: This CME/CE activity will be a live symposium consisting of lectures with panel discussion and audience participation.

Accreditation: The National Kidney Foundation is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The National Kidney Foundation is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.



The National Kidney Foundation is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR).

Designation Statements: The National Kidney Foundation designates this live activity for a maximum of 1.5 *AMA PRA Category 1 Credits*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Awarded 1.5 contact hours of continuing nursing education (includes 0.6 contact hours in the area of pharmacology).

Registered dietitians (RDs) and Dietetic Technicians, Registered (DTRs) will receive 1.5 continuing professional education units (CPEUs) for completion of this program/material.

This program is pending approval with the American Association of Nurse Practitioners.

Pharmacy continuing education is being sought for this program through the University of Illinois at Chicago, College of Pharmacy, an accredited provider by the Accreditation Council for Pharmacy Education (ACPE).

Declaration of Disclosure: It is the policy of the National Kidney Foundation (NKF) to ensure balance, independence, objectivity, and scientific rigor in all CME/CE activities. Any individual who has control over CME/CE content is required to disclose to learners prior to the activity any relevant financial relationship(s) they may have with commercial supporters of this activity or whose products or devices are discussed in this activity. If, on the basis of information disclosed, a perceived conflict exists, resolution will be achieved based on NKF's Disclosure and Conflict of Interest policy. Accredited status does not imply endorsement by the NKF or ANCC of any commercial products displayed in conjunction with this activity.

Unlabeled/Investigational Use Declaration: During their presentations, faculty may discuss an unlabeled use or an investigational use not approved for a commercial product. Each faculty member is required to disclose this information to the audience when referring to an unlabeled or investigational use.

Disclaimer: The faculty, National Kidney Foundation, Fresenius Medical Care, and The Med Ed Group, Inc. do not recommend the use of any pharmaceutical, diagnostic test, or device outside of the labeled indications as approved by the FDA. Please refer to the official prescribing information for each product for approved indications, contraindications, and warnings. Information contained in this National Kidney Foundation (NKF) educational resource is based upon current data available at the time of presentation. Information is intended to help clinicians become aware of new scientific findings and developments. This NKF educational resource is not intended to set out a preferred standard of care and should not be construed as one. Neither should the information be interpreted as prescribing an exclusive course of management. Variations in practice will inevitably and appropriately occur when clinicians take into account the needs of individual patients, available resources, and limitations unique to an institution or type of practice. Every health care professional making use of information in this NKF educational resource is responsible for interpreting the data as it pertains to clinical decision making in each individual patient.

Agenda and Faculty

12:00 P.M. Lunch

12:30 P.M. Introduction by Program Moderator

Kamyar Kalantar-Zadeh, MD, MPH, PhD, FAAP, FACP, FASN, FAHA, FNKF

Chief, Division of Nephrology & Hypertension
Professor of Medicine and Public Health
University of California Irvine, School of Medicine
Orange, California

12:40 P.M. Overview of Phosphate Homeostasis, GI Absorption and Dietary Sources

Kamyar Kalantar-Zadeh, MD, MPH, PhD

1:00 P.M. Traditional and Newer Phosphate Binders

Bruce S. Spinowitz, MD, FACP

Associate Director, Nephrology and
Vice Chairman Department of Medicine
New York Hospital Queens
Clinical Professor of Medicine
Weill Medical College of Cornell University
New York, New York

1:20 P.M. Integrating Dietary Restrictions and Therapeutic Agents to Control Phosphate

Stuart M. Sprague, DO, FACP, FASN, FNKF

Chairperson, Division of Nephrology and Hypertension
North Shore University Health System
Clinical Professor of Medicine
University of Chicago Pritzker School of Medicine
Evanston, Illinois

1:40 P.M. Question and Answers / Panel Discussion

2:00 P.M. Closing Remarks by Moderator

- Pre-registration for this symposium is not required. Seating is limited and will be available on a first come, first serve basis.
- You must be registered for the NKF 2014 Spring Clinical Meetings to attend this symposium and receive CME/CE credit.



National Kidney Foundation[™]



**FRESENIUS
MEDICAL CARE**

Supported by an educational grant
from Fresenius Medical Care

Heart-Kidney Interaction & THE ROLE OF VASOPRESSIN & HYPONATREMIA in Heart Failure

Wednesday
APRIL 23 2014
7:30-9:30 PM
Plated Dinner
Premier Ballroom 318-319
MGM Grand, Las Vegas

AGENDA

The Heart-Kidney Interaction in Heart Failure and the Pathogenesis of Hyponatremia

Matthew R. Weir, MD (Program Chair)

Professor of Medicine, University of Maryland School of Medicine • Director of the Division of Nephrology, Department of Medicine, University of Maryland Hospital • Baltimore, Maryland

The Utility of Current Treatment Options in Management of Hyponatremia in the Heart Failure Patient

Joseph G. Verbalis, MD

Professor of Medicine and Physiology • Chief, Division of Endocrinology and Metabolism | Co-Director, Georgetown-Howard Universities Center for Clinical and Translational Science, Georgetown University Medical Center • Washington, DC

Lessons From Clinical Trials of Vasopressin Receptor Antagonists in Heart Failure

James E. Udelson, MD

Professor of Medicine and Radiology, Tufts University School of Medicine • Chief, Division of Cardiology, Tufts Medical Center • Boston, Massachusetts

Case Study: Treating Hyponatremia in the HF Patient With Impaired Kidney Function

ACCREDITATION STATEMENTS

The National Kidney Foundation is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The NKF is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

 The NKF is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR).

DESIGNATION STATEMENTS

The National Kidney Foundation designates this live activity for a maximum of 1.5 *AMA PRA Category 1 Credits*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Awarded 1.5 contact hours of continuing nursing education (includes 0.4 contact hours in the area of pharmacology).

Registered dietitians (RDs) and Dietetic Technicians, Registered (DTRs) will receive 1.5 continuing professional education units (CPEUs) for completion of this program/material.

This program is pending approval with the American Academy of Nurse Practitioners.

Pharmacy continuing education is being sought for this program through the University of Illinois at Chicago, College of Pharmacy, an accredited provider by the Accreditation Council for Pharmacy Education (ACPE).

DECLARATION OF DISCLOSURE

It is the policy of the National Kidney Foundation (NKF) to ensure balance, independence, objectivity, and scientific rigor in all CME/CE activities. Any individual who has control over CME/CE content is required to disclose to learners prior to the activity any relevant financial relationship(s) they may have with commercial supporters of this activity or whose products or devices are discussed in this activity. If, on the basis of information disclosed, a perceived conflict exists, resolution will be achieved based on NKF's Disclosure and Conflict of Interest policy. Accredited status does not imply endorsement by the NKF or ANCC of any commercial products displayed in conjunction with this activity.

UNLABELED/INVESTIGATIONAL USE DECLARATION

During their presentations, faculty may discuss an unlabeled use or an investigational use not approved for a commercial product. Each faculty member is required to disclose this information to the audience when referring to an unlabeled or investigational use.

DISCLAIMER

The faculty, National Kidney Foundation, and Otsuka America Pharmaceutical, Inc. do not recommend the use of any pharmaceutical, diagnostic test, or device outside of the labeled indications as approved by the FDA. Please refer to the official prescribing information for each product for approved indications, contraindications, and warnings. Information contained in this National Kidney Foundation (NKF) educational resource is based upon current data available at the time of presentation. Information is intended to help clinicians become aware of new scientific findings and developments. This NKF educational resource is not intended to set out a preferred standard of care and should not be construed as one. Neither should the information be interpreted as prescribing an exclusive course of management. Variations in practice will inevitably and appropriately occur when clinicians take into account the needs of individual patients, available resources, and limitations unique to an institution or type of practice. Every health care professional making use of information in this NKF educational resource is responsible for interpreting the data as it pertains to clinical decision making in each individual patient.

EDUCATIONAL OBJECTIVES

Upon successful completion of this activity, participants will be able to:

1. Describe the role of vasopressin in the heart-kidney relationship and the pathogenesis of hypervolemic hyponatremia
2. Summarize the clinical benefits and limitations of current therapeutic options for treating hyponatremia in patients with heart failure (HF), including those with impaired kidney function
3. Discuss findings from clinical trials with vasopressin antagonists in HF
4. Diagnose and identify a treatment plan for a HF patient with impaired kidney function and hyponatremia

ACTIVITY PURPOSE


This symposium addresses the common medical problem of hyponatremia in heart failure (HF), and its clinical management in the presence of kidney disease. Content will review mechanistic responses to disequilibrium in the heart-kidney interaction that lead to alterations in water and sodium balance, the role of vasopressin in the pathogenesis of hyponatremia, and the relationship between hyponatremia and mortality risk. Expert faculty will address differential diagnosis, evaluation and treatment of hyponatremia in HF patients, and will provide insight to clinical evidence for available treatment options, including the benefits and limitations of vasopressin receptor antagonists.

TARGET AUDIENCE

This activity is designed to meet the educational needs of physicians, fellows and residents, pharmacists, physician assistants, nurse practitioners, nephrology nurses and technicians, nephrology social workers, and renal and clinical dietitians.


LEARNING DESIGN

This CME/CE activity is a live interactive symposium incorporating a case study, didactic lectures and audience participation using the audience response system (ARS).



Otsuka
Otsuka America Pharmaceutical, Inc.
Supported by an educational grant from
Otsuka America Pharmaceutical, Inc.

2014 NKF
SPRING
CLINICAL
MEETING



A CERTIFIED CME/CE SYMPOSIUM

Persistent Hyperuricemia:

A Multi-Pronged Approach to the Management of **SERUM URATE LEVELS**

WEDNESDAY, APRIL 23, 2014

7:30 PM – 9:30 PM (Dinner will be served)

MGM Grand Hotel

Room: 310/311 3rd Floor Conference Center
Las Vegas, Nevada

FACULTY

Louis Kuritzky, MD
Clinical Assistant Professor
University of Florida
Gainesville, Florida

Robert Terkeltaub, MD
Professor of Medicine
Division of Rheumatology, Allergy, and Immunology
Rheumatology Training Program Director
University of California, San Diego
Rheumatology Section Chief
San Diego VA Medical Center
San Diego, California

Jay B. Wish, MD
Professor of Clinical Medicine
Indiana University
Medical Director
Out-Patient Dialysis Unit
Indiana University Hospital
Indianapolis, Indiana

ACTIVITY PURPOSE

Gout is one of the most common inflammatory arthritis conditions, affecting up to 1% to 2% of men in Western countries and causing morbidity, disability, and poor quality of life. The clinical manifestations of gout are the result of chronic hyperuricemia which can lead to the deposition of monosodium urate crystals in soft tissues, resulting in a typical manifestation of gout as an acute inflammatory arthritis. Individuals with hyperuricemia have been associated with a greater incidence of end-stage renal disease (ESRD); hyperuricemia is also an independent predictor of ESRD in women. This symposium will review the pathophysiology of gout and the influence of renal dysfunction on its presentation, in addition to its management in this at-risk population.

This case-based presentation will demonstrate the application of the American College of Rheumatology (ACR) guidelines in this patient population in order to optimize the management of this chronic disease.

EDUCATIONAL OBJECTIVES

- Review the pathophysiology of gout and the influence of renal dysfunction on its presentation
- Apply the ACR gout guidelines in the setting of reduced kidney function
- Describe the available treatment options for the management of acute and chronic gout

TARGET AUDIENCE

This program is intended to meet the educational needs of nephrologists, renal dietitians, and nurses who treat patients with gout.

ACCREDITATION STATEMENTS

Physicians / The National Kidney Foundation is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Nurses / The National Kidney Foundation is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Dietitians / The National Kidney Foundation is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR).

DESIGNATION STATEMENTS

Physicians / The National Kidney Foundation designates this live activity for a maximum of 1.5 *AMA PRA Category 1 Credits*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses / Awarded 1.5 contact hours of continuing nursing education (includes 0.4 contact hours in the area of pharmacology).

Dietitians / Registered dietitians (RDs) and Dietetic Technicians, Registered (DTRs) will receive 1.5 continuing professional education units (CPEUs) for completion of this program/material.

Nurse Practitioners / This program is pending approval with the American Association of Nurse Practitioners.

Pharmacists / Pharmacy continuing education is being sought for this program through the University of Illinois at Chicago, College of Pharmacy, an accredited provider by the Accreditation Council for Pharmacy Education (ACPE).

PROGRAM AGENDA

7:30 PM – 7:45 PM
Registration and Dinner

7:45 PM – 7:50 PM
Welcome and Introduction

7:50 PM – 8:15 PM
Jay B. Wish, MD
Renal Dysfunction and the Management of Hyperuricemia

8:15 PM – 8:45 PM
Louis Kuritzky, MD
Managing Risk Factors and Comorbid Conditions in the Hyperuricemic Patient

8:45 PM – 9:15 PM
Robert Terkeltaub, MD
Application of Guidelines for Long-Term Treatment of Gout

9:15 PM – 9:30 PM
Questions and Answers

9:30 PM
Adjourn

You must be registered for the NKF 2014 Spring Clinical Meetings to attend this symposium and receive CME/CE credit.

DISCLOSURE INFORMATION

Declaration of Disclosure / It is the policy of the National Kidney Foundation (NKF) to ensure balance, independence, objectivity, and scientific rigor in all CME/CE activities. Any individual who has control over CME/CE content is required to disclose to learners prior to the activity any relevant financial relationship(s) they may have with commercial supporters of this activity or whose products or devices are discussed in this activity. If, on the basis of information disclosed, a perceived conflict exists, resolution will be achieved based on NKF's Disclosure and Conflict of Interest policy. Accredited status does not imply endorsement by the NKF or ANCC of any commercial products displayed in conjunction with this activity.

Unlabeled/Investigational Use Declaration / During their presentations, faculty may discuss an unlabeled use or an investigational use not approved for a commercial product. Each faculty member is required to disclose this information to the audience when referring to an unlabeled or investigational use.

Disclaimer / The faculty, National Kidney Foundation, Takeda, and Quintiles Medical Education, Inc., do not recommend the use of any pharmaceutical, diagnostic test, or device outside of the labeled indications as approved by the FDA. Please refer to the official prescribing information for each product for approved indications, contraindications, and warnings. Information contained in this National Kidney Foundation (NKF) educational resource is based upon current data available at the time of presentation. Information is intended to help clinicians become aware of new scientific findings and developments. This NKF educational resource is not intended to set out a preferred standard of care and should not be construed as one. Neither should the information be interpreted as prescribing an exclusive course of management. Variations in practice will inevitably and appropriately occur when clinicians take into account the needs of individual patients, available resources, and limitations unique to an institution or type of practice. Every health care professional making use of information in this NKF educational resource is responsible for interpreting the data as it pertains to clinical decision making in each individual patient.



Supported by an educational grant from Takeda.

Changing Profile of Chronic Hyperkalemia

A Breakfast Symposium during the National Kidney Foundation 2014 Spring Clinical Meetings

Program Purpose

Chronic kidney disease is a common disease in a growing number of Americans and is associated with a variety of electrolyte disorders. Hyperkalemia is a common clinical problem, which is most often a result of impaired urinary excretion due to acute or chronic kidney disease complicated by drugs that inhibit the renin-angiotensin-aldosterone system. This electrolyte disturbance is a patient safety issue with associated adverse cardiac outcomes including dysrhythmias and sudden death. The process of preventing and managing hyperkalemia requires a multidisciplinary approach including dietary avoidance of high-potassium foods, medication changes, and treatment of hyperkalemia based on the rate of change and severity of potassium elevation along with electrocardiographic changes. This symposium will provide current information about the clinical significance, prevention, and treatment of hyperkalemia in patients with chronic kidney disease, highlighting patient populations in scenarios at risk for this important complication.

Program Objectives

- Develop awareness of the predictors and prevalence of hyperkalemia in clinical settings with and without chronic kidney disease.
- Acquire recent information about the serum potassium thresholds associated with escalating risk of death.
- Assemble information to formulate strategies to protect the safety of patients with profiles at high risk for hyperkalemia.
- Be aware of emerging clinical agents to reduce potassium absorption.

Agenda and Faculty

6:00 A.M. Breakfast

6:30 A.M. Introduction by Program Moderator

Peter A. McCullough, MD, MPH, FACC, FACP, FAHA, FCCP, FNKF
Baylor University Medical Center,
Baylor Heart and Vascular Institute,
Baylor Jack and Jane Hamilton Heart and Vascular Hospital
Dallas, Texas
The Heart Hospital
Plano, Texas

6:40 A.M. Frequency and Clinical Significance of Hyperkalemia in Chronic Kidney Disease

Robert D. Toto, MD
Professor of Medicine
Associate Dean for Clinical and Translational Research
University of Texas Southwestern Medical Center
Dallas, Texas

6:55 A.M. Risks of Hyperkalemia in Special Kidney Disease Populations

Michael Emmett, MD
Chairman of Internal Medicine
Baylor University Medical Center
Dallas, Texas

7:10 A.M. Emerging Therapies for Treating Hyperkalemia

John P. Middleton, MD
Associate Professor
Division of Nephrology
Duke University
Durham, North Carolina

7:25 A.M. Question and Answers / Panel Discussion

7:45 A.M. Closing Remarks by Moderator

- Pre-registration for this symposium is not required. Seating is limited and will be available on a first come, first serve basis.
- You must be registered for the NKF 2014 Spring Clinical Meetings to attend this symposium and receive CME/CE credit.

Thursday, April 24, 2014
6:00 A.M. - 7:45 A.M.
MGM Grand, Las Vegas
Premier Ballroom 318/319
Las Vegas, Nevada

Target Audience: Nephrology professionals

How You Will Learn: This CME/CE activity will be a live symposium consisting of lectures with panel discussion and audience participation.

Accreditation: The National Kidney Foundation is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The National Kidney Foundation is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.



The National Kidney Foundation is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR).

Designation Statements: The National Kidney Foundation designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Awarded 1.5 contact hours of continuing nursing education (includes 0.5 contact hours in the area of pharmacology).

Registered dietitians (RDs) and Dietetic Technicians, Registered (DTRs) will receive 1.5 continuing professional education units (CPEUs) for completion of this program/material.

This program is pending approval with the American Association of Nurse Practitioners.

Pharmacy continuing education is being sought for this program through the University of Illinois at Chicago, College of Pharmacy, an accredited provider by the Accreditation Council for Pharmacy Education (ACPE).

Declaration of Disclosure: It is the policy of the National Kidney Foundation (NKF) to ensure balance, independence, objectivity, and scientific rigor in all CME/CE activities. Any individual who has control over

CME/CE content is required to disclose to learners prior to the activity any relevant financial relationship(s) they may have with commercial supporters of this activity or whose products or devices are discussed in this activity. If, on the basis of information disclosed, a perceived conflict exists, resolution will be achieved based on NKF's Disclosure and Conflict of Interest policy. Accredited status does not imply endorsement by the NKF or ANCC of any commercial products displayed in conjunction with this activity.

Unlabeled/Investigational Use Declaration: During their presentations, faculty may discuss an unlabeled use or an investigational use not approved for a commercial product. Each faculty member is required to disclose this information to the audience when referring to an unlabeled or investigational use.

Disclaimer: The faculty, National Kidney Foundation, ZS Pharma, and The Med Ed Group, do not recommend the use of any pharmaceutical, diagnostic test, or device outside of the labeled indications as approved by the FDA. Please refer to the official prescribing information for each product for approved indications, contraindications, and warnings. Information contained in this National Kidney Foundation (NKF) educational resource is based upon current data available at the time of presentation. Information is intended to help clinicians become aware of new scientific findings and developments. This NKF educational resource is not intended to set out a preferred standard of care and should not be construed as one. Neither should the information be interpreted as prescribing an exclusive course of management. Variations in practice will inevitably and appropriately occur when clinicians take into account the needs of individual patients, available resources, and limitations unique to an institution or type of practice. Every health care professional making use of information in this NKF educational resource is responsible for interpreting the data as it pertains to clinical decision making in each individual patient. individual patient.



National Kidney Foundation™



Supported by an educational grant from ZS Pharma

A Breakfast Symposium During
the NKF 2014 Spring Clinical Meetings

The Role of BIOSIMILARS in Chronic Kidney Disease

Thursday, April 24, 2014

6:00–7:45 AM | Premier Ballroom 310–311
MGM Grand Hotel & Casino | Las Vegas, Nevada



AGENDA

- 6:15–6:20 AM Introduction
- 6:20–6:40 AM The State of Biosimilar Regulation and Development in the United States
Edward Li, PharmD, BCOP
- 6:40–7:00 AM A Review of Biosimilars Versus Reference Biologics
Graham Jones, PhD, DSc
- 7:00–7:30 AM The Potential Role of Biosimilars in Chronic Kidney Disease
Francesco Locatelli, MD, FRCPB
- 7:30–7:35 AM Questions and Answers
- 7:35–7:45 AM Concluding Remarks

FACULTY

Graham Jones, PhD, DSc
Professor and Chair
Department of Chemistry
Northeastern University
Boston, Massachusetts

Edward Li, PharmD, BCOP
Associate Professor
Department of Pharmacy Practice
University of New England College of Pharmacy
Portland, Maine

Francesco Locatelli, MD, FRCPB
Professor and Head
Department of Nephrology & Dialysis and Renal Transplant
Alessandro Manzoni Hospital
Lecco, Italy

ACTIVITY PURPOSE: Over the next few years, biosimilars are expected to emerge as options for the treatment of anemia and chronic kidney disease. Clinicians who manage patients with these conditions will be challenged with the advent of these agents due to an overall lack of experience with biosimilars and the understanding of how they factor in as an option in the nephrology practice. This activity will review biosimilars, including similarities and differences with their reference products, as well their potential role in the management of anemia and chronic kidney disease.

TARGET AUDIENCE: This activity is intended for clinicians who manage anemia and chronic kidney disease, including physicians, pharmacists, physician assistants, advanced practitioners, and nephrology nurses and technicians.

EDUCATIONAL OBJECTIVES: Upon completion of this course, the participants should be able to:

- State the current FDA definition of a biosimilar
- Describe differences and similarities between biosimilars and reference biologics
- Summarize key aspects of the current FDA guidance for approval of biosimilars
- Evaluate clinical trial data on biosimilar therapies in development for anemia

You must be registered for the NKF 2014 Spring Clinical Meetings to attend this symposium and receive CME/CE credit. This CME/CE activity will be a live symposium consisting of lectures with panel discussion and audience participation.

ACCREDITATION STATEMENT: The National Kidney Foundation is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The National Kidney Foundation is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.



The National Kidney Foundation is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR).

DESIGNATION STATEMENTS: The National Kidney Foundation designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Awarded 1.5 contact hours of continuing nursing education (includes 0.4 contact hours in the area of pharmacology).

Registered dietitians (RDs) and Dietetic Technicians, Registered (DTRs) will receive 1.5 continuing professional education units (CPEUs) for completion of this program/material.

This program is pending approval with the American Association of Nurse Practitioners.

Pharmacy continuing education is being sought for this program through the University of Illinois at Chicago, College of Pharmacy, an accredited provider by the Accreditation Council for Pharmacy Education (ACPE).

DECLARATION OF DISCLOSURE: It is the policy of the National Kidney Foundation (NKF) to ensure balance, independence, objectivity, and scientific rigor in all CME/CE activities. Any individual who has control over CME/CE content is required to disclose to learners prior to the activity any relevant financial relationship(s) they may have with commercial supporters of this activity or whose products or devices are discussed in this activity. If, on the basis of information disclosed, a perceived conflict exists, resolution will be achieved based on NKF's Disclosure and Conflict of Interest policy. Accredited status does not imply endorsement by the NKF or ANCC of any commercial products displayed in conjunction with this activity.

UNLABELED/INVESTIGATIONAL USE DECLARATION: During their presentations, faculty may discuss an unlabeled use or an investigational use not approved for a commercial product. Each faculty member is required to disclose this information to the audience when referring to an unlabeled or investigational use.

DISCLAIMER: The faculty, National Kidney Foundation, Hospira, and The France Foundation do not recommend the use of any pharmaceutical, diagnostic test, or device outside of the labeled indications as approved by the FDA. Please refer to the official prescribing information for each product for approved indications, contraindications, and warnings. Information contained in this National Kidney Foundation (NKF) educational resource is based upon current data available at the time of presentation. Information is intended to help clinicians become aware of new scientific findings and developments. This NKF educational resource is not intended to set out a preferred standard of care and should not be construed as one. Neither should the information be interpreted as prescribing an exclusive course of management. Variations in practice will inevitably and appropriately occur when clinicians take into account the needs of individual patients, available resources, and limitations unique to an institution or type of practice. Every health care professional making use of information in this NKF educational resource is responsible for interpreting the data as it pertains to clinical decision making in each individual patient.

NEW INSIGHTS INTO THE ROLE OF **P**HOSPHORUS BALANCE IN CHRONIC KIDNEY DISEASE



*A Dinner Symposium at the National Kidney Foundation
2014 Spring Clinical Meeting*

Thursday, April 24, 2014

7:30 PM – 9:30 PM

MGM Grand Hotel, Las Vegas, Nevada
PREMIER BALLROOM 318-319



National
Kidney
Foundation™

COURSE CHAIR:

Myles S. Wolf, MD, MMSc

*Director, Center for Translational Metabolism and Health
Institute for Public Health and Medicine
Margaret Gray Morton Professor of Medicine
Feinberg School of Medicine
Northwestern University
Chicago, Illinois*

FACULTY:

Geoffrey A. Block, MD, CCRI

*Director of Clinical Research, Denver Nephrology
Associate Professor of Medicine
University of Colorado Health Sciences Center
Denver, Colorado*

Sylvia E. Rosas, MD, MSCE, FNKF

*Kidney and Hypertension Section
Joslin Diabetes Center
Beth Israel Deaconess Medical Center
Harvard Medical School
Boston, Massachusetts*

ACTIVITY PURPOSE: The goal of this activity is to improve learners' strategies for managing serum phosphorus and anemia in patients with chronic kidney disease (CKD) or end-stage renal disease (ESRD).

TARGET AUDIENCE: Physicians, Fellows, Residents; Nephrology Nurses and Technicians; Pharmacists; Physician Assistants; Advanced Practitioners

EDUCATIONAL OBJECTIVES: After completing the program, participants are expected to be able to

1. Discuss the physiology of phosphorus homeostasis in patients with CKD
2. Review the current data on managing hyperphosphatemia in patients with ESRD
3. Discuss the potential role and unique attributes of iron-based phosphate binders in CKD

HOW YOU WILL LEARN: This CME/CE activity will be a live symposium during which didactic and case presentations will be interwoven with interactive faculty discussion and "Test Your Knowledge and Skills" activities.

ACCREDITATION STATEMENTS:

The National Kidney Foundation is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The National Kidney Foundation is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.



The National Kidney Foundation is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR).

DESIGNATION STATEMENTS:

The National Kidney Foundation designates this live activity for a maximum of 1.5 *AMA PRA Category 1 Credits*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Awarded 1.5 contact hours of continuing nursing education (includes 0.4 contact hours in the area of pharmacology).

Registered dietitians (RDs) and Dietetic Technicians, Registered (DTRs) will receive 1.5 continuing professional education units (CPEUs) for completion of this program/material.

This program is pending approval with the American Association of Nurse Practitioners.

Pharmacy continuing education is being sought for this program through the University of Illinois at Chicago, College of Pharmacy, an accredited provider by the Accreditation Council for Pharmacy Education (ACPE).

You must be registered for the NKF 2014 Spring Clinical Meetings to attend this symposium and receive CME/CE credit.

PROGRAM AGENDA:

- 7:30 PM** Dinner
- 8:00 PM** Introduction; Pre-test
Myles S. Wolf, MD, MMSc
- 8:05 PM** Understanding the physiology and therapeutic targets of phosphorus homeostasis in patients with chronic kidney disease
Myles S. Wolf, MD, MMSc
- 8:25 PM** Emerging treatment options for serum phosphorus levels
Sylvia E. Rosas, MD, MSCE, FNKF
- 8:50 PM** Strategies to improve care in patients with hyperphosphatemia and chronic kidney disease
Geoffrey A. Block, MD, CCRI
- 9:15 PM** Q & A; Post-test
Faculty
- 9:30 PM** Program concludes

DECLARATION OF DISCLOSURE: It is the policy of the National Kidney Foundation (NKF) to ensure balance, independence, objectivity, and scientific rigor in all CME/CE activities. Any individual who has control over CME/CE content is required to disclose to learners prior to the activity any relevant financial relationship(s) they may have with commercial supporters of this activity or whose products or devices are discussed in this activity. If, on the basis of information disclosed, a perceived conflict exists, resolution will be achieved based on NKF's Disclosure and Conflict of Interest policy. Accredited status does not imply endorsement by the NKF or ANCC of any commercial products displayed in conjunction with this activity.

UNLABELED/INVESTIGATIONAL USE DECLARATION: During their presentations, faculty may discuss an unlabeled use or an investigational use not approved for a commercial product. Each faculty member is required to disclose this information to the audience when referring to an unlabeled or investigational use.

DISCLAIMER: The faculty, National Kidney Foundation, and Keryx Biopharmaceuticals, Inc., do not recommend the use of any pharmaceutical, diagnostic test, or device outside of the labeled indications as approved by the FDA. Please refer to the official prescribing information for each product for approved indications, contraindications, and warnings. Information contained in this National Kidney Foundation (NKF) educational resource is based upon current data available at the time of presentation. Information is intended to help clinicians become aware of new scientific findings and developments. This NKF educational resource is not intended to set out a preferred standard of care and should not be construed as one. Neither should the information be interpreted as prescribing an exclusive course of management.

Variations in practice will inevitably and appropriately occur when clinicians take into account the needs of individual patients, available resources, and limitations unique to an institution or type of practice. Every health care professional making use of information in this NKF educational resource is responsible for interpreting the data as it pertains to clinical decision making in each individual patient.

Supported by an educational grant from
Keryx Biopharmaceuticals, Inc.





Expert Perspectives in the Management of BONE-MINERAL-VASCULAR DISORDERS:

A Pathophysiological AND Evidence-Based Approach TO Care

FRIDAY, APRIL 25, 2014

6:00 AM – 7:45 AM (Breakfast will be provided)
MGM Grand Hotel
Room: Premier Ballroom 318/319
Las Vegas, Nevada

Faculty

Kathleen M. Hill Gallant, PhD, RD

Assistant Professor
Director of the Didactic Program in Dietetics
Department of Nutrition Science
Purdue University
West Lafayette, Indiana

Ellie Kelepouris, MD, FAHA

Professor, Department of Medicine
Vice Chair for Academic Affairs
Chief, Division of Nephrology and Hypertension
Director, Nephrology Training Program
Drexel University College of Medicine
Philadelphia, Pennsylvania

Matthew R. Weir, MD

Professor of Medicine
University of Maryland School of Medicine
Director, Division of Nephrology
University of Maryland Hospital
Baltimore, Maryland

Activity Purpose

Chronic kidney disease (CKD) is one of the most commonly encountered diseases in clinical practice. CKD-related alterations of mineral and bone metabolism may ultimately lead to CKD-mineral bone disorder (CKD-MBD) which can manifest itself as one or a combination of: (1) abnormalities of calcium, phosphorus, PTH, or vitamin D metabolism; (2) abnormalities in bone turnover, mineralization, volume, linear growth, or strength; and (3) vascular or other soft tissue calcification. There are many potential deleterious effects of disordered mineral metabolism, including increased risk for cardiovascular (CV) disease and mortality. These complications remain clinically challenging in patients with CKD and state-of-the-art management in this regard continues to evolve. This case-based symposium will focus on the pathophysiologic consequences of CKD-related mineral and bone abnormalities, as well as their relationships to CV risk and other comorbidities. Strategies to optimize management of CKD-MBD via dietary and treatment intervention will be explored in detail.

Educational Objectives

- Review the metabolic dysregulation of CKD-associated MBD and its CV effects
- Discuss the mineral abnormalities associated with CKD and their negative end-organ consequences
- Describe approaches to minimize the biochemical and clinical effects of calcium and phosphorus imbalance associated with CKD

Target Audience

This program is intended to meet the educational needs of nephrologists, renal dietitians, and nurses who treat patients with CKD.

Accreditation Statements

Physicians / The National Kidney Foundation is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Nurses / The National Kidney Foundation is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Dietitians / The National Kidney Foundation is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR).

Designation Statements

Physicians / The National Kidney Foundation designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses / Awarded 1.5 contact hours of continuing nursing education (includes 0.41 contact hours in the area of pharmacology).

Dietitians / Registered dietitians (RDs) and Dietetic Technicians, Registered (DTRs) will receive 1.5 continuing professional education units (CPEUs) for completion of this program/material.

Nurse Practitioners / This program is pending approval with the American Association of Nurse Practitioners.

Pharmacists / Pharmacy continuing education is being sought for this program through the University of Illinois at Chicago, College of Pharmacy, an accredited provider by the Accreditation Council for Pharmacy Education (ACPE).

PROGRAM AGENDA

6:00 AM – 6:15 AM
Registration and Breakfast

6:15 AM – 6:20 AM
Welcome and Introduction

6:20 AM – 6:45 AM

Matthew R. Weir, MD

**Metabolic and Mineral Disturbances in CKD-MBD:
A Discussion of Pathophysiology and Risk**

6:45 AM – 7:10 AM

Kathleen M. Hill Gallant, PhD, RD

**Dietary Calcium and Phosphorus:
A Focus on Cardiovascular Risk in CKD-MBD**

7:10 AM – 7:35 AM

Ellie Kelepouris, MD, FAHA

**Evolving Clinical Perspectives:
Application of Phosphorus and Calcium Management
Strategies in Patients With CKD-MBD**

7:35 AM – 7:45 AM

Questions and Answers

7:45 AM

Adjourn

{ You must be registered for the NKF 2014 Spring Clinical Meetings to attend this symposium and receive CME/CE credit. }

Disclosure Information

Declaration of Disclosure

It is the policy of the National Kidney Foundation (NKF) to ensure balance, independence, objectivity, and scientific rigor in all CME/CE activities. Any individual who has control over CME/CE content is required to disclose to learners prior to the activity any relevant financial relationship(s) they may have with commercial supporters of this activity or whose products or devices are discussed in this activity. If, on the basis of information disclosed, a perceived conflict exists, resolution will be achieved based on NKF's Disclosure and Conflict of Interest policy. Accredited status does not imply endorsement by the NKF or ANCC of any commercial products displayed in conjunction with this activity.

Unlabeled/Investigational Use Declaration

During their presentations, faculty may discuss an unlabeled use or an investigational use not approved for a commercial product. Each faculty member is required to disclose this information to the audience when referring to an unlabeled or investigational use.

Disclaimer

The faculty, National Kidney Foundation, sanofi-aventis U.S., and Quintiles Medical Education, Inc., do not recommend the use of any pharmaceutical, diagnostic test, or device outside of the labeled indications as approved by the FDA. Please refer to the official prescribing information for each product for approved indications, contraindications, and warnings. Information contained in this National Kidney Foundation (NKF) educational resource is based upon current data available at the time of presentation. Information is intended to help clinicians become aware of new scientific findings and developments. This NKF educational resource is not intended to set out a preferred standard of care and should not be construed as one. Neither should the information be interpreted as prescribing an exclusive course of management. Variations in practice will inevitably and appropriately occur when clinicians take into account the needs of individual patients, available resources, and limitations unique to an institution or type of practice. Every health care professional making use of information in this NKF educational resource is responsible for interpreting the data as it pertains to clinical decision making in each individual patient.





AJKD

AMERICAN JOURNAL OF KIDNEY DISEASES

www.ajkd.org



eAJKD the official AJKD blog!

www.eajkd.org

- Learn more about the research and other behind-the-article stories via author interviews
- Check out perspectives on the latest nephrology news
- Test your knowledge with quizzes and puzzles
- Share your perspective and see what your colleagues are saying



American Journal of Kidney Diseases

www.ajkd.org

Andrew S. Levey, MD, Editor-in-Chief

- The leader in clinical nephrology content, publishing the latest findings in kidney disease, hypertension, dialysis therapies, and kidney transplantation, as well as educational and special features such as editorials, reviews, and teaching cases!
- Online at www.ajkd.org for the latest issue, articles in press, online-only case reports and supplements, full text archives of past issues, and more!
- **2012 Impact Factor 5.294, ranked 5th of 73 journals** in the Urology/Nephrology category (©Thomson Reuters, *Journal Citation Reports*®, 2013)

Official journal of the



iPad® App
AVAILABLE TO DOWNLOAD NOW!

Available on the App Store

AJKD on Facebook

www.facebook.com/ajkdonline



- Follow AJKD on Facebook!
- Access freely available AJKD articles
- Receive summaries of highlighted journal content

D P P S

DIALYSIS OUTCOMES AND PRACTICE PATTERNS STUDY PROGRAM

The DOPPS Program collects extensive longitudinal data on patients nationally and across the globe to emphasize the effects of clinical practice patterns on patient outcomes. Several studies make up the DOPPS program including:

The Dialysis Outcomes and Practice Patterns Study (DOPPS) is a prospective cohort study of in-center hemodialysis practices based on observing longitudinal data for randomly selected patients and dialysis facilities in more than 20 countries.

The Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS) is a prospective cohort study of peritoneal dialysis (PD) practices. This study collects longitudinal data for a random sample of patients within a random sample of facilities in multiple countries.

The Chronic Kidney Disease Outcomes and Practice Patterns Study (CKDopps) is a facility-based cohort study of practices treating chronic kidney disease, based on observing longitudinal prospective and retrospective data for random samples of patients in Germany, France, Brazil, and the United States.

For more information about these studies and to view over 180+ peer-reviewed DOPPS publications please visit

**Please visit
the DOPPS
Booth 420**

www.DOPPS.org

The DOPPS projects are coordinated by the research scientists and staff of





Research Fellowship Award Program in Nephrology

Questcor Medical Affairs is pleased to announce the 2014 Research Fellowship Award Program in Nephrology.

The objective of the program is to provide grants to fellows, junior clinicians, residents and post-doctoral researchers pursuing a research-oriented career in the area of clinical, translational, or basic research. Research will be conducted at eligible institutions and fulfills an unmet medical need or addresses essential scientific questions in glomerular diseases and related disorders.

The Research Fellowship Award will be paid directly to the awardee's institution. Fellowship grant awards are funded for one year in the amount of \$50,000 per year and may be renewable for a second year provided sufficient progress has been made towards the research objectives.

Deadline for Submission: September 30th, 2014

For more information on the application process or to apply, please visit www.Questcor.com.

Invokana[®]

canagliflozin tablets

Join us for an exhibitor showcase

Speaker: **Gregory Mitchell, MD, PA**

Date: **Thursday, April 24, 2014**

Time: **1:15 PM – 1:50 PM**

Location: **Exhibitor Showcase in the Exhibit Hall**

Learn more at INVOKANAhcp.com

Janssen Pharmaceuticals, Inc.

Canagliflozin is licensed from Mitsubishi Tanabe Pharma Corporation.

© Janssen Pharmaceuticals, Inc. 2014 March 2014 011313-140305

janssen 
PHARMACEUTICAL COMPANIES
OF *Johnson & Johnson*



FIND OUT WHAT'S REALLY GOING DOWN
AT BOOTH #136

Please join us
for an
Exhibitor Showcase

Friday, April 25
8:15 AM to 8:50 AM



Save with a 2-year membership!



National
Kidney
Foundation™

There's an NKF professional membership just right for you!

JOIN NKF TODAY


Thousands of healthcare professionals in the U.S. and around the world, and more than 1,500 at the NKF Spring Clinical Meetings, are taking advantage of the resources and savings NKF membership offers.

ALL NKF MEMBERS RECEIVE

- Discounts on NKF publications, NKF Store materials, events, and educational programs
- Eligibility to apply for research grants, educational stipends, and award recognition

HIGHLIGHTS FOR EACH MEMBERSHIP TYPE

- **PHYSICIANS** – Subscriptions to both the monthly *American Journal of Kidney Diseases* and the bimonthly *Advances in Chronic Kidney Disease* (a \$450 savings!)
- **COUNCIL OF NEPHROLOGY SOCIAL WORKERS** – Receive the *Journal of Nephrology Social Work* and apply for *Nephrology Social Worker* certification (NSW-C) through the NKF
- **COUNCIL OF NEPHROLOGY NURSES AND TECHNICIANS** – Bimonthly issues of *Advances in Chronic Kidney Disease* and the new online Conversion Calculators resource
- **COUNCIL ON RENAL NUTRITION** – Bimonthly issues of the *Journal of Renal Nutrition* and a copy of the *Pocket Guide to Nutrition Assessment of the Patient with Chronic Kidney Disease*
- **COUNCIL OF ADVANCED PRACTITIONERS** – Receive a copy of NKF's respected *Primer on Kidney Diseases*, a valuable resource examining all aspects of kidney and related diseases (an \$85 value!)



3

EASY WAYS
TO
JOIN TODAY!

1. STOP BY the membership desk
2. VISIT KIDNEY.ORG, click on 'Get Involved'
3. CALL 888.JOIN.NKF

WHAT'S INSIDE



Welcome to SCM14	20
SCM14 Program Committee	21
NKF Leadership	22
NKF Distinguished Lecture and Award Recipients	23
NKF Professional Council Awards	30
SCM14 Contributors	36
General Information	
Meeting Objectives	37
Poster Presentation Information	38
Exhibit Hall Information	38
Corporate Supporters	40
Corporate Supported Symposia	41
Disclosure Information	42
NKF CME Mission Statement	47
Program Tracks	
Physician	49
Pharmacist	69
Advanced Practitioner	79
Nephrology Nurse and Technician	91
Renal and Clinical Dietitian	100
Nephrology Social Worker	110
FNKF Inductees	119
Exhibit Hall Map and Index	120
SCM14 Exhibitors	122
Faculty	128
Hotel Map	134

Dear Colleague:

Welcome to the National Kidney Foundation (NKF) 2014 Spring Clinical Meetings (SCM14)! The Program Committee has worked hard this year to improve the diversity of educational offerings, ranging from patient care to health policy, on topics that directly impact providers in the field and are clinically challenging. In addition to medical sciences, we are making deliberate efforts to emphasize patient-centered outcomes, including various psycho-social aspects. This year, we are offering newly developed pre-conference workshops for numerous tracks including Physician, Advanced Practitioner, Nurse, Technician, Dietitian, and Social Worker. In addition, the Program Committee and NKF staff has worked to enhance social media and mobile app capabilities. We hope everyone enjoys the changes this year.

The meeting will begin with our Opening Ceremonies and Faculty Reception on Wednesday evening, April 23, at 6:00pm, where you will have an opportunity to network with colleagues, view the outstanding selection of poster presentations, and learn about the newest and best products and services in kidney care. Nephrology fellows and trainees from all disciplines are particularly welcomed at the SCM14. We have a number of career development sessions by academicians and practitioners as well as small-group discussions. To encourage our future generation of clinician investigators and biomedical scientists, we will highlight poster abstracts and award prizes for trainees, as well as junior faculty members from all disciplines.

Don't forget to attend our annual Presidential Address from Dr. Beth Piraino, who will outline the future of the NKF, and our distinguished Shaul G. Massry Lecture, delivered this year by Dr. Mark Sarnak. We also have a number of distinguished award recipients, including our international distinguished medal recipients Dr. Daniel Cattran, Dr. David Johnson, Dr. Paul Stevens, and Dr. Xueqing Yu. Other program highlights include important updates from KDOQI® as well as KEEP® interspersed throughout the meeting. During the pre-conference courses, workshops, and general sessions, there are a number of outstanding offerings on hypertension, diabetes, electrolyte disorders, glomerular and genetic-based diseases, acute kidney injury, bone-mineral disorders, vascular access, peritoneal dialysis, and hemodialysis.

Before leaving on Saturday, please take a few moments to complete your Program Evaluation. The Program Committee and staff value your comments and suggestions as a critical component of planning for upcoming Spring Clinical Meetings. Also, it's not too early to mark your calendars for the NKF 2015 Spring Clinical Meetings, March 25–29, 2015, at the Gaylord Texan in Dallas, TX.

We are confident this year's SCM activities will meet the objective of translating education and science into practice, while providing a lot of fun. Whatever happens in Vegas, please feel free to share it with the world. Enjoy the meeting!

Sincerely,

Alfred K. Cheung, MD, FNKF
SCM14 Program Chair

Adam Whaley-Connell, DO,
MSPH, FNKF, FAHA, FASN, FACP
SCM14 Program Co-Chair

Beth Piraino, MD, FNKF
NKF President

SCM14 PROGRAM COMMITTEE

Alfred K. Cheung, MD, FNKF

Program Chair
University of Utah
Salt Lake City, UT

**Adam Whaley-Connell, DO, MSPH, FAHA,
FNKF, FASN, FACP**

Program Co-Chair
Harry S. Truman Memorial Veterans Hospital
Columbia, MO

Marie Becker, MS, RD, LDN

Renal and Clinical Dietitian Program Chair
DaVita Central Orlando Dialysis
Orlando, FL

David Cherney, MD, PhD, FNKF

University Health Network—
Toronto General Hospital
Toronto, ON, Canada

Kristine D'Angelo David, RD

Renal and Clinical Dietitian Program Co-Chair
Sigma-Tau Pharmaceuticals, Inc.
Gaithersburg, MD

Kim Deaver, RN, BSN, CNN

*Nephrology Nurse and Technician Program
Co-Chair*
University of Virginia Health System
Charlottesville, VA

Bina George-Figueroa, MS, CCMEP

Senior Director, Continuing Medical Education
National Kidney Foundation
New York, NY

Debbie Gipson, MD, MS, FNKF

University of Michigan Health System
Ann Arbor, MI

Joni Hansson, MD, FNKF

Yale University
New Haven, CT

Jessica Joseph, MBA

Senior Director, Professional Membership Programs
National Kidney Foundation
New York, NY

Timmy Lee, MD, MSPH, FACP, FASN, FNKF

University of Alabama at Birmingham
Birmingham, AL

Charmaine Lok, MD, MSc, FNKF

University Health Network—
Toronto General Hospital
Toronto, ON, Canada

Michal Melamed, MD, MHS, FNKF

Albert Einstein College of Medicine
Bronx, NY

Carol Moore, PharmD, BCPS, FNKF

Henry Ford Health System
Detroit, MI

Chirag Parikh, MD, FNKF

Yale University School of Medicine
New Haven, CT

Cintia Perez, RN, BSN, CNN

*Nephrology Nurse and Technician
Program Chair*
Saint Joseph Hospital
Orange, CA

Dena Rifkin, MD, MS, FNKF

University of California
San Diego, CA

Sylvia E. Rosas, MD, MSCE, FNKF

Harvard University Joslin Diabetes Center
Boston, MA

Amma Sewaah-Bonsu, MSN, DNP, NP-C

Advanced Practitioner Program Co-Chair
Nephrology Associates of Central Florida
Orlando, FL

Fuad Shihab, MD, FNKF

University of Utah
Salt Lake City, UT

Vernon Silva, LCSW, NSW-C

Nephrology Social Worker Program Co-Chair
U.S. Renal Care
Lomita, CA

Kristin Stockard, MSW, LICSW

Nephrology Social Worker Program Chair
Seattle Children's Hospital
Seattle, WA

Daniel Weiner, MD, MS, FNKF

Tufts Medical Center
Boston, MA

**Wolfgang Winkelmayr, MD, ScD,
MPH, FASN**

Stanford University School of Medicine
Palo Alto, CA

Kim Zuber, MS, PA-C, FNKF

Advanced Practitioner Program Chair
Metropolitan Nephrology
Alexandria, VA

Ex Officio

Beth Piraino, MD, FNKF

NKF President
University of Pittsburgh
School of Medicine
Pittsburgh, PA

Joseph Vassalotti, MD, FASN, FNKF

Chief Medical Officer
National Kidney Foundation
New York, NY

LEADERSHIP OF THE NATIONAL KIDNEY FOUNDATION

For over 60 years, the NKF has grown to become the leading organization in the U.S. dedicated to the awareness, prevention, and treatment of kidney disease for hundreds of thousands of healthcare professionals, millions of patients and their families, and tens of millions of Americans at risk.

The Foundation has made tremendous advances in its mission through the visionary leadership of the National Presidents and Chairmen.

The mission of the National Kidney Foundation is to prevent kidney and urinary tract diseases, improve the health and well-being of individuals and families affected by these diseases and increase the availability of all organs for transplantation.

PRESIDENT

Beth Piraino, MD, FNKF
2012-Present

PAST PRESIDENTS

Lynda A. Szczech, MD, MSCE, FNKF
2010-2012

Bryan Becker, MD
2008-2010

Allan J. Collins, MD, FACP
2006-2008

David Warnock, MD
2004-2006

Brian J.G. Pereira, MD
2002-2004

William F. Keane, MD
2000-2002

Joel D. Kopple, MD
1998-2000

Garabed Eknoyan, MD
1996-1998

Alan R. Hull, MD
1994-1996

Neil A. Kurtzman, MD
1992-1994

Shaul G. Massry, MD
1990-1992

Saulo Klahr, MD
1988-1990

Richard J. Glasscock, MD
1986-1988

Robert W. Schrier, MD
1984-1986

David A. Ogden, MD
1982-1984

Richard M. Freeman, MD
1980-1982

Stuart A. Kleit, MD
1978-1980

Arvin Weinstein, MD
1976-1978

James C. Hunt, MD
1973-1976

E. Lovell Becker, MD
1970-1973

George E. Schreiner, MD
1968-1970

George Lingua
1967-1968

William J. Jones, MD
1966-1967

Wallace W. McCrory, MD
1964-1966

Daniel P. Richman, MD
1960-1964

William A. Wargo
1959-1960

Henry Kessler, MD
1954-1959

Mrs. John E. Tedford
1952-1954

Mrs. Ada U. DeBold
1950-1952 (Founder)

CHAIRMAN

Gregory W. Scott
2013-Present

PAST CHAIRMEN

W. Edward Walter
2011-2013

William Cella
2009-2011

Tom McDonough
2007-2009

Charles B. Fruit
2005-2007

Fred L. Brown, MBA, FACHE
2003-2005

Andrew Baur
2001-2003

Frederick A. Herbert
1999-2001

Joseph L. Brand
1997-1999

Wendy Brown, MD
1995-1997

A. Bruce Bowden
1993-1995

Donald R. Wilson
1991-1993

Charles E. Westcott
1989-1991

William P. Hunter, Jr.
1987-1989

The Honorable John N. Kirkendall
1985-1987

John Hoag

1983-1985

E. Burns McLindon
1981-1983

Oliver W. Porter
1979-1981

Harold D. Schwartz
1977-1979

Jack C. Kent
1975-1977

Jordan E. Ringel
1973-1975

The office of Chairman was created in 1973.



NKF DISTINGUISHED LECTURE AND AWARD RECIPIENTS

The Shaul G. Massry Distinguished Lecture

This lectureship was established to honor Dr. Shaul G. Massry for his scientific achievements and his contributions to the kidney healthcare community and the National Kidney Foundation. The 2014 honored lecturer is Mark J. Sarnak, MD, MS. Dr. Sarnak will be presenting "Vascular Disease in Chronic Kidney Disease: Progress and Challenges" on Wednesday, April 23.



MARK J. SARNAK, MD, MS, is Professor of Medicine at Tufts University School of Medicine (TUSM), and Director of Research in the Division of Nephrology at Tufts Medical Center (TMC). He obtained his MD from Columbia

University College of Physicians and Surgeons and completed his residency at Massachusetts General Hospital. He trained in nephrology at TMC and received a Master's Degree in Clinical Research from TUSM. His research encompasses the relationship of CKD to aging, cognition, and cardiovascular disease. He has been funded by the NIH for the last 13 years. He has authored more than 200 publications and was Co-Editor of *AJKD* from 2006 to 2007 and was on the Editorial Board of the *Annals of Internal Medicine* from 2010 to 2013. He was a workgroup member of the KDIGO Guideline for the Management of Blood Pressure in CKD and is current Co-Chair of the KDOQI Commentary workgroup of the KDIGO Guideline for Lipid Management in CKD. He has mentored numerous fellows and junior faculty in clinical research. He has received a Teaching Award from the Tufts Medical Center Residents as well as several citations for Excellence in Teaching from Tufts Medical Students. He has been named in *Boston Magazine's* "Best Doctors" from 2010-2012.

PAST RECIPIENTS

2013 Barry I. Freedman, MD
2012 Ravi Thadhani, MD, MPH
2011 Glenn M. Chertow, MD, MPH
2010 Allan J. Collins, MD, FACP
2009 Mohamed Sayegh, MD
2008 Tom Greene, PhD

2007 Eberhard Ritz, MD
2006 Giuseppe Remuzzi, MD, FRCP
2005 Edmund J. Lewis, MD
2004 Hans-Henrik Parving, MD, DMSc
2003 Robert Alpern, MD
2002 Joseph V. Bonventre, MD, PhD
2001 Andrzej S. Krolewski, MD, PhD
2000 Richard J. Glassock, MD
1999 Giuseppe Bianchi, MD
1998 Josephine Briggs, MD
1997 Gary E. Striker, MD
1996 Alfred Michael, MD

The Donald W. Seldin Award

The Donald W. Seldin Award was established to recognize excellence in clinical nephrology in the tradition of one of the foremost teachers and researchers in the field, Dr. Donald W. Seldin. The 2014 award recipient is Ronald Perrone, MD, FNKF.



DR. RONALD PERRONE is the Medical Director of Kidney Transplantation at Tufts Medical Center in Boston, MA. He received his MD at Hahnemann Medical College in Philadelphia, PA. Dr. Perrone has had a long-stand-

ing and wide-ranging interest in the translation of basic science discoveries to clinical medicine. Starting with a laboratory focused on epithelial transport, he subsequently focused on work with immortalized epithelia, including human intrahepatic biliary epithelium, human polycystic liver cysts, and human bladder. His present work focuses on clinical research in polycystic kidney disease and the role of total kidney volume as a biomarker in response to clinical therapies. Dr. Perrone has been a member of the Scientific Advisory Committee of the Polycystic Kidney Disease Foundation since 1999 (Chairman 2006-2010) and frequently lectures at national and local patient meetings. He served as Co-investigator with Dr. Andrew Levey in the pilot and planning phases (Phase I and II) of the Modification of Diet in Renal Disease (MDRD) Study and played a fundamental

continued

role in the validation and use of the 125I-iothalamate protocol used for the MDRD and other clinical trials of progressive kidney disease. Over the past four years, Dr. Perrone has initiated the PKD Outcomes Consortium and has been the principal individual involved in bringing together contributors from academia, pharma, NIH, FDA, CDISC, and C-Path. He has led this large and diverse consortium that is creating the groundwork for validation of total kidney volume as a clinical trial and regulatory endpoint in ADPKD.

PAST RECIPIENTS

- 2013 Joanne M. Bargman, MD, FRCPC
- 2012 Gerald B. Appel, MD
- 2011 Sharon G. Adler, MD, FASN
- 2010 Fredric L. Coe, MD, FACP, FASN
- 2009 William F. Keane, MD
- 2008 Thomas DuBose, Jr., MD
- 2007 L. Lee Hamm, MD, FACP
- 2006 Heine Murer, MD, and
Bernard Rossier, MD
- 2005 Roland C. Blantz, MD
- 2004 Gerhard H. Giebisch, MD
- 2003 William M. Bennett, MD
- 2002 Professor Carl Erik Mogensen
- 2001 Friedrich K. Port, MD, MS, FACP
- 2000 Tilman B. Drüeke, MD
- 1999 Shaul G. Massry, MD
- 1998 Alan R. Hull, MD
- 1997 Thomas F. Parker, III, MD
- 1996 Floyd C. Rector, MD
- 1995 Barry M. Brenner, MD
- 1994 Manuel Martinez-Maldonado, MD

The David M. Hume Memorial Award

The David M. Hume Award was created in memory of one of the National Kidney Foundation's most distinguished members. The Hume Award is the highest honor given to a distinguished scientist-clinician in the field of kidney and urologic diseases. It is bestowed upon an individual who exemplifies the high ideals of scholarship and humanitarianism in an outstanding manner. The 2014 award recipient is Friedrich K. Port, MD, MS, FACP.



DR. PORT is Senior Investigator at Arbor Research, Emeritus Professor of Medicine (Nephrology) and Epidemiology at the UM Schools of Medicine and Public Health, and former President of Arbor Research (2002–2009). Dr. Port

has recently served as PI for Scientific Registry of Transplant Recipients (SRTR), the Dialysis Outcomes and Practice Patterns Study (DOPPS), and several demonstration projects for the CMS. Dr. Port has over 30 years of experience in quantitative analyses of kidney disease patients. He served as the Deputy Director of the NIH-funded United States Renal Data System (USRDS) Coordinating Center from 1988 to 1999, and is the recipient of the highest awards from the American Society of Nephrology (Scribner Award), as well as the National Kidney Foundation (Seldin Award). He has authored/coauthored more than 400 scientific publications.

PAST RECIPIENTS

- 2013 Tomas Berl, MD
- 2012 Andrew S. Levey, MD, FNKF
- 2011 Jeremy R. Chapman, MD
- 2010 John Sedor, MD
- 2009 Brian J.G. Pereira, MD, MBA
- 2008 Lawrence Hunsicker, MD
- 2007 William G. Couser, MD
- 2006 Frank Delmonico, MD
- 2005 Roland C. Blantz, MD
- 2004 John Stewart Cameron, MD
- 2003 Franklin H. Epstein, MD
- 2002 Barry M. Brenner, MD
- 2001 William E. Mitch, MD
- 2000 [No Award]
- 1999 Neil A. Kurtzman, MD
- 1998 Jared J. Grantham, MD
- 1997 Thomas E. Andreoli, MD
- 1996 Edmund G. Lowrie, MD
- 1995 Joseph W. Eschbach, MD
- 1994 Wadi N. Suki, MD
- 1993 Joel D. Kopple, MD
- 1992 Saulo Klahr, MD
- 1991 Professor August Heidland
- 1990 Richard J. Glasscock, MD
- 1989 Professor Priscilla Kincaid-Smith
- 1988 Shaul G. Massry, MD
- 1987 Robert W. Schrier, MD
- 1986 Robert Heptinstall, MD
- 1985 Willem J. Jolff, MD
- 1984 Charles R. Kleeman, MD
- 1983 Robert W. Berliner, MD
- 1982 Professor Hugh E. de Wardener
- 1981 Donald W. Seldin, MD
- 1980 George E. Schreiner, MD
- 1979 John P. Merrill, MD
- 1978 Thomas E. Starzl, MD
- 1977 Henry L. Barnett, MD
- 1976 Carl W. Gottschalk, MD
- 1975 Belding Scribner, MD
- 1974 Robert M. Kark, MD
- 1973 Jean Hamburger, MD

The Garabed Eknoyan Award

The Garabed Eknoyan Award was created to recognize an individual who has promoted the mission of the National Kidney Foundation in Making Lives Better for people with kidney disease through exceptional contributions to key initiatives of NKF, such as the Kidney Disease Outcomes Quality Initiative (KDOQI®) or clinical research in the field of kidney disease. The 2014 award recipient is Katrin Uhlig, MD, MS.



KATRIN UHLIG is the Director, Guideline Development at the Tufts Center for Kidney Disease Guideline Development and Implementation, Boston, MA, Associate Professor of Medicine at Tufts University School of

Medicine, and a staff nephrologist at Tufts Medical Center. Dr. Uhlig completed her training in internal medicine, nephrology, and rheumatology in Germany (Aachen University Hospital and Munich University Hospital) and the USA (Georgetown University Medical Center and Tufts Medical Center). Since 2001, she has been participating in or directing the evidence review for KDOQI and KDIGO guidelines. As Director of Guideline Development, Dr. Uhlig has a substantial role in coordinating the ERT. She orchestrates and supervises the guideline development process and didactic curriculum that provides Work Group members with formal instruction on topics related to guideline development. As project director on individual guidelines, she directs and supervises the collection, evaluation, grading, and synthesis of evidence, and the drafting and revisions of the final evidence report. She provides methodological guidance and training to Work Group members at meetings regarding topic refinement, key question formulation, data extraction, study assessment, evidence grading, and recommendation formulation. She provides nephrology expertise in the interpretation and review of guideline recommendations and evidence reports. In this capacity, Dr. Uhlig possesses unique knowledge as a methods expert in evidence synthesis and critical literature appraisal in the domain of nephrology. In 2005, she co-chaired the KDIGO Evidence Rating Group to develop a consensus on grading of KDIGO guidelines and also co-chaired the KDIGO Consensus Conference on Guideline Methodology in October 2007. From 2006 to 2007, she served as Co-Editor of *American Journal of Kidney Diseases*. Her teaching and research focus includes evidence-based medicine, systematic review, clinical practice guideline development, and critical

literature appraisal. Dr Uhlig lectures on guideline topics and is a co-instructor of an annual course on meta-analysis in the Master of Science Program at the Sackler School of Graduate Biomedical Sciences at Tufts University.

PAST RECIPIENTS

- 2013 Michael V. Rocco, MD, MSCE, FACP, FNKF
- 2012 Bryan N. Becker, MD, MMM, FNKF
- 2011 Kai-Uwe Eckardt, MD
- 2010 Josef Coresh, MD
- 2009 Sharon M. Moe, MD
- 2008 Adeera Levin, MD, FRCP(C)
- 2007 Norbert H. Lameire, MD
- 2006 Francesco Locatelli, MD
- 2005 Nathan W. Levin, MD, FACP
- 2004 Neil R. Powe, MD, MPH, MBA
- 2003 Bertram L. Kasiske, MD
- 2002 Andrew S. Levey, MD

The J. Michael Lazarus Lecture

This lectureship was established to honor Dr. J. Michael Lazarus for his major contributions to the clinical science and care of dialysis patients, and to recognize individuals whose research has yielded novel insights related to renal replacement therapy. The 2014 award recipient is Claudio Ronco, MD.



PROFESSOR CLAUDIO

RONCO is currently Director of the Department of Nephrology and Transplantation at the International Renal Research Institute (IRRI), San Bortolo Hospital, Vicenza, Italy. He received his MD from

the University of Padua, Italy, in 1976 and then specialized in nephrology at the University of Padua and in pediatric nephrology at the University of Naples.

Professor Ronco has also held positions as an Assistant and Associate Professor at the Division of Nephrology in Vicenza, and Director of the Renal Laboratory of Research at the Renal Research Institute, and Professor of Medicine at the Albert Einstein College of Medicine and Beth Israel Medical Center of New York in 1999 and 2000.

He has co-authored 1147 papers, 70 books, and 86 book chapters, and has delivered more than 750 lectures at international meetings and universities. He is or has been a council member of several scientific societies. He is Editor Emeritus of the *International Journal of Artificial Organs*, Editor-in-Chief of *Blood Purification and Contributions to Nephrology*.

Professor Ronco has received numerous awards, including the Lifetime Achievement Award for Hemodialysis in 2005, an honorary membership from the Spanish Society of Nephrology in 2004, the National Kidney Foundation International Medal of Excellence, the ISN Bywaters Award for Acute Renal Failure in 2009, the 2010 Belding Scribner Award of the ISHD, the 2012 Lifetime Achievement Award for Peritoneal Dialysis, and the 2013 Dimitris Oreopoulos Memorial Award.

He is considered the pioneer in many areas of nephrology, including critical care nephrology, CRRT, cardiorenal syndromes, and wearable dialysis technology.

PAST RECIPIENTS

- 2013 Bradley A. Warady, MD, FNKF
- 2012 Jonathan Himmelfarb, MD
- 2011 John T. Daugirdas, MD

Joel D. Kopple Award

The Joel D. Kopple Award is an annual award honoring an individual who has made significant contributions to the field of renal nutrition. This year's Joel D. Kopple Award recipient is Juan Jesus Carrero, PharmD, PhD, MSc, MBA who will be giving a presentation on "Renal Nutrition and the Road Less Traveled" on Wednesday, April 23 at 4:00pm.



DR. CARRERO is Associate Professor in Renal Medicine at Karolinska Institutet (KI), Stockholm, Sweden. He holds a Master's Degree in Business and Administration (MBA), a PhD from the University of Granada (Spain) in Pharmacy/Nutrition, and a PhD from KI in Medicine.

His academic and research career are focused on nutrition and catabolism among patients with CKD, encompassing the malnutrition-inflammation syndrome, endocrine alterations, clinical monitoring of nutritional status as well as the study of dietary patterns and habits.

Dr. Carrero has authored more than 150 peer-reviewed publications and 15 book chapters, and is currently serving as a council member of the International Society of Renal Nutrition and Metabolism (ISRNM).

Dr. Carrero is the theme editor for *Nephrology, Dialysis and Transplantation (NDT)* and participates on the editorial boards of the *Journal of Renal Nutrition*, *Journal of Nephrology*, and *NDT Education*, where he also leads the Renal Nutrition blog. Since 2009, Dr. Carrero has organized the annual "Advanced Renal Nutrition Conference" at KI. He is a frequent invited speaker at international meetings and congresses worldwide.

PAST RECIPIENTS

- 2013 Jordi Goldstein-Fuchs, DSc, APN, RD
- 2012 Nathan W. Levin, MD, FACP
- 2011 T. Alp Ikizler, MD
- 2010 Laura Byham-Gray, PhD, RD
- 2009 Raymond Hakim, MD
- 2008 Alison Steiber, PhD, RD, LD
- 2007 Kamyar Kalantar-Zadeh, MD, PhD, MPH
- 2006 Mary Pat Kelly, MS, RD, GNP
- 2005 Jerrilynn D. Burrowes, PhD, RD
- 2004 Judith Beto, PhD, RD, FADA
- 2003 Linda M. McCann, RD, LD, CSR
- 2002 Linda Moore, RD, LDN



SCM14 INTERNATIONAL DISTINGUISHED MEDAL RECIPIENTS

The International Distinguished Medal was established in 1990 to honor the achievements of individuals who have made significant contributions to the field of kidney disease and extended the goals of the National Kidney Foundation. The Foundation President presents medals each year to recognize the accomplishments of individuals through their clinical work, roles in academia, scientific discoveries or volunteer work in organizations similar to the Foundation.

DANIEL C. CATTRAN, MD, FRCPC, FACP – CANADA



Dr. Cattran is currently a Professor of Medicine at the University of Toronto and a senior scientist at the Toronto General Research Institute. A graduate of the University of Toronto Medical School, his postgraduate training

was in both Toronto, Canada and Sydney, Australia.


Grant support for Dr. Cattran's research, mainly in the field of glomerular research, has come from the Kidney Foundation of Canada, PSI, the National Institutes of Health, and the Canadian Institutes for Health Research. He was the principle organizer, and remains the Chair, of the Toronto Glomerulonephritis Registry, which currently includes over 10,000 cases of biopsy proven GN. He has published over 200 articles in peer-review journals and more than 30 book chapters related to the natural history, outcomes and treatment studies in glomerulonephritis.

In recognition of his career in clinical investigation, the Kidney Foundation of Canada awarded him their Medal for Research Excellence in 2005. He was also the recipient of the Conrad Pirani award from Columbia University in 2008.

Dr. Cattran has served on the editorial boards of both the *American Journal of Kidney Diseases* and the *Journal of the American Society of Nephrology*, and is currently an associate editor for *Kidney International*. He is also on the editorial board of *Up-to-Date*, and is the author/co-author of several of their cards in glomerular disease.

In addition to holding a number of positions in the Canadian Society of Nephrology, including a term as president, Dr. Cattran has held a number of positions within the American Society of Nephrology, including two terms on the PGE Committee. He is currently a member of the Glomerular Disease Advisory Group.

DAVID JOHNSON, PHD, FRACP, MBBS – AUSTRALIA



David Johnson is Director of the Metro South and Ipswich Nephrology and Transplant Service (MINTS) and Medical Director of the Queensland Renal Transplant Service at Princess Alexandra Hospital, Brisbane,

Australia. He is also a Professor of Medicine and Professor of Population Health at the University of Queensland.

Dr. Johnson is the principal investigator on a number of large, multicenter, randomized controlled trials and is the chair of the Data Safety and Monitoring Board for the FINESSE trial. He is the author of more than 540 original manuscripts in peer-reviewed journals and has presented over 350 abstracts at national and international scientific meetings. He has won numerous research awards for his clinical and basic science studies in the areas of peritoneal dialysis outcomes, cardiovascular risk factor modification in uremia, renal transplantation, dialysis unit infection control, treatment of acute renal failure, and mechanisms of progressive chronic kidney disease. In 2005, Dr. Johnson was awarded the TJ Neale Award by the Australian and New Zealand Society of Nephrology for "outstanding contributions to nephrologic science." He was a Queensland finalist in the Australian of the Year Awards for 2009, and on Australia Day 2011, he was awarded a Public Service Medal by the Governor-General of Australia for outstanding public service.

In addition, Dr. Johnson serves as:

- Chair of the Queensland Statewide Renal Clinical Network
- Chair of the CARI Guidelines Working Parties on Peritoneal Dialysis Adequacy, Evaluation of Renal Function and Management of Early CKD
- Chair of the Kidney Check Australia Taskforce

- Co-Chair of the Australasian Creatinine and eGFR Consensus Working Party
- Co-Chair of the Australasian Proteinuria Consensus Working Party
- Founding Member and Deputy Chair of the Australasian Kidney Trials Network
- Founding Member of the NHMRC-endorsed Cardiovascular and Renal Centre of Clinical Research Excellence (CCRE)
- Member of the ANZDATA Registry Peritoneal Dialysis Working Group
- International Society of Peritoneal Dialysis Councillor
- International Society of Nephrology Councillor

PAUL E. STEVENS, MBBS, BSC, FRCP – UNITED KINGDOM



Paul Stevens trained in medicine at The London Hospital Medical College and he completed higher medical training in the Royal Air Force and at the Charing Cross Hospital in London. Dr. Stevens was appointed as Consultant

Physician and Nephrologist to the Royal Air Force in 1990. He returned to the NHS in April 1995 as Clinical Director of the Kent Kidney Care Centre, implementing a program of modernization and development, and establishing a predominantly clinical research program in kidney disease. A former President of the British Renal Society and a member of the Department of Health Renal Advisory Group, he also served on a number of national and college committees. His interest in guideline development began with commissioning guidance for the development of renal services and the UK CKD guideline. He has since served as clinical advisor on a number of the UK National Institute for Health and Care Excellence (NICE) Clinical Guidelines and was a member of the UK consensus panel for management of AKI. He is Chair of the NICE CKD Topic Expert Reference Group, chairs the current NICE CKD Guideline Update, and was privileged to have co-chaired the Kidney Disease Improving Global Outcomes (KDIGO) CKD guideline.

Dr. Stevens' research interests include the evaluation of kidney function, the variability of biochemical indicators of complications of kidney disease, the epidemiology of AKI and CKD (in particular the unmet need), and the development of information technology-based solutions for identification of kidney disease, both acute and chronic.

XUEQING YU, PHD, MBBS – CHINA



Professor Xueqing Yu is the Vice President of The First Affiliated Hospital of Sun Yat-sen University, Director of the Institute of Nephrology of Sun Yat-sen University, and Director of the Key Laboratory

of Nephrology, Ministry of Health. He is a COMGN member of the International Society of Nephrology, Director of the International Society of Peritoneal Dialysis, and Executive Director of the Asia-Pacific Society of Nephrology. Dr. Yu's major academic titles include the Council of State Academic Committee, President-elect of the Chinese Society of Nephrology, Chairman of the Chinese Nephrologists Association, Professor of the Changjiang Scholarship Program, and is on the Ministry of Education. He is also the deputy Editor-in-Chief of the *Chinese Journal of Nephrology*, Associate Editor of *American Journal Kidney Diseases*, and Subject Editor of *Nephrology*. To date, Professor Yu has committed 30 scientific research funds at all levels, including the National Science Fund for Distinguished Young Scholars of China and the National Natural Science Foundation of China (Key Program), among many others. He is the author of 269 publications, of which 96 papers are indexed by SCI, including papers published in *Nature Genetics*, *Lancet*, *JASN*, *KI*, and *AJKD*. He has issued 11 academic monographs, and is the editor-in-chief of four of them. He has also won seven awards for Provincial or Ministerial Science and Technology Achievements, including the Second Prize in the National Sci-Tech Advance Award.

PAST RECIPIENTS

2013

Ricardo Correa-Rotter, MD, Mexico
Simon Davies, MD, United Kingdom
Marcello Tonelli, MD, FRCPC, SM, Canada

2012

Jianghua Chen, MD, China
Raymond Krediet, MD, PhD, The Netherlands
Philip K.T. Li, MD, FRCP, FACP, FNKF, China
Peter Stenvinkel, MD, PhD, Sweden

2011

Nan Chen, MD, China
Angela D'Angelo, MD, Italy
Ron T. Gansevoort, MD, PhD, The Netherlands
David C. Wheeler, MD, FRCP, United Kingdom

2010

Jonathan Craig, MD, Westmead, Australia
Paul E. de Jong, MD, Groningen,
The Netherlands
Alison MacLeod, MD, Aberdeen, United Kingdom
Dimitrios Oreopoulos, MD, Toronto, ON, Canada

2009

Guillermo Garcia Garcia, MD,
Guadalajara, Mexico
Donal O'Donoghue, MD, Salford, England
Gregorio Obrador, MD, Mexico City, Mexico
Kim Solez, MD, Edmonton, AB, Canada

2008

Bernard Charra, MD, Tassin, France
Wendy Hoy, MD, Queensland, Australia
Michel Jadoul, MD, Bruxelles, Belgium
Yves Vanrenterghem, MD, PhD, Leuven, Belgium

2007

Mona Al-Rukhaimi, MD, Dubai, UAE
Dick de Zeeuw, MD, PhD, Groningen,
The Netherlands
Sayyid Ali Jaffer Naqvi, MD, Karachi, Pakistan
Susumu Takahashi, MD, PhD, Tokyo, Japan
Christoph Wanner, MD, Wurzburg, Germany

2006

Jorge Cannata-Andia, MD, Oviedo, Spain
Prakesh Keshaviah, MD, Dehradun
Uttaranchal, India
Gabriel Mircescu, MD, Bucharest, Romania
Yusuke Tsukamoto, MD, Tokyo, Japan
Haiyan Wang, MD, Beijing, China

2005

John Dirks, MD, Toronto, Ontario, Canada
Saraladevi Naicker, MD
Johannesburg, South Africa
Luis Revert, MD, Barcelona, Spain
Wu Chang Yang, MD, Taiwan, China

2004

Peter G. Blake, MB, FRCP, Toronto, ON, Canada
Kai-Uwe Eckardt, MD, Erlangen, Germany
S. Adibul Hasan Rizvi, MBBS, FRCS, FRCSE,
FCPS, FRCP, Karachi, Pakistan
Bernardo Rodriguez-Iturbe, MD,
Maracaibo, Venezuela
Claudio Ronco, MD, Vicenza, Italy

2003

Georgi Abraham, MD, Chennai, India
Shanyan Lin, MD, Shanghai, China
Nester Schor, MD, PhD, Sao Paolo, Brazil
Carmine Zoccali, MD, Reggio, Italy

2002

Gavin Becker, MD, Victoria, Australia
Francesco Locatelli, MD, Lecco, Italy
Sergio Mezzano, MD, Valdivia, Chile
Giuseppe Piccoli, MD, Torino, Italy
Wladyslaw Sulowica, MD, PhD, Krakow, Poland

2001

Elvira Emilia Arrizurieta, MD,
Buenos Aires, Argentina
Hans-Henrick Parving, MD, DMSC,
Copenhagen, Denmark
Yahya Sagliker, MD, Adana, Turkey
Fernando Valderrababo, MD, PhD, Madrid, Spain

2000

Vittorio Andreucci, MD, PhD, Naples, Italy
Norbert Lameire, MD, PhD, Ghent, Belgium
Florian Lang, MD, PhD, Tubingen, Germany

1999

Jonas Bergstrom, MD, PhD, Huddinge, Sweden
Walter H. Hörl, MD, PhD, Vienna, Austria
Vincenzo Savica, MD, Messina, Italy
Gianfranco Guarnieri, MD, Trieste, Italy

1998

Professor Rosario Maiorca, Brescia, Italy
John Walls, MD, Leicester, England
Shaul M. Shasha, MD, Nahariya, Israel
Professor Jean-Pierre Grunfeld, Paris, France

1997

Professor Guido Bellinghieri, Sicily, Italy
Professor Hirotooshi Morii, Osaka, Japan
Professor Momir H. Polenakovic,
Skopje, Macedonia
Professor Boleslaw Rutkowski, Gdansk, Poland

1996

Professor Judit Nagy, Pecs, Hungary
Professor Karel Opatrny, Pizen, Czech Republic
Miguel C. Riella, MD, Curitiba, Brazil

1995

Alexander P. Disney, MD, Adelaide, South Australia
David N. Kerr, MD, London, England
Andrzej Ksiazek, MD, Lublin, Poland
Guy Laurent, MD, Tassin, France
Maurice Slapak, MD, Hampshire, England

1994

Stefan Angielski, MD, Gdansk, Poland
Natale G. De Santo, MD, Naples, Italy
Professor Miroslaw Mydilk, Kosice, Slovak Republic

1993

Jamie Herrera-Acosta, MD, Mexico City, Mexico
Jose L. Rodicio, MD, Madrid, Spain
Professor Sandor, Sonkodi, Hungary
Visith Sitprija, MD, Bangkok, Thailand

1992

Professor Albert Valek, Czechoslovakia
Professor Mary G. McGeown, Ireland
Professor Ori Better, Haifa, Israel
Professor Rashad Barsoum, Cairo, Egypt
Professor Karl M. Koch, Hannover, Germany
M. Derome Tremblay, France

1991

Professor Nobuhiro Sugino, Tokyo, Japan
Professor K.S. Chugh, Mumbai, India
Professor Renee Habib, Paris, France
Professor Franciszek Kokot, Poland
Professor Sevrin Ringoir, Ghent, Belgium

1990

Professor Kazimierz Baczyk, Poznan, Poland
Professor Vittorio Bonomini, Bologna, Italy
Professor J. Stewart Cameron, London, England
T.T. Durai, MD, Singapore
Professor Henri Jahn, Strasbourg-Cedex, France
Professor Eberhard Ritz, Heidelberg, Germany

NKF PROFESSIONAL COUNCIL AWARDS

Council of Advanced Practitioners

Tim Poole Memorial Award:

Laurie E. Benton, PhD, PA-C, RN



This award was established in honor of Tim Poole, PAC, who passed away in 2008. Tim was an exceptional clinician and incredible human being who dedicated his life to the care and well-being of CKD patients and their families. The Tim Poole Memorial Award

is given to a CAP member who follows in Tim's footsteps and demonstrates the qualities that made him so outstanding.

Laurie E. Benton, PhD, PA-C, RN, began her career more than 30 years ago and her accomplishments and quest for knowledge have never slowed down. She is a Physician Assistant, a certified Emergency Medical Technician, a Registered Nurse, and a Major in the Texas National Guard. She holds an Associate's Degree in Nursing, and a Bachelor's Degree in Clinical Health Services from the University of Washington, where she also completed her PA training. She received a Master of Cardiothoracic Surgery Physician Assistant Degree from the University of Nebraska Medical Center, and recently completed requirements for a PhD in Health Administration from Kennedy Western/Warren National University of California. Dr. Benton currently works in the Nephrology/Hypertension/Internal Medicine Unit at Scott and White Memorial Hospital in Temple, TX.

To classify Dr. Benton as simply an academic is an error. In addition to her many academic accomplishments, she remains an achiever and a teacher. Together with Charles Foulks, MD, she has developed educational programs used first at Scott and White and later adapted for use in national nephrology organizations. Before the NKF Council of Advanced Practitioners was even a consideration, she was a driving force behind designing and offering programs specifically for advanced practitioners. It was largely through her enthusiasm and tenacity that the Council was formed, bringing together all nephrology advanced practitioners into one professional organization for the

first time. Under her leadership, NKF-CAP now offers a full program track at the NKF Spring Clinical Meetings. In addition, she has served on the American Association of Physician Assistants' CME Committee for three times longer than anyone else, further exemplifying her dedication to education and passion for program planning.

When she is not at work or tending her many animals (most of whom are rescue animals), Dr. Benton is giving back to the community. She volunteers at low-income clinics, organizes cooking demonstrations for nephrology patients and their families, teaches CPR and advanced life support, and continues to serve in the Texas National Guard.

Nostradamus Award: Ambrose Tsang, MD



A 16th century seer, Nostradamus has long been portrayed as someone who could see into the future. This award is given annually to an individual or organization that, through forethought and vision, recognizes and promotes the contributions of advanced practitioners in nephrology.

Through over 30 years of practice, **Dr. Ambrose Tsang** has exemplified leadership, mentorship, and advocacy. In 2012, he was the first MD to be sent to the Philippines by DaVita in their Bridge of Life Program to assist in forming an acute dialysis care system clinic and teach the local nephrologist and staff how to best provide care to their CKD and dialysis patients. He volunteers his time teaching students in a DO program to pique their interest in nephrology; for three years in a row he has been nominated by the students and awarded Professor of the Year.

Janett Delacruz, MSN, FNP-C, has worked with Dr. Tsang and attests that he fits the dictionary definition of mentor—"someone who teaches or gives help and advice to a less experienced and often younger person"—and then some. In her nomination, Ms. Delacruz describes how, through forethought and vision, Dr. Tsang recognizes and promotes the contributions of advanced practitioners. She states: "By recruiting me as his nurse practitioner, he was the first MD

in the DaVita Wild West Division to incorporate an NP into a nephrology practice. Since then, dozens of nephrologists have followed suit. From the very beginning, he has guided me in learning everything I can to better my craft. He has included me in decision making for numerous unit-specific protocols he's created or amended for dialysis units where he sits as Medical Director. He has also encouraged me to assist him in creating his lectures to the DO students he teaches and his dialysis in-services materials and plans. I agree with the old adage that younger generations truly learn by example. As a nephrologist, Dr. Tsang teaches me by example. He brings hard work, humor, and kindness to his combined roles as great teacher, smart advisor, caring and loving caregiver, patient advocate, and leader. It gives me great pleasure whenever I hear how our patients frequently comment that I sound just like him. Or, as one patient said, I am his 'mini-me', because imitation is the sincerest form of gratitude."

For the last 15 years, Dr. Tsang has also allowed Ms. Delacruz to function as his Sub-Investigator/Study Coordinator on more than 20 clinical trials where he was Principal Investigator. Dr. Tsang's enthusiasm for education and recognition of the NP role makes working in nephrology exciting and rewarding.

Council of Nephrology Social Workers

Robert W. Whitlock Lifetime Achievement Award: Stephanie Johnstone, LCSW



This award is named in honor of Robert W. Whitlock, MSSW, MHA, LCSW, Director of the Missouri Kidney Program (MoKP), a leader in the kidney community, who passed away in 2008. Bob was a dedicated nephrology social worker and an outstanding contributor

to research, teaching, and clinical practice in nephrology social work.

Stephanie Johnstone, LCSW, has been the Regional Lead Social Worker at Fresenius Medical Care North America (FMCNA) since October 1983. During her tenure, she developed innovative social work programs such as "Outcomes-Driven Nephrology Social Work Practice," "Patient-Provider Conflict Resolution," "Team-Oriented Problem Solving," "Project Professionalism," and "Staff

Continuing Education Series: Treating the Chronically Ill Patient." *Modern Healthcare* magazine presented Ms. Johnstone and FMCNA with the "Spirit of Excellence" Award in recognition of the company's innovative new social work program that she developed, which has increased patients' adherence to dialysis treatments by addressing quality of life issues. In addition to her work at FMCNA, she has been a research consultant on various projects including, "Evaluating the Impact of a Group Cognitive-Behavioral Intervention on Depression, Perceived Social Support, and QOL for Patients on Hemodialysis." She also designed a psycho-educational/behavioral intervention to enhance adherence, which was turned into the nationally released program, "Living Longer, Living Better."

Ms. Johnstone is active with NKF-CNSW, serving on the editorial board of the *Journal of Nephrology Social Work (JNSW)*, and as Chair of the San Diego CNSW Chapter. She is the co-developer of the NKF-CNSW "Outcomes Training Program," and has been honored twice nationally by CNSW for outstanding achievements. She has been published in *JNSW*, *Nephrology News and Issues*, and *Advances in Chronic Kidney Disease*. In addition, she has presented nationally on topics such as in depression in dialysis, quality of life, conflict management, outcomes improvement, and improving adherence.

It is clear that Ms. Johnstone's various programs, publications, and teachings have had a profound impact on the field of nephrology social work. What is even more impressive, however, is the impact her presence has had on those around her. She has inspired and mentored countless social workers, is very generous with her time, and makes herself available to discuss difficult cases and explore clinical options. What is singularly unique about Stephanie is her visionary thinking style. With the FMCNA Missed Treatment Initiative, she accomplished her life-long objective to empower nephrology social workers to use their clinical skills and training to improve patients' quality of life. Not only are thousands of patients suffering less, but thousands of nephrology social workers are achieving their professional potential and experiencing more satisfaction in their work lives.

Merit Award



Melissa Fry, MSW, CAPSW, NSW-C, is currently the Director of Social Services at Mile Bluff Medical Center in Mauston, WI. She is very active within the CNSW Wisconsin Chapter and served as its Chair from 2008 to 2012. During that time, she made

herself available to Chapter members for questions and support as they navigated the new Conditions for Coverage and incorporated them into their practices. After her term, she actively assisted other Chairs, and contributed to an update of the Chapter's New Worker Manual. She has been involved in professional education programs as part of the planning committees for both the NKF Spring Clinical Meetings and the NKF of Wisconsin Fall Symposium, facilitated roundtable sessions at Chapter meetings, and presented nationally on the topic of managing personality disorders in the dialysis unit. Ms. Fry takes an active role in providing education to patients, families, staff and other professionals. She identifies issues needing more attention and takes on leadership roles to address these concerns through research to further develop dialysis interdisciplinary teams' skill sets and improve quality of care for patients.

New Worker Award



Temima Danzig, MSW, LSW, has been a nephrology social worker for one and a half years, employed at DaVita St. Joseph's Hospital and Medical Center 2B Subacute and Getty Avenue Dialysis Centers. In this short time, she has fully acclimated to her role on the

interdisciplinary team, acting as a champion of transplant, CVC reduction, skilled nursing facilities' outreach efforts to promote the Fistula First initiative, and protection of the frail, elder population. She belongs to the New Jersey CNSW Chapter and has fully embraced, both personally and professionally, her scope of practice and the national mission of NKF-CNSW to promote the optimal adjustment and overall quality of life for kidney patients.

A keen student of human behavior and organizational construct, Ms. Danzig truly exemplifies the key roles of the nephrology social worker as liaison, patient champion, vested colleague, and communicator. In addition to all of her responsibilities as a full-time nephrology social

worker, Ms. Danzig has tirelessly given of herself to fellow colleagues and newer social workers in the field as a mentor and trainer. Her energy and brilliant assessment of skill levels and strengths supports colleagues and patients alike. She will continue to grow in this field, demonstrating leadership and keeping the nephrology social work profession strong and enduring.

New Worker Award



Ola Labisi, LCSW, found information from the CNSW membership listserv and the NKF website invaluable to her professional development as she navigated the field of nephrology social work over the past year and a half. To celebrate the 40th anniversary

of the NKF-CNSW, and in appreciation of the wealth of information and support she received, she submitted a flyer highlighting the accomplishments and strategic goals of CNSW. Her flyer was chosen to commemorate the anniversary and was showcased at the NKF 2013 Spring Clinical Meetings in Orlando, FL.

As an eager new worker, Ms. Labisi not only gained knowledge through her participation in NKF-CNSW, but also shared what she had learned to further educate members of the interdisciplinary team at her clinic. She created an in-service presentation emphasizing the importance of a team-based approach in the provision of clinical services to her patients, who are dealing with chronic illness. She also introduced her clinic staff to how current research on STI (Symptom Targeted Interventions) have scientifically shown an improvement in patient outcomes.

Regional Social Work Award – Region 1



Anita Kahan, MSW, LSW, represents five clinics as Area Lead Social Worker for Fresenius Medical Care (FMC) in New Jersey, and is also a PhD student. Due to her professional expertise, she has led area social work meetings and mentored new social workers,

providing support and guidance. She joined the Corporate Quarterly Social Work Publication Committee at its inception and is a frequent contributor. She has presented research posters at several Quality Insights Renal Network 3 Meetings. Ms. Kahan is a strong believer in using cognitive behavioral therapy to improve clinical outcomes. She also serves as Manager of the Treatment Options Program, where she has the opportunity to educate the community's pre-ESRD patients. Anita is currently one of two members of the FMC Social Work Advisory Board representing the North Division.

Among her successes, nothing has compared to the way Ms. Kahan stepped up during Superstorm Sandy in October 2012 when her Hoboken clinic was destroyed by flooding. All patients and staff were displaced for seven months while the clinic was being rebuilt. She was a "rock" for both patients and staff, even when she was without power in her own home for more than 10 days. While the storm was raging outside, she was present on conference calls to make sure her displaced patients would all be situated in neighborhood clinics and that transportation was set up so they did not miss even one dialysis treatment. By traveling to clinics where her patients had been scattered and reassigned, she made sure they were well cared for, providing stability and continuity of care during their time of crisis. Her advocacy abilities were apparent once she returned with her patients to the Hoboken clinic in 2013 and learned that some who were dependent on county transportation were in jeopardy of having their service discontinued. With determination and tenacity, she proceeded to help the patients write a petition, get signatures, and even contacted a local politician who was able to have their transportation resumed. Ms. Kahan is recognized by her social work peers for being consistently willing to go beyond the scope of her job, volunteering at every turn.

Regional Social Work Award – Region 5



Babitha Ramakrishna, LCSW, NSW-C, has proven herself a quiet leader since entering the nephrology subspecialty 10 years ago as a pre-licensed MSW. Stable, even-keeled, approachable, and soft-spoken, she addresses her duties and responsibilities as

a frontline social work practitioner and a social work supervisor with proficiency, consistency, and persistence to achieve high-quality outcomes. She has contributed to NKF-CNSW by participating on the member listserv, volunteering as a CEU Review Board member, and serving as part of the Greater Los Angeles CNSW Chapter leadership. Professionally, she provides supervision to pre-licensed MSWs, co-created a psychosocial assessment form which has been used as a template for several companies, presented at corporate social work meetings, and served on a panel as social work representative at a community CKD education event. Ms. Ramakrishna builds crucial, trusting relationships with each individual patient and staff member, and functions as an expert nephrology social work resource.

Council on Renal Nutrition

Outstanding Service Award



Karen Wiesen, MS, RD, LDN, received her Bachelor of Science in Nutrition from Pennsylvania State University and her Master of Science in Clinical Dietetics from St. Louis University. She has been a clinical dietitian for 34 years, and has over 25 years of experience as a renal dietitian.

Ms. Wiesen has served as a clinical preceptor for St. Louis University, Barnes Jewish Hospital and VA Hospital renal dietetic internships and was an adjunct clinical instructor and a guest faculty member in the graduate program at St. Louis University's Department of Nutrition and Dietetics. She has authored numerous articles, two book chapters, and was Co-Editor of the first and second editions of *A Clinical Guide to Nutrition Care in Kidney Disease*. She has spoken at local, regional, and national conferences on nutrition, addressing chronic kidney disease and home dialysis. In 2007, she received the NKF-CRN Recognized Renal Dietitian Award. She has served on the Executive Committee of NKF-CRN for 10 years in numerous positions, including *RenalLink* Editor, Region III Representative, Associate Chair, and Chair.

Karen is currently an inpatient dietitian coordinator at Geisinger Health System in Danville, PA, where she continues to mentor dietetic interns. She remains active in the renal community and is serving on the committee updating the "Standards of Practice and Standard of Professional Performance for Dietitians in Nephrology." In the realm of professional education programs, this marks her ninth year on the planning committee for the University of Missouri School of Medicine's Annual Dialysis Conference.

Susan C. Knapp Award for Excellence in Education



Katy Wilkens, MS, RD, believes the primary role of the renal dietitian is to teach. Whether through writing, speaking at events, educating peers and students, demonstrating healthy cooking techniques on television, developing patient education materials, or sitting down with one of

her hemodialysis patients, she finds it rewarding to offer information that can lead others to a healthier future.

Ms. Wilkens has worked in renal nutrition for over 35 years, and is currently the Nutrition and Fitness Services Manager of Northwest Kidney Centers in Seattle, WA. In addition to helping her patients navigate their dialysis diets, she mentors multiple dietetic students in yearly rotations at Northwest Kidney Centers, and educates fellow healthcare professionals, such as physicians, nurses, and social workers. She founded the Washington State CRN Chapter and the Northwest Renal Dietitians' Conference, helping renal dietitians across the region to learn and network. Ms. Wilkens is heavily involved in community outreach, assisting in planning the Northwest Kidney Centers' Kidney Health Fest for African-American Families each year, speaking at numerous community health events and nutrition and renal conferences, and discussing healthy nutrition on radio and television.

Ms. Wilkens is the author of the renal chapter in the internationally-recognized *Food, Nutrition, and Diet Therapy* textbook and of the original American Dietetic Association's "Suggested Guidelines for the Care of Renal Patients." She is the long-time Editor and author of a nutrition workbook for patients, "Nutrition: The Art of Good Eating for People on Dialysis." She writes regular nutrition columns for the *Ballard News-Tribune*, *AgeWise King County* (a senior services newsletter), and *Renal Business Today*.

Recognized Renal Dietitian



Cathy Goeddeke-Merickel, MS, RDN, LD, has a passion for “all things renal” that stems from her undergraduate studies during a clinical practicum at a dialysis center. She has many years of work experience as a renal dietitian, and was the first dietitian to be hired as Abbot Renal Care Regional Clinical Specialist, a position held only by RNs.

In addition to her professional roles, Ms. Goeddeke-Merickel has been involved both locally and nationally with NKF-CRN in numerous positions. She is currently the *Journal of Renal Nutrition* Feature Editor for Patient Education, an NKF KLS CPE Clinical Reviewer, CRN Publications Co-Chair, and a member and contributor to the CRN-RPG project workgroup to update and revise the “Standards of Practice and Standard of Professional Performance for Dietitians in Nephrology.” She has served as CRN Program Chair for the annual NKF Spring Clinical Meetings, and as CRN Region Representative for two different regions! Ms. Goeddeke-Merickel’s contributions to the field and involvement in leadership roles show she is truly most deserving of this year’s honor as Recognized Renal Dietitian.

Recognized Regional Renal Dietitian – Region 2



Christine Swafford, MS, RDN, CSR, LD, quickly realized while completing her internship that her passion lay in the field of renal nutrition. After gaining experience during a brief stint in clinical nutrition, she found her dream job working for a large

dialysis provider in a typically low-income, underserved area of South Atlanta. To her, this was the perfect setting and provided the challenge she was looking for early in her renal career. She truly blossomed in this position, working with teams in nine dialysis facilities around the Metro Atlanta area, ultimately touching the lives of over 550 patients. Her many roles as a renal dietitian include precepting dietetic interns, conducting nutrition research, and being a regional point dietitian for DaVita. Ms. Swafford has also been involved with the Georgia CRN Chapter (GCRN), leading charitable events it sponsors. She is currently the GCRN Treasurer, newsletter editor, and liaison for the Georgia Academy of Nutrition and Dietetics.

Her recent contributions have earned her a promotion to Facility Manager, where she enters into the operational realm of dialysis.

Recognized Regional Renal Dietitian – Region 3



Connie Yost, RD, CD, has 22 years of experience working with hemodialysis patients and, in the past, peritoneal dialysis patients. She has been involved with bone management, Quality Assessment Performance Improvement (QAPI), development

of the “Protein Pass Program,” development of patient nutrition contests and monthly patient nutrition bulletin boards, and has participated in the development of electronic medical record patient care plans. She has also been a preceptor for University of Wisconsin-Green Bay dietetic interns. Ms. Yost’s community and professional involvement as a renal dietitian is commendable. Her community experience includes facilitating an education program with the NKF of Wisconsin, entitled “Learning About Chronic Kidney Disease,” and volunteering for the NKF of Wisconsin Kidney Screenings at the local YWCA. Her professional activities include membership in the Wisconsin CRN Chapter, serving as Secretary, and membership in the Academy of Nutrition and Dietetics (AND) and the AND-Renal Practice Group (RPG).

The National Kidney Foundation gratefully acknowledges the support of the following organizations that helped make the NKF 2014 Spring Clinical Meetings possible:



CORPORATE SUPPORTED SYMPOSIA

AMAG Pharmaceuticals, Inc.

American Regent

Amgen

Fresenius Medical Care

Hospira, Inc.

Keryx Biopharmaceuticals, Inc.

Otsuka America Pharmaceutical, Inc.

Sanofi Renal

Takeda Pharmaceuticals

ZS Pharma, Inc.

GENERAL CONTRIBUTORS

Conference Materials, Events, and General Support

Amgen

Fresenius Medical Care

Genentech and Biogen Idec

Keryx Biopharmaceuticals, Inc.

Pfizer

Questcor Pharmaceuticals, Inc.

Spectra Laboratories



National
Kidney
Foundation™

GENERAL INFORMATION

Meeting Objectives

At the conclusion of this activity, participants will be able to:

- Identify recent changes in healthcare policy and advances in clinical and translational research, and discuss how these may impact the care of patients with kidney disease
- Integrate new discoveries in dialysis and non-dialysis chronic kidney disease, transplantation, hypertension, and general nephrology into clinical practice for improved care of patients with kidney disease
- Enhance skills of the interprofessional team to improve care of patients with kidney disease

Target Audience

- Physicians
- Physician Assistants
- Dialysis Technicians
- Pharmacists
- Nurse Practitioners
- Dietitians
- Fellows & Residents
- Nurses
- Social Workers

NKF's Expectation of Presenters

Through the National Kidney Foundation Spring Clinical Meetings and continuing education programs, NKF promotes excellence in kidney healthcare education. NKF expects that all presenters affiliated with the NKF 2014 Spring Clinical Meetings will provide informative and fully accurate content that reflects the highest level of scientific rigor and integrity.

ADA Compliance

NKF makes every effort to comply with the Americans with Disabilities Act. For assistance, please contact us at clinicalmeetings@kidney.org.

Criteria for Successful Completion

Criteria for successful completion includes attendance at one or more sessions, which will be verified by scanning of attendee badges at each pre-conference and general program session. Partial credits/contact hours will be awarded based on number of sessions attended.

Note to U.S. Physicians

To ensure compliance with the Physician Payment Sunshine Act, the NKF reserves the right to provide information to appropriate funding entities about U.S. physicians who participate in specific SCM14-related activities.

How to Obtain CME/CE Credit

NKF has established an online system for tracking your CME/CE credits. With an easy scan of a badge, attendance at sessions will be automatically recorded! CME and CE credit information will be uploaded to a website for easy viewing after the conference. You will be able to print a certificate of attendance at your own convenience and without any hassle. Access this system conveniently by visiting www.expobadge.com/certification/nkf2014.

The online service is available through August 30, 2014. Pharmacists please note specific instructions on page 69.

NKF REGISTRATION, TICKET SALES, AND INFORMATION

Location: Level 1, MGM Convention Center

Registration Hours are:

- Monday 3:00pm – 8:00pm
- Tuesday 6:30am – 6:00pm
- Wednesday 5:30am – 6:00pm
- Thursday 7:00am – 5:00pm
- Friday 7:00am – 5:00pm
- Saturday 7:00am – 2:00pm (*information only*)

Tickets for programs requiring separate registration and/or a separate fee are available at the Ticket Sales Booth in the Registration Area. Staff members are available at the Meeting Information Booth to answer any questions you may have.

Poster Presentations

Over 400 abstracts will be presented as poster presentations. Take advantage of this outstanding opportunity to share in the authors' research experience and discuss significant areas of development in the ever-evolving field of kidney disease. The 2014 posters are available for viewing in the Exhibit Hall beginning on **Wednesday, April 23, at 6:00pm** through **Friday, April 25, until 11:30am**.

Exhibit Hall Information

Exhibits and posters are located in the Marquee Ballroom of the MGM Grand. Exhibitors are a vital part of the NKF Spring Clinical Meetings. The NKF thanks our exhibitors for their continued support of our educational programs, and cordially invites attendees to the following receptions:

- **Wednesday, April 23**, for the Exhibit Hall Opening Reception which will be held at 6:00pm in the Exhibit Hall. Posters will also be on display with authors present. Top poster presenters announced!
- **Thursday, April 24**, for a Networking Reception held in the Exhibit Hall from 6:00pm to 7:30pm. Meet colleagues for cocktails and hors d'oeuvres in a relaxed atmosphere before you attend one of the dinner symposia.

Badges

Please wear your registration badge for admission to all sessions and activities. There is a \$10 replacement fee for lost badges.

SCM14 Evaluations – *Your Feedback Really Matters*

Session evaluations are available electronically through the SCM14 Mobile App or via the SCM14 website. To access a session evaluation, select the session on your mobile app or desktop, and click the evaluation link listed below the session information.

The planning and execution of useful and sound continuing education programs are largely guided by input provided by program participants—such as you. Your responses will help ensure that future programs are informative and meet your educational needs. Please take a few minutes to let us know what you think.

2014 Poster Presentation and Exhibit Hall Activities

WEDNESDAY, APRIL 23

TIME	SESSION
6:00pm – 7:30pm	OPENING CEREMONIES AND FACULTY RECEPTION – POSTER AUTHORS AVAILABLE FOR Q&A

THURSDAY, APRIL 24

TIME	SESSION
7:00am – 8:00am	CONTINENTAL BREAKFAST – VISIT POSTERS/EXHIBITS
12:00pm – 2:00pm	LUNCH 12:15PM – 1:15PM – VISIT POSTERS/EXHIBITS
6:00pm – 7:30pm	NETWORKING RECEPTION – VISIT POSTERS/EXHIBITS

FRIDAY, APRIL 25

TIME	SESSION
8:00am – 11:30am	CONTINENTAL BREAKFAST SERVED 8:00AM – 9:00AM – VISIT POSTERS/EXHIBITS
11:30am	EXHIBIT HALL CLOSES

A maximum of 1.0 CME/CE credit only will be awarded for poster sessions.

National Young Investigator's Forum

Tuesday, April 22

The National Kidney Foundation is pleased to host the 9th National Young Investigators Forum chaired by Donald Kohan, MD, and Katherine Tuttle, MD. Participants include the winners of the four regional Young Investigators Forums held in the first quarter of 2014, as well as those from the 2013 Forums. Presenters will compete in the Clinical Research or Basic Science categories. A panel of faculty judges will select the award winners in each category.

Participation is by invitation only.

NKF gratefully acknowledges the support of Amgen who has made this program possible.

Daily Clinicals E-Newsletter

Look for the Daily Clinicals in your email each day for the latest news, information, and much more on SCM14.

Membership Questions?

NKF professional membership provides numerous benefits for physicians, pharmacists, advanced practitioners, nurses, technicians, dietitians, and social workers. Stop by the NKF Booth located in the Exhibit Hall to learn more about how to become an NKF member.

Fellows Event:

*Career Choices in Nephrology/Fellows Reception
Held in association with Women in Nephrology*

Tuesday, April 22, 6:30pm – 8:00pm

Moderator: Sylvia E. Rosas, MD, MSCE, FNKF

PANELISTS:

Alfred Cheung, MD, FNKF

Michael Choi, MD, FNKF

J. Brian Copley, MD

Ajay Israni, MD

Rajnish Mehrotra, MBBS, MD, FNKF

Michal Melamed, MD, MHS, FNKF

Beth Piraino, MD, FNKF

Francesca, Tentori, MD

Career Choices in Nephrology is a special session perfect for trainees in internal medicine and nephrology (of all genders) who are trying to decide what career path to choose in nephrology. In a friendly and fun "speed networking/mentoring" environment, meet a range of experienced individuals currently active in private practice, academic medicine, and industry. Learn why these individuals decided on their career paths, their backgrounds, what they did to secure their jobs, and if (and how) they would do it again if they were starting over. There will be time for questions and answers, followed by a beer/wine reception. Come join us to learn how others made career decisions and to meet your colleagues and the SCM14 faculty.

The Learning Continues

Recordings

Most sessions will be recorded*. Mp3s will be available following the meeting. Please check the SCM14 website for additional information.

**Speaker permission must be granted in order to tape a session or a particular speaker.*

Faculty Slide Presentations

Final slide presentations* are available on the SCM14 Mobile App as well as the NKF website.

**Presentations available with faculty permission only.*

Questions? Comments?
Write on our wall or tweet using

#NKFCLINICALS



Follow us for conference news, updates, and reminders.

SPOTLIGHT ON OUR SUPPORTERS

The National Kidney Foundation gratefully acknowledges those Corporate Supporters who have helped the Foundation further its mission of preventing kidney and urinary tract diseases, improving the health and well-being of individuals and families affected by these diseases, and increasing the availability of all organs for transplantation through our programmatic efforts.

The NKF wishes to recognize and thank the following Corporate Supporters:

AbbVie	Embassy of the United Arab Emirates	Nestle Health Science
Affymax, Inc.	Fresenius	Nipro Medical Corporation
Alexion Pharmaceuticals, Inc.	Gambro	Novartis
American Access Care	Genentech	Novo Nordisk
Amgen	General Motors Corporation	NxStage Medical, Inc.
Astellas Pharmaceuticals	Genzyme	Pentech Health
Bohringer-Ingelheim USA	Hemosphere	Pfizer
Bristol-Myers Squibb	Keryx Biopharmaceuticals	Questcor
ChemoCentryx, Inc.	Lilly	Reata Pharmaceuticals
CM&D Pharma	Merck	Sanofi
Covidien	Mitsubishi Tanabe Pharma	Satellite Healthcare, Inc.
Cranberry Marketing Committee	Musculoskeletal Transplant Foundation	Shire Pharmaceuticals
DaVita	Nephroceuticals	Takeda Pharmaceuticals
Daiichi Sankyo	NephroPath	Teva Pharmaceuticals
		Vifor International, Inc.



CORPORATE SUPPORTED SYMPOSIA BREAKFAST, LUNCH, AND DINNER SYMPOSIA

WEDNESDAY, APRIL 23

6:00am – 7:45am

CLINICAL ASPECTS OF FIBROBLAST GROWTH FACTOR 23 IN CHRONIC KIDNEY DISEASE

Supported by an educational donation provided by Amgen

6:00am – 7:45am

HIGH-DOSE IRON: TAKING TREATMENT OF IRON DEFICIENCY ANEMIA TO A NEW LEVEL

Supported by an educational grant from AMAG Pharmaceuticals, Inc. and American Regent, Inc.

12:00pm – 2:00pm

REVISITING PHOSPHATE MANAGEMENT IN CHRONIC KIDNEY DISEASE

Supported by an educational grant from Fresenius Medical Care

7:30pm – 9:30pm

HEART-KIDNEY INTERACTION AND THE ROLE OF VASOPRESSIN AND HYPONATREMIA IN HEART FAILURE

Supported by an educational grant from Otsuka America Pharmaceutical, Inc.

7:30pm – 9:30pm

PERSISTENT HYPERURICEMIA: A MULTI-PRONGED APPROACH TO THE MANAGEMENT OF SERUM URATE LEVELS

Supported by an educational grant from Takeda Pharmaceuticals North America, Inc.

THURSDAY, APRIL 24

6:00am – 7:45am

CHANGING PROFILE OF CHRONIC HYPERKALEMIA

Supported by an educational grant from ZS Pharma, Inc.

6:00am – 7:45am

THE ROLE OF BIOSIMILARS IN CHRONIC KIDNEY DISEASE

Supported by an educational grant from Hospira, Inc.

7:30pm – 9:30pm

NEW INSIGHTS INTO THE ROLE OF PHOSPHORUS BALANCE IN CHRONIC KIDNEY DISEASE

Supported by an educational grant from Keryx Biopharmaceuticals, Inc.

FRIDAY, APRIL 25

6:00am – 7:45am

EXPERT PERSPECTIVES IN THE MANAGEMENT OF BONE-MINERAL-VASCULAR DISORDERS: A PATHOPHYSIOLOGICAL AND EVIDENCE-BASED APPROACH TO CARE

Supported by an educational grant from Sanofi Renal

DISCLOSURES OF COMMERCIAL RELATIONSHIPS

It is the policy of the National Kidney Foundation (NKF) to ensure balance, independence, objectivity, and scientific rigor in all CME/CE activities. Any individual who has control over CME/CE content is required to disclose to learners any relevant financial relationship(s) they or their family members may have with commercial interests supporting this activity or whose products or devices are discussed in this activity. If, on the basis of information disclosed, a conflict exists, resolution will be achieved based on established policy by the NKF. Accredited status does not imply endorsement by the NKF or ANCC of any commercial products displayed in conjunction with this activity.

During their presentations, faculty may discuss an unlabeled use or an investigational use not approved for a commercial product. Each faculty member is required to disclose this information to the audience when referring to an unlabeled or investigational use.

The faculty and National Kidney Foundation do not recommend the use of any pharmaceutical, diagnostic test, or device outside of the labeled indications as approved by the FDA. Please refer to the official prescribing information for each product for approved indications, contraindications, and warnings.

Information presented in this National Kidney Foundation (NKF) educational activity is based upon current data available at the time of presentation. The information is intended to help clinicians become aware of new scientific findings and developments. This NKF educational activity is not intended to set out a preferred standard of care and should not be construed as one. Neither should the information be interpreted as prescribing an exclusive course of management. Variations in practice will inevitably and appropriately occur when clinicians take into account the needs of individual patients, available resources, and limitations unique to an institution or type of practice. Every healthcare professional making use of information in this NKF educational activity is responsible for interpreting the data as it pertains to clinical decision making in each individual patient.

During their presentations, faculty may discuss an unlabeled use or an investigational use not approved for a commercial product. Each faculty member is required to disclose this information to the audience when referring to an unlabeled or investigational use.

Individuals who have nothing to disclose are listed with no information next to their name. Meeting participants may also refer to the Session Chair introductory remarks for each session for disclosure information and discussion of off-label or unapproved usages of a product.

Suhail Ahmad

Kim Alleman

Michael Allon

Consultant/Scientific Advisor: CorMedix

Felipe Amaya

Gerald Appel

Significant Financial Interest: Pfizer,

UpToDate Royalty

Spouse Stock: Merck & Co.

Grant/Research Support: Alexion, NIH,

Questcor, Teva

Consultant/Scientific Advisor: Alexion,

Takeda, Merck & Co., Pfizer, Bristol-Myers

Squibb, Abbott, Novartis, Astellas, Teva,

Genentech, Onyx, Amgen, Merck & Co.,

Senomo

Speaker's Bureau: Takeda, Genentech

Cristina Arce

Carolyn Atkins

George Bakris

Grant/Research Support: Takeda

Speaker's Bureau: Takeda, AbbVie,

Daichi-Sankyo, Janssen, Medtronic, CVRx,

Relypsa

James Balow

Joanne Bargman

Grant/Research Support:

Baxter Extramural Grants

Speaker's Bureau: DaVita Healthcare

Partners, Baxter International Inc., Amgen

Deborah Barnett

Cathy Wilson Bates

Lynn Beaulieu

Marie Becker

Jeffrey Berns
Judith Beto
Consultant/Scientific Advisor: Amgen
Speaker's Bureau: Amgen
Cynthia Bhola
Gurjeet Birdee
Geoffrey Block
Significant Financial Interest: Ardelyx
Grant/Research Support: Amgen
Consultant/Scientific Advisor: Amgen, Keryx, Shield
Officer, Director or Holder of More: DaVita
Carl Boethel
Steve Bogatz
Debbie Brady
Teri Browne
Jennifer Bruns
Susan Busch
Karyn Buxman
Mary Beth Callahan
Juan Jesus Carrero
Daniel Cattran
Kerri Cavanaugh
Christopher Chan
Tara Chang
David Cherney
Grant/Research Support: Boehringer-Ingelheim
Consultant/Scientific Advisor: Astellas, Janssen
Speaker's Bureau: Boehringer-Ingelheim
Alexis Chettiar
Alfred Cheung
Christine Chmielewski
Michael Choi
Consultant/Scientific Advisor: Glaxo Smith Kline, Sanofi
Benjamin Chung
Louise Clement
Steven Coca
Carolyn Cochran
Debbie Cohen
Denise Collins
Deborah Collinsworth
Danilo Concepcion
Della Connor
Josef Coresh
Deborah Cote
Daniel Coyne
Consultant/Scientific Advisor: Abbott Laboratories
Speaker's Bureau: Abbott Laboratories

Deidra Crews
Michael Cronyn
Kristine D'Angelo David
Full/Part-Time Employment: Sigma-Tau Pharmaceuticals
Connie Davis
Jane Davis
Kim Deaver
Andrea DeKam
Sheila Deziel
Full/Part-Time Employment: Fresenius Renal Technologies
Rita Dimmitt
Full/Part-Time Employment: Fresenius, B. Braun
Anne Diroll
Significant Financial Interest: Keryx, Xoma
Full/Part-Time Employment: Fresenius Medical Care - North America
John Duncan
Michael Emmett
Consultant/Scientific Advisor: ZS Pharma
Wendy Escobedo
Elizabeth Evans
Harvey Feldman
Fernando Fervenza
Grant/Research Support: Genentech, Inc., Biogen Idec, Questcor Pharmaceuticals, Genzyme
Kristen Fischer
Rachel Fissell
Significant Financial Interest: Silicon Kidney LLC
Officer, Director or Holder of More: Silicon Kidney LLC
Agnes Fogo
Charles Foulks
Linda Fried
Melissa Fry
Kathleen Hill Gallant
Paul Gasser
Jennifer Geiger
Sean George
Bina George-Figueroa
Debbie Gipson
Grant/Research Support: NIH, PCORI
Consultant/Scientific Advisor: GSK
Jeff Giullian
Speaker's Bureau: Otsuka, Genentech

Richard Glassock
Significant Financial Interest: Oxford Medical Publishers, Reata, La Jolla Pharm
Consultant/Scientific Advisor: Bristol-Myers Squibb, Eli Lilly, Chemocentrix, Novartis, QuestCor, Vifor, BioMarin, Gilead Sciences, Sanofi-Genzyme, Mayo Clinic, NIH, LightHouse Learning
Speaker's Bureau: Genentech
Full/Part-Time Employment: UpToDate Stipend, Karger (American Journal of Nephrology)
Jess Goldman Foug
Janelle Gonyea
David Goodkin
Significant Financial Interest: Xenon, Cembra Pharmaceuticals
Consultant/Scientific Advisor: Alnylam, AlloCure, Anaptys, Arbor Collaborative for Health (DOPPS), Baxter International Inc., ChemoCentryx, FibroGen, Isis, Pieris, Xenon
Paula Goodman Crews
John Gowan
Tracy Greene-Mintz
Darlene Griffin
Margarita Gurri
Kim Gusse
Lisa Gutekunst
Full/Part-Time Employment: DaVita
Orlando Gutierrez
Raymond Hakim
Kevin Hall
Lisa Hall
Joni Hansson
Full/Part-Time Employment: Pfizer
Rebecca Hays
Significant Financial Interest: Canada Society for Transplant, American Kidney Fund
Speaker's Bureau: Canada Society for Transplant, American Kidney Fund
Connie Jo Hemeyer
Michael Heung
Michelle Hladunewich
Lynn Hornick
Donald Hricik
Hassan Ibrahim
Tamara Isakova
Ajay Israni
Consultant/Scientific Advisor: Astellas
Aimee Jarenowicz
Jeff Jin
Kirsten Johansen

David Johnson

Significant Financial Interest: Baxter International Inc., Fresenius

Grant/Research Support: Baxter Extramural, Fresenius (balANZ)

Consultant/Scientific Advisor: Baxter International Inc., Fresenius

Speaker's Bureau: Baxter International Inc., Fresenius, Amgen, Merck & Co. Sharpe & Dohme, Boehringer-Ingelheim

Sharon Johnson

Stephanie Johnstone

Graham Jones

Jessica Joseph

Peter Juergensen

Speaker's Bureau: Amgen, Sanofi

Kamyar Kalantar-Zadeh

Grant/Research Support: NIH

Consultant/Scientific Advisor: Amgen, Abbott, Fresenius, DaVita, Genzyme, Shire, Otsuka

Speaker's Bureau: Otsuka, Amgen

Kamel Kamel

Alex Karmazsin

Ellie Kelepouris

Grant/Research Support: NEPTUNE

Consultant/Scientific Advisor: Questcor Pharmaceuticals

Lois Kelley

Steve Kelley

Bryan Kestenbaum

Alan Kliger

Consultant/Scientific Advisor: NxStage

Jeffrey Kopp

Csaba Kovesdy

Significant Financial Interest: UpToDate Royalty

Grant/Research Support: Shire

Consultant/Scientific Advisor: Amgen

Holly Kramer

Louis Kuritzky

Jane Kwatcher

Barbara Landreth

Philip Lavin

Consultant/Scientific Advisor: ZS Pharma

Grant/Research Support: ZS Pharma

Timmy Lee

Nelson Leung

Edward Li

Consultant/Scientific Advisor: Amgen, Hospira

Anne Marie Liles

Timothy Lineberry

Denise Link

Eileen Lischer

Francesco Locatelli

Robert Lockridge

Consultant/Scientific Advisor: Fresenius Medical Care

Speaker's Bureau: NxStage

Charmaine Lok

Claudia Lora

Joy Lutz

Speaker's Bureau: Renal Therapies Group, a division of Fresenius Medical Care – North America

Stephanie Mahooty

Barbara Weis Malone

Melinda Martin-Lester

Nancy Mason

Linda McCann

Speaker's Bureau: Amgen, Sanofi

Maureen McCarthy

Jennifer McClain

Peter McCullough

Janie McDaniel

Deb McGrath

Diane McRae

Rajnish Mehrotra

Grant/Research Support: DaVita

Consultant/Scientific Advisor: Johnson & Johnson

Speaker's Bureau: DaVita, Baxter International Inc.

Michal Melamed

Joseph Merighi

Miriam Michael

Officer, Director or Holder of More: American Renal Associates

John Middleton

Louise Moist

Carol Moore

Eileen Moore

Significant Financial Interest: Pentec Health, Inc.

Full/Part-Time Employment: Pentec Health, Inc.

Alvin Moss

Stuart Mott

Patrick Nachman

Andrew Narva

Cynthia Nast

Danielle Nathan

Mark Neumann

Kenneth Newell

Duc Nguyen

Bobby Nibhanupudy

Significant Financial Interest: Pfizer, Gilead

Consultant/Scientific Advisor: Biologic Tx

Sagar Nigwekar

John Nilsson

Douglas Norman

Akinlolu Ojo

Matthew Oliver

Significant Financial Interest: Oliver Medical Management Inc.

Patricia Painter

Grant/Research Support: Baxter International Inc.

Consultant/Scientific Advisor: Amgen

Chirag Parikh

Jessie Pavlinac

Glenda Payne

Leanne Peace

Bill Peckham

Aldo Peixoto

Carmen Peralta

Mark Perazella

Angella Perez

Cintia Perez

Ronald Perrone

Grant/Research Support: Otsuka

Consultant/Scientific Advisor: Otsuka, Vertex, Sanofi-Genzyme, Kluwers Wolte

Glen Peterson

Gary Petingola

Jessica Phipps

Nicole Pinkerton

Beth Piraino

Alan Platt

Tina Podymow

Lynn Poole

Friedrich Port

Michael Powe

Megan Prescott

Officer, Director or Holder of More: Highlands Coach

Melissa Prest

Lynn Puma

Wajeh Qunibi

Grant/Research Support: ZS Pharma

Consultant/Scientific Advisor: American Regent

American Regent

Speaker's Bureau: American Regent

Erma Rainey
Ken Renel
Dena Rifkin
Janice Ritchie
Dana Rizk
Claudio Ronco
Consultant/Scientific Advisor: Alere Astute GE, ASAHI, Toray
Irene Rosario
Sylvia E. Rosas
Brad Rovin
Elanderia Rowe
Andrew Rule
Mary Rzeszut
George Saab
Officer, Director or Holder of More: Fresenius Medical Care
William Salzer
Milagros Samaniego
Grant/Research Support: Alexion Pharmaceuticals
Consultant/Scientific Advisor: Sanofi, Thermo-Fisher Corporation
Speaker's Bureau: Alexion Pharmaceuticals
Matt Sampson
Mark Sarnak
Heidi Schaefer
Jane Schell
Brigitte Schiller
Consultant/Scientific Advisor: ZS Pharma
Speaker's Bureau: Takeda
Full/Part-Time Employment: Satellite Healthcare, DaVita (spouse)
Kathy Schiro-Harvey
Sanjeev Sethi
Amma Sewaah-Bonsu
Beth Shanaman
Stuart Shankland
Fuad Shihab
Anushree Shirali
Allison Shukraft
Vernon Silva
Jerry Simons
Bhupinder Singh
Rachel Skumanich
Lonnie Smith
Alexis Snead
Sandeep Soman
Bruce Spinowitz
Grant/Research Support: Vifor, Akebia, Bayer, OPKO, Rockwell

Stuart Sprague
Grant/Research Support: OPKO/Cytochroma, Amgen, Vifor, Deltanoid
Wendy St. Peter
Robert Stanton
Consultant/Scientific Advisor: Boehringer-Ingelheim Global Renal Advisory Board
Paul Stevens
Kristin Stockard
Matt Stricherz
Mary Sundell
Duane Sunwold
Paul Szczybor
Manjula Kurella Tamura
Speaker's Bureau: Satellite Healthcare
Francesca Tentori
Robert Terkeltaub
Consultant: Takeda, AZ, Novartis, Pfizer, Regeneron, Relbum, Sobi, BioCryst, Savient
Kirsten Thompson
Robert Toto
Grant/Research Support: Novartis, Reata
Speaker's Bureau: Amgen, Merck & Co.
Raymond Townsend
Mandy Trolinger
Lara Tushla
Katherine Tuttle
Consultant/Scientific Advisor: Eli Lilly and Company
James Udelson
Grant/Research Support: Otsuka
Katrin Uhlig
Mark Unruh
Tushar Vachharajani
Consultant/Scientific Advisor: Fistula First Breakthrough Initiative, American Society of Nephrology, ISN, ASDIN
James Van Rhee
Joseph Vassalotti
Consultant/Scientific Advisor: Gore Creative Technologies, Inc., Baxter International Inc., Janssen Pharmaceuticals, Inc.
Joseph Verbalis
Grant/Research Support: Otsuka Pharma U.S.
Consultant/Scientific Advisor: Cardiokine, Ferring, Otsuka Pharma U.S., Ferring
Speaker's Bureau: Otsuka Europe

Flavio Vincenti
Grant/Research Support: Bristol Myers Squibb, Astellas, Novartis, Genentech, Alexion, Pfizer, Sanofi
Bradley Warady
Grant/Research Support: Baxter International Inc.
Consultant/Scientific Advisor: Amgen, Genzyme, GSK
Sarah Washburn
Daniel Weiner
Matthew Weir
Consultant/Scientific Advisor: Relypsa, Bristol-Myers Squibb, Lexicon, Otsuka, Keryx, Abbvie, Amgen, Sandoz, Janssen
Steven Weisbord
Catherine Wells
Adam Whaley-Connell
Karen Wiesen
Aaron Wightman
Helen Williams
Katy Wilkens
Rebecca Wingard
Wolfgang Winkelmayr
Consultant/Scientific Advisor: Acumen, Amgen, Bayer, GlaxoSmithKline, Keryx, Medtronic, Medgenics
Jay Wish
Beth Witten
Monica Wofford
Myles Wolf
Grant/Research Support: Amgen
Consultant/Scientific Advisor: Kai, Luitpold, Shire, Diasorin
Speaker's Bureau: Abbott, Genzyme
Kristine Wyatt
Jerry Yee
Bessie Young
Xueqing Yu
Speaker's Bureau: Baxter International Inc.
Camille Yucsak
Speaker's Bureau: Amgen
Jessica Zeman
Shaoling Zhang
Jana Zimmer
Deborah Zimmerman
Grant/Research Support: Baxter International Inc.
Speaker's Bureau: Baxter International Inc.
Troy Zimmerman
Kim Zuber

The National Kidney Foundation gratefully acknowledges that the Research Grant Program is made possible by support from, or in honor of, the following organizations and individuals:

THANK YOU!



NKF RESEARCH GRANT SUPPORTERS

American Society of Nephrology

Amgen

John Bower, MD Foundation

Bristol Myers Squibb

Victor Chaltiel Foundation

Fresenius Medical Care

Gambro

GSK

Ira Greifer, MD

Mitsubishi Tanabe

Satellite Dialysis

Shaul G. Massry, MD

Pfizer Laboratories

Solomon Papper, MD

Patricia Welder Robinson

Donald Seldin, MD

George Schreiner, MD

Robert Schrier, MD

Hilda Gershon Sugarman



National
Kidney
Foundation™

CONTINUING MEDICAL EDUCATION PROGRAM

MISSION STATEMENT

The mission of the National Kidney Foundation (NKF) Continuing Medical Education Program is to provide education for academic as well as private practitioners in nephrology and other specialties/disciplines impacted by kidney disease. These educational activities are offered to regional, national, and international audiences.

Purpose

To change clinical practice and improve patient outcomes through education, information, and the opportunity to practice in a virtual clinical setting. To provide all members of the kidney healthcare community with current, state-of-the-art scientific information on prevention, diagnosis, and treatment of chronic kidney disease (CKD) and urinary tract diseases in order to improve the care of individuals with CKD and those at risk for developing it.

Content Area

Content areas span the scope of kidney disease and include: risk factors, screening, diagnosis, staging, comorbidities and complications, such as diabetes, hypertension, cardiovascular disease, anemia, mineral and bone disorder (MBD), chronic kidney disease, kidney failure, dialysis, acute kidney injury, infectious diseases as they relate to kidney disease, all aspects of kidney transplantation, and patient safety issues. Selected topics are based on identified need and gaps in physician knowledge, competence, and performance regarding the care and treatment of individuals affected by kidney disease. Kidney Disease Outcomes Quality (KDOQI™) and Kidney Disease Improving Global Initiatives (KDIGO®) evidence-based guidelines and the latest peer-reviewed clinical science provide the foundation for developing much of the content associated with best practice, as do professional interests, expert opinions, literature reviews and needs assessment data from patients and caregivers that identify gaps in quality of care relative to physician implementation of the science.

Target Audiences

Practicing physicians, residents, and fellows in nephrology, and other specialties, including internal medicine, cardiology, endocrinology, family practice, hospitalists, advanced practitioners (physician assistants, nurse practitioners), nurses, pharmacists, and other disciplines in any setting who care for individuals who are at increased risk for, or affected by, kidney disease.

Types of Activities

Activities are carefully designed to provide opportunities to maximize learning and retention. Strategies to engage the physician/other learners based on adult learning principles, along with critical thinking techniques to facilitate use of higher order cognitive skills (reflection on what they know, challenging assumptions, exploring/weighing alternatives) are incorporated into all activities to facilitate application of new learning and/or clinical strategies for patient care. Teaching/learning methodologies include case study presentation and discussion, virtual patient problem solving, question and answer, multi-media teaching/learning tools, and others, such as breakout sessions, small group/individual exercises, depending on format (live or enduring). Live activities include conferences, symposia, courses, grand rounds, hands-on workshops, audience response sessions, and debates. Enduring materials include monographs, CD-ROMs and internet-based activities such as webcasts and webinars.

Expected Results:

Expected results include improved physician knowledge, competence and performance in order to maximize the quality of care given to patients. Expected changes in care focus on earlier identification of CKD and its risk factors and use of evidence-based treatment strategies to slow CKD onset and reduce risk of CKD progression and development of kidney failure and need for renal replacement therapy; earlier and more up-to-date and evidence based treatment of comorbid conditions to avoid premature death from cardiovascular disease and other complications; pre-emptive kidney transplantation which yields better outcomes than dialysis; and improved patient safety relative to drug dosing, medication therapies, quality of life, and early mortality. The expected results will be accomplished through physician and other clinician education by providing comprehensive educational activities that incorporate up-to-date science, evidence-based practice guidelines, and expert opinion, and by

offering a variety of learning formats to meet the diverse needs and preferences of learners. Results/learning outcomes are evaluated immediately post-participation by post-testing and feedback from activity evaluations that ask learners about applicability of the activity content to their scope/practice; commitment to change; and how they plan to apply content to make changes in clinical practice to improve patient outcomes. A 3 to 6 month outcomes study collects data and measures the resulting changes in knowledge acquisition, perception, competency and behavior/clinical practices related to activity content and learning objectives, as well as identify barriers to implementation. Indication by the learners of the number of patients seen per week allows for projection of potential beneficial impact of changes in practice on patients. NKF's data and other national screening and mortality data will indicate trends over time in key CKD patient outcomes metrics. This data will also help in ongoing quality improvement of the CME Program.

PHYSICIAN PROGRAM

Accreditation Statement

The National Kidney Foundation is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statement

The National Kidney Foundation designates this live activity for a maximum of 31.0 AMA PRA Category 1 Credits™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Note: Acquiring 31.0 credits requires continuous participation from Wednesday morning through Saturday morning. Many participants opt for periodic breaks, which make their reported credit hours somewhat less. Additional credits are provided for courses requiring separate registration, as noted below.

Kidney Transplantation 2014	8.25 credits
Integrated Hemodialysis/ Peritoneal Dialysis	8.0 credits
CKD Management Along the Continuum: From Predialysis to Policy	7.25 credits
Glomerular Diseases: Updates on Pathogenesis and Treatment	8.5 credits

PRE-CONFERENCE COURSES

REQUIRED: Separate registration fee of \$200 for members, \$225 for non members, \$100 for fellows and residents.

Includes syllabus, breakfast, boxed lunch, and CME credits.

Kidney Transplantation 2014

Tuesday, April 22, 7:30am – 6:00pm

Course Director: Fuad Shihab, MD, FNKF

Session 220, 8.25 credits

TARGET AUDIENCE

Designed for community nephrologists, transplant nephrologists, nephrology fellows, transplant coordinators, transplant pharmacists and other professionals involved in the care of the kidney transplant patient.

COURSE DESCRIPTION

This course is designed to offer the attendee a comprehensive understanding of basics of immunology, pathology and organ allocation, the issues surrounding living kidney donation, the role of the antibody on graft outcomes, and management of common problems after kidney transplantation.

LEARNING OBJECTIVES

Upon completion of this course, participants will be able to:

- Discuss basic principles of transplant immunobiology and HLA typing
- Describe current and future organ allocation policies
- Engage in discussions of best practices for evaluation of the living donor and complications after donation in addition to paired-kidney donation
- Recognize the REMS program
- Identify the management of certain post-transplant complications, such as recurrence of FSGS and post-transplant hypertension

Kidney Transplantation 2014

TIME	TOPIC	SPEAKER
7:30am – 8:00am	Continental Breakfast	
	SESSION I	
8:00am – 8:30am	How Does Rejection Occur?	Kenneth Newell, MD, PhD
8:30am – 9:00am	Clinical Applications of Transplant Immunology	Douglas Norman, MD
9:00am – 9:30am	Organ Allocation: Principles and What's New?	Ajay Israni, MD
9:30am – 9:45am	Panel Discussion: Question and Answer Session	Session I Faculty
9:45am – 10:00am	Break	
	SESSION II	
10:00am – 10:30am	Evaluation of the Potential Living Kidney Donor	Connie Davis, MD
10:30am – 11:00am	Evaluation of the Potential Transplant Recipient	Donald Hricik, MD
11:00am – 11:30am	Transplantation in Minorities	Akinlolu Ojo, MD, PhD, MPH
11:30am – 11:45am	Panel Discussion: Question and Answer Session	Session II Faculty
11:45am – 12:45pm	Lunch	
	SESSION III	
12:45pm – 1:15pm	What's New in the Treatment of AMR?	Milagros Samaniego, MD, FACP, FASN
1:15pm – 1:45pm	The Donor-Specific Antibody	Douglas Norman, MD
1:45pm – 2:15pm	The Kidney Transplant Biopsy	Agnes Fogo, MD
2:15pm – 2:30pm	Panel Discussion: Question and Answer Session	Session III Faculty
2:30pm – 2:45pm	Break	
	SESSION IV	
2:45pm – 3:15pm	The REMS Program	Lonnie Smith, PharmD
3:15pm – 3:45pm	FSGS: How to Prevent and Manage Recurrence?	Flavio Vincenti, MD
3:45pm – 4:15pm	Management of Post-Transplant Hypertension	Ajay Israni, MD
4:15pm – 4:30pm	Panel Discussion: Question and Answer Session	Session IV Faculty
4:30pm – 4:45pm	Break	
	SESSION V	
4:45pm – 6:00pm	The Kidney Transplant Quiz	Donald Hricik, MD Douglas Norman, MD Flavio Vincenti, MD Milagros Samaniego, MD, FACP, FASN Fuad Shihab, MD, FNKF

Integrated Hemodialysis/ Peritoneal Dialysis Course

Tuesday, April 22, 7:00am – 5:00pm

Course Director: Joanne Bargman, MD, FRCPC

Session 221, 8.0 credits

TARGET AUDIENCE:

Designed for nephrologists, nephrology fellows, advanced practitioners, and nephrology nurses.

COURSE DESCRIPTION:

This course will deliver an integrated and comprehensive approach to the physiologic underpinnings and “nuts and bolts” of chronic dialysis therapy. Approaches to the optimal management of chronic dialysis patients with respect to extracellular fluid volume control, solute removal, access complications, and other infectious and non-infectious complications will be discussed for both peritoneal dialysis and hemodialysis.

COURSE OBJECTIVES:

Upon completion of this course, participants will be able to:

- Discuss the physics and techniques of hemodialysis
- Discuss the physiology and techniques of peritoneal dialysis
- Describe the importance of proper access in both peritoneal dialysis and hemodialysis, and potential complications of access problems
- Discuss the basis and practical application of dialysis dose prescription in peritoneal dialysis and hemodialysis
- Discuss the management of ultrafiltration and volume control in peritoneal dialysis
- Discuss infectious complications of hemodialysis and peritoneal dialysis
- Identify special issues pertaining to dialysis in infants and children
- Identify and describe the noninfectious complications of hemodialysis
- Describe how a home dialysis modality can improve quality of life for both the patient and physician

TIME	TOPIC	SPEAKER
7:00am – 7:30am	Continental Breakfast	
7:30am – 7:45am	Introduction – Why are We Here?	Joanne Bargman, MD, FRCPC
7:45am – 8:15am	How Hemodialysis Works	Daniel Coyne, MD
8:15am – 8:45am	The Physiology of Peritoneal Dialysis	Joanne Bargman, MD, FRCPC
8:45am – 9:15am	Access in Peritoneal Dialysis	Rajnish Mehrotra, MD, MBBS, FNKF
9:15am – 9:45am	Access in Hemodialysis	Charmaine Lok, MD, MSc, FNKF
9:45am – 10:30am	Hemodialysis Prescription Adequacy and Volume Control	Daniel Coyne, MD
10:30am – 10:45am	Break	
10:45am – 11:30am	Peritoneal Dialysis Prescription and Adequacy	Beth Piraino, MD, FNKF
11:30am – 12:15pm	Managing Ultrafiltration and Volume Control in Peritoneal Dialysis	Rajnish Mehrotra, MD, MBBS, FNKF
12:15pm – 1:15pm	Lunch	
1:15pm – 1:45pm	Prevention and Management of Infections in Hemodialysis	Michael Allon, MD
1:45pm – 2:15pm	Prevention and Management of Infections in Peritoneal Dialysis	Beth Piraino, MD, FNKF
2:15pm – 2:45pm	Special Considerations in Infants and Children	Bradley Warady, MD, FNKF
2:45pm – 3:15pm	Non-Infectious Complications of Hemodialysis	Michael Allon, MD
3:15pm – 3:30pm	Break	
3:30pm – 4:00pm	Non-Infectious Complications of Peritoneal Dialysis	Joanne Bargman, MD, FRCPC
4:00pm – 4:30pm	Home Dialysis: Better Quality of Life for Both Patient and Physician	Brigitte Schiller, MD
4:30pm – 5:00pm	Question & Answer/Evaluations	

CKD Management Along the Continuum: From Predialysis to Policy

Tuesday, April 22, 7:30am – 4:30pm

Course Co-Directors: Charmaine Lok, MD, MSc, FNKF, and Christopher Chan, MD, FRCPC

Session 222, 7.25 credits

TARGET AUDIENCE:

Designed for physicians, medical directors, nurse managers, quality managers, advanced practitioners, physician trainees, and administrators.

COURSE DESCRIPTION:

This integrated course is designed to offer the attendee an update on the optimal management of CKD, from the needs for operationalizing a CKD clinic to understanding the practical issues for dialysis facility management and quality improvement (QI). This course is taught by a diverse group of experts who will review best practices for CKD management and the transition to dialysis, the external financial and regulatory forces of managing a dialysis unit, quality and

accountability issues, and the internal technical and patient management issues pertinent to delivering excellent care.

LEARNING OBJECTIVES:

Upon completion of this course, participants will:

- Realize the need for a multidisciplinary CKD clinic in their practice domain matching local resources and utilizing best practices to optimize its efficiency
- Implement best practices in the management of diabetes, hypertension, proteinuria, anemia, bone and mineral disorders, and vascular access in patients with CKD
- Identify the benefits of implementing technology, including automation and computerized clinical decision support systems to help with patient management, guideline adoption, and adherence
- Anticipate and prepare for state and local regulatory inspections in dialysis facilities
- Identify the financial imperatives for running a successful dialysis facility, and the impact of bundling
- Discuss strategies to best position your dialysis unit to deliver safe, high-quality dialysis treatment
- Align patient-centered care with regulatory compliance

TIME	TOPIC	SPEAKER
7:30am – 8:00am	Continental Breakfast	
8:00am – 8:05am	Welcome and Introductions	Charmaine Lok, MD, MSc, FNKF Christopher Chan, MD, FRCPC
8:05am – 8:40am	Multidisciplinary CKD Clinics: Is It Worth It?	Charmaine Lok, MD, MSc, FNKF
8:40am – 9:15am	Multidisciplinary Care Clinic – Putting Theory into Practice	Jane Davis, DNP, CRNP, MSN, FNKF
9:15am – 9:50am	Update in CKD Management	Jerry Yee, MD, FACP, FASN, FNKF
9:50am – 10:05am	Break	
10:05am – 10:40am	Automation, Decision Support and Expert Systems in CKD Management	Sandeep Soman, MD, FNKF
10:40am – 11:05am	Time to Start Dialysis – Which One and How?	Janice Ritchie, RN, MSN
11:05am – 12:00pm	Dialysis Access: Functioning Starts for a Lifelong “Lifeline”	Cynthia Bhola, BN, MSN
12:00pm – 1:00pm	Lunch	
1:00pm – 1:35pm	The Benefits of Home Dialysis	Christopher Chan, MD, FRCPC
1:35pm – 2:10pm	How to Ensure Quality in ESRD Care	Alan Kliger, MD
2:10pm – 2:45pm	Accountability, CMS, the Networks, and QIP	Jay Wish, MD
2:45pm – 3:20pm	Home Dialysis and Finances	Robert Lockridge, MD
3:20pm – 4:15pm	How to Make “Real” Changes in a Dialysis Facility	Daniel Weiner, MD, MS, FNKF
4:15pm – 4:30pm	Wrap-Up, Evaluations, and Burning Q&A	Christopher Chan, MD, FRCPC Charmaine Lok, MD, MSc, FNKF

Glomerular Diseases: Updates on Pathogenesis and Treatment

Tuesday, April 22, 8:00am – 6:00pm

Course Co-Directors: Michael Choi, MD, FNKF, and Fernando Fervenza, MD, PhD, FNKF
Session 223, 8.5 credits

TARGET AUDIENCE

Designed for nephrologists, nephrology fellows, advanced practitioners, and nephrology nurses.

COURSE DESCRIPTION

In the last few years, a number of new diagnostic and therapeutic tools have emerged. Practicing nephrologists will greatly benefit by having an update regarding their

utility in the diagnosis and management of patients with glomerular diseases. The course format includes lectures, question-and-answer sessions, case-based discussions, and panel sessions to review this evidence. Faculty are composed of outstanding teachers who are experts in their respective fields. The course should be of special interest to nephrologists who deal with patients with glomerular diseases or are looking for an update on the subject.

COURSE OBJECTIVES

At the conclusion of this activity, participants will be able to:

- Review current research and clinical findings in the pathophysiology of glomerular diseases
- Examine novel diagnostic tools in glomerular diseases
- Identify current therapeutic options in glomerular diseases

TIME	TOPIC	FACULTY
8:00am – 8:30am	Minimal Change	Michael Choi, MD, FNKF
8:30am – 9:00am	FSGS	Stuart Shankland, MD
9:00am – 9:30am	Membranous Nephropathy	Fernando Fervenza, MD, PhD, FNKF
9:30am – 10:00am	Break	
10:00am – 10:30am	MPGN	Richard Glasscock, MD, MACP
10:30am – 11:00am	Monoclonal Gammopathies	Nelson Leung, MD
11:00am – 11:30am	ANCA Vasculitis	Patrick Nachman, MD, FASN
11:30am – 12:00pm	Break	
12:00pm – 2:00pm	Working Lunch—Clinical Issues in MC, FSGS, IgA, MN, and MPGN	Sanjeev Sethi, MD, PhD
2:00pm – 2:30pm	Lupus Nephritis	James Balow, MD
2:30pm – 3:00pm	New Data and New Questions on IgA Nephropathy	Gerald Appel, MD
3:00pm – 3:30pm	Thrombotic Microangiopathies	Michael Choi, MD, FNKF
3:30pm – 4:00pm	Break	
4:00pm – 4:30pm	Hereditary Nephropathies	Agnes Fogo, MD
4:30pm – 6:00pm	Clinical Issues in MG, ANCA, SLE, HUS/TTP	All Afternoon Faculty

LUNCH WORKSHOPS

Separate registration and an additional fee of \$50 per workshop is required. Includes a boxed lunch and CME credits. Tickets for these workshops may be purchased at the NKF Ticket Sales Booth in the Registration Area. Space is limited, so participation is available on a first-come, first-served basis.

WEDNESDAY, APRIL 23, 12:00PM – 2:00PM

WHAT THE NEPHROLOGIST NEEDS TO KNOW TO MANAGE THE PREGNANT PATIENT; SESSION 230

Chairs: Michelle Hladunewich, MD, and Shaoling Zhang, PhD

Presenter(s): Heidi Schaefer, MD, FNKF, Michelle Hladunewich, MD, and Tina Podymow, MD

Workshop Description: This workshop will use a case-based approach to review “What the Nephrologist Needs to Know to Manage the Pregnant Patient.” The first topic will review the management of renal transplants during pregnancy. The second will review the management of pregnant patients with kidney disease, including pre-eclampsia. The final topic will review dialysis management during pregnancy.

CHOOSING THE HEMODIALYSATE BATH: AN UPDATE; SESSION 231

Chair: Alfred Cheung, MD, FNKF

Presenter(s): Brigitte Schiller, MD, Raymond Hakim, MD, PhD, Francesca Tentori, MD, and Deborah Zimmerman, MD, MSc

Workshop Description: The composition of the hemodialysate bath is an often overlooked, but critical aspect of providing dialysis, and the optimal composition of the dialysate remains controversial. There is uncertainty on topics like: sodium modeling and sodium balance; whether a 1K bath is safe; issues relating to bicarbonate concentrations that have spawned lawsuits across the U.S.; and one recent publication suggesting risks with low calcium baths that contrasts with a push toward avoidance of modest hypercalcemia. Prescribing the optimal dialysate bath represents a considerable challenge to dialysis professionals. This workshop will provide an overview of the current best evidence for optimizing the dialysate for individual patients, helping participants make the best choices for their patients.

FISTULA FIRST/CATHETER LAST; SESSION 232

Chairs: Timmy Lee, MD, MSPH, FACP, FASN, FNKF, and Joseph Vassalotti, MD, FASN, FNKF

Presenter(s): Tushar Vachharajani, MD, FASN, FACP, and Michael Allon, MD

Workshop Description: This workshop will provide a practical and evidence-based review of the impact of the Fistula First Initiative on fistula use in the United States, and the future role of the Fistula First Initiative to reduce dialysis catheter use. Moreover, there will be an in-depth talk on the role of the interventionalist to further improve fistula use and reduce catheter prevalence. This will be a unique opportunity for interactive learning between the audience and internationally recognized experts in the field of vascular access.

NEPHROTIC SYNDROME IN 2014; SESSION 233

Chairs: Daniel Cattran, MD, FRCPC, FACP, and Debbie Gipson, MD, MS, FNKF

Presenter(s): Debbie Gipson, MD, MS, FNKF, Cynthia Nast, MD, and Daniel Cattran, MD, FRCPC, FACP

Workshop Description: This workshop will provide attendees with an overview of the epidemiology of nephrotic syndrome and associated conditions, and the prognostic importance of the biopsy on clinical care and will review evidence-based guidelines for patient management. Practical aspects of managing the nephrotic patient will be discussed, including tailoring treatment based on proteinuria and eGFR, complication prevention strategies, and a review of the new findings ready for the clinical arena.

GROWING FAST: CHALLENGES FOR HISPANIC PATIENTS WITH CKD; SESSION 234

Chairs: Sylvia E. Rosas, MD, MSCE, FNKF, and Carmen Peralta, MD

Presenter(s): Sylvia E. Rosas, MD, MSCE, FNKF, Claudia Lora, MD, MS, and Cristina Arce, MD, MS

Workshop Description: Hispanic individuals constitute the largest and fastest-growing minority in the U.S. Hispanics are at particular risk for kidney disease and face particular challenges in their access to and delivery of care. This session will provide an overview of the epidemiology and outcomes of kidney disease in the Hispanic minority and will focus on particular issues in delivering culturally competent care. In addition, we will cover the special challenge of caring for undocumented immigrants who require treatment for ESRD.

ELECTROLYTES/ACID-BASE; SESSION 235

Chair: Kamel Kamel, MD, FRCPC

Presenter(s): Mark Perazella, MD, FNKF, Kamel Kamel, MD, FRCPC, and Joseph Verbalis, MD

Workshop Description: This session will cover three complex clinical areas that relate to and are critical for the practicing nephrologist. The first topic will be a review of the clinical presentation and management of acid-base abnormalities that occur as a result of toxic ingestions. The second will review the use of aquaporin-2 antagonists in chronic hyponatremia and kidney diseases, including polycystic disease. The final topic will review clinical manifestations, including electrolyte disturbances and nephrotoxicity of recreational drug ingestion, and related management strategies. Each session will include the presentation of a few interesting cases in an interactive format.

NUTS 'N' BOLTS OF HOME HD: PART I – SET-UP; SESSION 236

Chair: Charmaine Lok, MD, MSc, FNKF, and Christopher Chan, MD, FRCPC

Presenter(s): Christopher Chan, MD, FRCPC, Robert Lockridge, MD, and Alan Kliger, MD

Workshop Description: Attendees of this workshop will learn how to implement a successful home hemodialysis program and understand strategies for recruitment of home hemodialysis patients. It will also provide an overview of how to develop and ensure a quality initiative in your home hemodialysis program.

FRIDAY, APRIL 25, 11:30AM – 1:00PM**CONTROVERSIES IN THE MANAGEMENT OF HYPERTENSION IN DIALYSIS PATIENTS; SESSION 237**

Chair: Wendy St. Peter, PharmD, FCCP, FASN, FNKF

Presenter(s): Aldo Peixoto, MD, Wendy St. Peter, PharmD, FCCP, FASN, FNKF, and Tara Chang, MD, MS

Workshop Description: Treating hypertension in both peritoneal dialysis and hemodialysis patients is complex, and involves many factors, such as dry weight estimation, volume gain and shifts during treatment, interdialytic changes in blood pressure, and limited data supporting the efficacy and evidence base for various antihypertensives. Choosing the appropriate blood pressure target and optimal medication in peritoneal dialysis and hemodialysis patients can be challenging. Gaining a working knowledge base of the data supporting various management strategies and blood pressure targets will help clinicians optimally manage hypertension in these patients. This workshop will provide participants with an evaluation of the current state of the literature in relation to blood pressure targets, and will focus on the utility and evidence base for the use of ACE inhibitors and diuretics in these patients.

KEY TOPICS IN HEMODIALYSIS MANAGEMENT; SESSION 238

Chairs: Alfred Cheung, MD, FNKF, and Timmy Lee, MD, MSPH, FACP, FASN, FNKF

Presenter(s): Raymond Hakim, MD, PhD, Deborah Zimmerman, MD, MSc, and Daniel Coyne, MD

Workshop Description: The majority of dialysis patients still utilize hemodialysis as their primary form of renal replacement therapy, but mortality rates still remain high. Management of key issues of the dialysis procedure, such as blood pressure and dry weight, volume and solute removal, and cannulation techniques, remains a challenge when delivering care for the hemodialysis patient. This workshop will provide an overview of these major clinical challenges and whether optimization of any of these techniques can improve morbidity and mortality for the hemodialysis patient. This workshop will provide a forum and an opportunity for interaction with faculty with expertise in these areas.

PD PRIMER; SESSION 239

Chairs: Claudio Ronco, MD, FNKF, and Joni Hansson, MD, FNKF

Presenter(s): Matthew Oliver, MD, MHS, FRCPC, Joni Hansson, MD, FNKF, and William Salzer, MD

Workshop Description: This workshop will lay the foundation for a better understanding of the fundamental principles of peritoneal dialysis (PD). Peritoneal membrane physiology, ultrafiltration, the Peritoneal Equilibration Test (PET), and use of standard PD solutions will be reviewed. Practical and innovative approaches to prescribing PD to achieve adequate dialysis will be presented. The session will conclude with a discussion of diagnosing and treating peritonitis. The ultimate goal of this workshop is to help the clinician feel more comfortable managing a patient on peritoneal dialysis.

MANAGING THE PRE-ESRD PATIENT; SESSION 240

Chair: Michal Melamed, MD, MHS, FNKF

Presenter(s): Jerry Yee, MD, FACP, FNKF, FASN, Carolyn Cochran, RD, MS, LD, CDE, and Jeffrey Berns, MD, FNKF

Workshop Description: The management of the pre-ESRD patient is often a complex balance of diet, medication, and other interventions in preparation for dialysis. As kidney function deteriorates, medication safety, nutrition, and discussions of renal replacement therapy become increasingly important. During this workshop, important classes of medications which need monitoring or stopping will be reviewed. A dietitian will review dietary recommendations for late-stage CKD when kidney function is almost gone, but patients are not yet on renal replacement therapy. Lastly, guiding patients and their families in a timely fashion towards appropriate renal replacement therapy options will be reviewed. This workshop will present a unique opportunity to discuss last-minute strategies for keeping patients safe and healthy before initiation of dialysis.

PALLIATIVE CARE AND INITIATION OF DIALYSIS IN THE ELDERLY: CAN “OPPOSITES” ATTRACT?; SESSION 241

Chairs: Dena Rifkin, MD, MS, FNKF, and Manjula Kurella Tamura, MD, MPH

Presenter(s): Alvin Moss, MD, FAAHPM, Manjula Kurella-Tamura, MD, MPH, and Tracy Greene-Mintz, MA, MSW, LCSW

Workshop Description: The initiation of chronic dialysis support in an older individual marks a pivotal moment in life, one which is both a time of “lifesaving” intervention and a time when issues of mortality and realistic life expectancy may arise. Traditionally, involvement of palliative care has been seen as an “either/or” choice versus an “aggressive” interventional course, including renal replacement therapy. Can these two approaches to care be merged if life expectancy of the older patient is short? How should caregivers weigh the pros and cons of approaching initiation of dialysis and end-of-life in tandem? Panelists will explore these issues through realistic cases and discussion.

KIDNEY STONE UPDATE FOR NEPHROLOGISTS; SESSION 242

Chair: Kamel Kamel, MD, FRCPC

Presenter(s): Kamel Kamel, MD, FRCPC, Andrew Rule, MD, MSc, and Benjamin Chung, MD

Workshop Description: The nephrologist should play an important role in the management of kidney stones. Yet, the exposure of nephrologists to stone management during fellowship training and in postgraduate educational programs is often inconsistent. In this session, the speakers will discuss recent data on the potential long-term effects of kidney stones on kidney function, as well as the up-to-date medical management and non-medical treatment of kidney stones.

NUTS ‘N’ BOLTS OF HOME HD: PART II – MAINTENANCE; SESSION 243

Chair: Charmaine Lok, MD, MSc, FNKF

Presenter(s): Robert Lockridge, MD, Joanne Bargman, MD, FRCPC, and Mark Unruh, MD

Workshop Description: This workshop will provide an understanding of how to prevent vascular complications in home dialysis. Attendees will also learn how to establish a fully integrated home dialysis program, and recognize the importance of caregiver burden and psychosocial aspects of home hemodialysis.

PHYSICIAN PROGRAM

TUESDAY, APRIL 22

TIME/ROOM	SESSION#	SESSION	COURSE DIRECTOR(S)	NOTES	CREDIT
7:30am – 6:00pm Room 112	220	KIDNEY TRANSPLANTATION 2014	Fuad Shihab, MD, FNKF	●	8.25
7:00am – 5:00pm Room 113	221	INTEGRATED HEMODIALYSIS/PERITONEAL DIALYSIS	Joanne Bargman, MD, FRCPC	●	8.0
7:30am – 4:30pm Room 114	222	CKD MANAGEMENT ALONG THE CONTINUUM: FROM PREDIALYSIS TO POLICY	Charmaine Lok, MD, MSc, FNKF Christopher Chan, MD, FRCPC	●	7.25
8:00am – 6:00pm Room 115	223	GLOMERULAR DISEASES: UPDATES ON PATHOGENESIS AND TREATMENT	Fernando Fervenza, MD, PhD, FNKF Michael Choi, MD, FNKF	●	8.5
6:30pm – 8:00pm Room 118	100	FELLOWS RECEPTION/CAREER CHOICES IN NEPHROLOGY <i>Supported in part by Fresenius Medical Care</i>	Sylvia E. Rosas, MD, MSCE, FNKF		--

WEDNESDAY, APRIL 23

TIME/ROOM	SESSION#	SESSION	FACULTY	NOTES
6:00am – 7:45am Rooms 318-319	800	CLINICAL ASPECTS OF FIBROBLAST GROWTH FACTOR 23 IN CHRONIC KIDNEY DISEASE <i>Supported by an educational donation provided by Amgen</i>	Chair: Csaba Kovesdy, MD, FASN	1.5
		A Clinician's Perspective on Fibroblast Growth Factor 23	Csaba Kovesdy, MD, FASN	
		FGF23 and Clinical Outcomes in Chronic Kidney Disease	Myles Wolf, MD, MMSc	
		Dietary and Pharmacologic Modifiers of FGF23	Orlando Gutierrez, MD, MMSc	
6:00am – 7:45am Rooms 310-311	807	HIGH-DOSE IRON: TAKING TREATMENT OF IRON DEFICIENCY ANEMIA TO A NEW LEVEL <i>Supported by an educational grant from AMAG Pharmaceuticals, Inc. and American Regent, Inc.</i>	Chair: Jay Wish, MD	1.5
		Iron Deficiency Anemia in ND-CKD: Mechanisms and Treatment Implications	Jay Wish, MD	
		Iron Therapy in ND-CKD Patients: Oral or Intravenous?	Wajeh Qunibi, MD, FACP	
		The Role of IV Iron Therapy in ND-CKD: Newest Evidence	Daniel Coyne, MD	
8:00am – 9:30am Room 123	260	DEBATES IN AKI	Chair: Chirag Parikh, MD, FNKF	1.5
		Introduction and Ground Rules	Chirag Parikh, MD, FNKF	
		Is Increase in Serum Creatinine Good or Bad in Cardiorenal Syndrome?		
		Pro: Increase in Serum Creatinine is Bad	Claudio Ronco, MD, FNKF	
		Con: Increase in Serum Creatinine is Good	Steven Coca, DO, MS	

WEDNESDAY, APRIL 23, *continued*

TIME/ROOM	SESSION#	SESSION	FACULTY	NOTES
8:00am – 9:30am Room 317	261	NEW APPROACHES TO IMMUNOSUPPRESSION: IS LESS BETTER?	Chairs: Fuad Shihab, MD, FNKF, and Milagros Samaniego, MD, FACP, FASN	1.5
		Corticosteroid Minimization and Avoidance Strategies	Donald Hricik, MD	
		Calcineurin Inhibitor Minimization and Avoidance Strategies	Flavio Vincenti, MD	
		Tolerance Induction in the Real World: Are We Ready for It?	Kenneth Newell, MD, PhD	
9:30am – 10:00am		BREAK		
10:00am – 11:30am Room 121	262	CONTROVERSIES IN LIVING KIDNEY DONATION	Chairs: Fuad Shihab, MD, FNKF, and Ronald Perrone, MD, FNKF	1.5
		Short- and Long-Term Outcomes in Kidney Donors	Hassan Ibrahim, MD, MS	
		Novel Approaches to Increasing the Living Kidney Donor Pool	Milagros Samaniego, MD, FACP, FASN	
		Incentives for Living Kidney Donors: Beyond the Pros and the Cons	Connie Davis, MD	
10:00am – 11:30am Room 120	263	WALK THIS WAY...IN CKD	Chairs: Daniel Weiner, MD, MS, FNKF, and Kirsten Johansen, MD	1.5
		Neuromuscular Functional Changes and Assessment in CKD – Implications for Patient Care and Outcomes	Charmaine Lok, MD, MSc, FNKF	
		Exercises that Really Work for CKD Patients	Patricia Painter, PhD, FACS	
		Renal Rehab Along the Continuum of CKD and Age	Kirsten Johansen, MD	
10:00am – 11:30am Room 118	264	LUPUS NEPHRITIS	Chairs: Michael Choi, MD, FNKF, and Xueqing Yu, PhD, MBBS	1.5
		Biomarkers from Bench to Bedside in Lupus Nephritis	Brad Rovin, MD	
		The Future of Steroids in Lupus Nephritis Therapy	Joanne Bargman, MD, FRCPC	
		Recent Trials of B Cell Depletion in Lupus Nephritis	Gerald Appel, MD	
10:00am – 11:30am Room 123	563	AMUSED AND AMAZED: HOW TO SURVIVE AND THRIVE AS A HEALTHCARE PROFESSIONAL	Karyn Buxman, RN, MS, CSP, CPAE	▲ 1.5
11:30am – 12:00pm		BREAK		
12:00pm – 2:00pm Rooms 318-319	801	REVISITING PHOSPHATE MANAGEMENT IN CHRONIC KIDNEY DISEASE	Chair: Kamyar Kalantar-Zadeh, MD, MPH, PhD, FNKF	1.5
		<i>Supported by an educational grant from Fresenius Medical Care</i>		
		Overview of Phosphate Homeostasis, GI Absorption, and Dietary Sources	Kamyar Kalantar-Zadeh, MD, MPH, PhD, FNKF	
		Traditional and Newer Phosphate Binders	Bruce Spinowitz, MD, FACP	
		Integrating Dietary Restrictions and Therapeutic Agents to Control Phosphate	Stuart Sprague, DO, FNKF	

● Separate registration and/or fee required ▲ Joint with Councils

TIME/ROOM	SESSION#	SESSION	FACULTY	NOTES
12:00pm – 2:00pm Rooms 301-302	230	WORKSHOP: WHAT THE NEPHROLOGIST NEEDS TO KNOW TO MANAGE THE PREGNANT PATIENT	Chairs: Michelle Hladunewich, MD, and Shaoling Zhang, PhD	● 2.0
		Case and Evidence-Based Management of the Pregnant Woman with a Kidney Transplant	Heidi Schaefer, MD, FNKF	
		Case and Evidence-Based Management of the Pregnant Woman with Kidney Disease	Tina Podymow, MD	
		Pregnancy in Dialysis	Michelle Hladunewich, MD	
12:00pm – 2:00pm Rooms 304-305	231	WORKSHOP: CHOOSING THE HEMODIALYSATE BATH: AN UPDATE	Chair: Alfred Cheung, MD, FNKF	● 2.0
		Sodium	Brigitte Schiller, MD	
		Potassium	Raymond Hakim, MD, PhD	
		Bicarbonate	Francesca Tentori, MD	
		Calcium	Deborah Zimmerman, MD	
12:00pm – 2:00pm Rooms 306-307	232	WORKSHOP: FISTULA FIRST/CATHETER LAST	Chairs: Timmy Lee, MD, MSPH, FACP, FASN, FNKF, and Joseph Vassalotti, MD, FASN, FNKF	● 2.0
		Physical Exam as Vascular Monitoring and Surveillance	Tushar Vachharajani, MD, FASN, FACP	
		The Role of Grafts in Catheter Reduction	Michael Allon, MD	
		The Role of Interventionalists in the “New Fistula First Era”	Tushar Vachharajani, MD, FASN, FACP	
12:00pm – 2:00pm Room 112	233	WORKSHOP: NEPHROTIC SYNDROME IN 2014	Chairs: Daniel Cattran, MD, FRCPC, FACP and Debbie Gipson, MD, MS, FNKF	● 2.0
		Epidemiology of Nephrotic Syndrome	Debbie Gipson, MD, MS, FNKF	
		Present and Future Role of Histopathology in Nephrotic Syndrome Classification	Cynthia Nast, MD	
		Nephrotic Syndrome Therapy: Guidelines, Practice, and Outcomes	Daniel Cattran, MD, FRCPC, FACP	
12:00pm – 2:00pm Rooms 206-207	234	WORKSHOP: GROWING FAST: CHALLENGES FOR HISPANIC PATIENTS WITH CKD	Chairs: Sylvia E. Rosas, MD, MSCE, FNKF, and Carmen Peralta, MD	● 2.0
		Hispanic Disparities in CKD and ESRD	Sylvia E. Rosas, MD, MSCE, FNKF	
		Health Literacy and Culturally Competent Care for Hispanic Patients	Claudia Lora, MD, MS	
		The Undocumented Immigrant with ESRD	Cristina Arce, MD, MS	
12:00pm – 2:00pm Rooms 109-110	235	WORKSHOP: ELECTROLYTES/ACID-BASE	Chair: Kamel Kamel, MD, FRCPC	● 2.0
		Acid-Base Abnormalities and Toxic Ingestions: A Case-Based Discussion	Mark Perazella, MD, FNKF	
		Is There a Role for Vasopressin Receptor Antagonists in the Management of Chronic Hyponatremia and Kidney Diseases?	Joseph Verbalis, MD	
		Electrolyte Disturbances, Nephrotoxicity, and Recreational Drugs	Kamel Kamel, MD, FRCPC	

WEDNESDAY, APRIL 23, *continued*

TIME/ROOM	SESSION#	SESSION	FACULTY	NOTES
12:00pm – 2:00pm Rooms 210-211	236	WORKSHOP: NUTS ‘N’ BOLTS OF HOME HD: PART 1 – SET-UP	Chairs: Christopher Chan, MD, FRCPC, and Charmaine Lok, MD, MSc, FNKF	● 2.0
		Successful Development and Implementation of a Home HD Program	Christopher Chan, MD, FRCPC	
		Recruitment and Training in Home HD	Robert Lockridge, MD	
		Safety and Quality in Home HD	Alan Kliger, MD	
2:00pm – 2:30pm		BREAK		
2:30pm – 3:30pm Room 115	265	NKF PRESIDENTIAL ADDRESS: BUILDING CKD AWARENESS	Beth Piraino, MD, FNKF	1.0
		SHAUL G. MASSRY DISTINGUISHED LECTURE: VASCULAR DISEASE IN CHRONIC KIDNEY DISEASE: PROGRESS AND CHALLENGES	Mark Sarnak, MD, MS	
3:30pm – 4:00pm		BREAK		
4:00pm – 5:30pm Room 123	266	KDOQI – ROLES, CONTROVERSIES, AND GUIDELINES IN CKD	Chair: Jeffrey Berns, MD, FNKF	1.5
		KDOQI – Merging Old and New Roles	Jeffrey Berns, MD, FNKF	
		Thresholds for 25(OH)D Supplementation in CKD	Holly Kramer, MD, MPH	
		KDOQI Commentary on KDIGO Clinical Practice Guidelines for CKD	Tamara Isakova, MD, MMSc	
4:00pm – 5:30pm Room 317	267	ACHIEVING GREAT RESULTS IN PERITONEAL DIALYSIS	Chairs: Beth Piraino, MD, FNKF, and David Johnson, PhD, FRACP, MBBS	1.5
		Working to Decrease Peritonitis Rates: Focus on Training	David Johnson, PhD, FRACP, MBBS	
		Appropriate and Timely Transition from PD to HD	Rajnish Mehrotra, MD, MBBS, FNKF	
		Urgent Start PD	Joni Hansson, MD, FNKF	
6:00pm – 7:30pm		OPENING CEREMONIES AND RECEPTION IN THE EXHIBIT HALL – VISIT POSTERS/EXHIBITS		1.0*
7:30pm – 9:30pm Rooms 318-319	802	HEART-KIDNEY INTERACTION AND THE ROLE OF VASOPRESSIN & HYPONATREMIA IN HEART FAILURE <i>Supported by an educational grant from Otsuka America Pharmaceutical, Inc.</i>	Chair: Matthew Weir, MD	1.5
		The Heart-Kidney Interaction in Heart Failure and the Pathogenesis of Hyponatremia	Matthew Weir, MD	
		The Utility of Current Treatment Options in the Management of Hyponatremia in the Heart Failure Patient with Impaired Kidney Function	Joseph Verbalis, MD	
		Lessons from Clinical Trials of Vasopressin Receptor Antagonists in Heart Failure	James Udelson, MD	
7:30pm – 9:30pm Rooms 310-311	808	PERSISTENT HYPERURICEMIA: A MULTI-PRONGED APPROACH TO THE MANAGEMENT OF SERUM URATE LEVELS <i>Supported by an educational grant from Takeda Pharmaceuticals North America, Inc.</i>	Chair: Robert Terkeltaub, MD	1.5
		Renal Dysfunction and the Management of Hyperuricemia	Jay Wish, MD	
		Managing Risk Factors and Comorbid Conditions in the Hyperuricemic Patient	Louis Kuritzky, MD	
		Application of Guidelines for Long-Term Treatment of Gout	Robert Terkeltaub, MD	

● Separate registration and/or fee required ▲ Joint with Councils

THURSDAY, APRIL 24

TIME/ROOM	SESSION#	SESSION	FACULTY	NOTES
6:00am – 7:45am Rooms 318-319	803	CHANGING PROFILE OF CHRONIC HYPERKALEMIA <i>Supported by an educational grant from ZS Pharma, Inc.</i>	Chair: Peter McCullough, MD, MPH, FACC, FCCP, FACP, FAHA, FNKF	1.5
		Frequency and Clinical Significance of Hyperkalemia in CKD	Robert Toto, MD	
		Risks of Hyperkalemia in Special Kidney Disease Populations	Michael Emmett, MD	
		Emerging Therapies for Treating Hyperkalemia	John Middleton, MD	
6:00am – 7:45am Rooms 310-311	806	THE ROLE OF BIOSIMILARS IN CHRONIC KIDNEY DISEASE <i>Supported by an educational grant from Hospira, Inc.</i>	Chair: Francesco Locatelli, MD	1.5
		The State of Biosimilar Regulation and Development in the United States	Edward Li, PharmD, BCOP	
		Review of Biosimilars vs. Reference Biologics	Graham Jones, PhD, DIC	
		The Potential Role of Biosimilars in Chronic Kidney Disease	Francesco Locatelli, MD	
7:00am – 8:00am		CONTINENTAL BREAKFAST IN THE EXHIBIT HALL – VISIT POSTERS/EXHIBITS		1.0*
8:30am – 10:00am Room 116	268	CHANGING THE COURSE OF DIABETIC NEPHROPATHY	Chairs: Adam Whaley-Connell, DO, MSPH, FAHA, FACP, FASN, FNKF, and Sylvia E. Rosas, MD, MSCE, FNKF	1.5
		Management of Hyperglycemia and General Diabetes Care in CKD	Katherine Tuttle, MD, FASN, FACP	
		Management of Dyslipidemia in Diabetes and CKD	Linda Fried, MD, MPH, FNKF	
		Primary Prevention of Diabetic Nephropathy	Robert Stanton, MD	
8:30am – 10:00am Room 317	269	LESSONS TO BE LEARNED IN PERITONEAL DIALYSIS FROM AROUND THE WORLD	Chairs: David Johnson, PhD, FRACP, MBBS, and Xueqing Yu, PhD, MBBS	1.5
		PD Utilization: Global Practice Patterns	Rajnish Mehrotra, MD, MBBS, FNKF	
		Home-Assisted Peritoneal Dialysis	Matthew Oliver, MD, MHS, FRCPC	
		New Peritoneal Dialysis Solutions	David Johnson, PhD, FRACP, MBBS	
10:00am – 10:30am		BREAK		
10:30am – 12:00pm Room 116	271	DIALYSIS ACCESS: STRENGTHENING THE ACHILLES HEEL	Chairs: Michael Allon, MD, and Charmaine Lok, MD, MSc, FNKF	1.5
		Barriers and Solutions for Vascular Access Placement: A Patient-Centered Approach	Louise Moist, MD, MSc, FRCPC	
		When a PD Catheter is the Most Appropriate Access	Rajnish Mehrotra, MD, MBBS, FNKF	
		Therapies for Vascular Access Dysfunction: Myth or Reality?	Timmy Lee, MD, MSPH, FACP, FASN, FNKF	

THURSDAY, APRIL 24, *continued*

TIME/ROOM	SESSION#	SESSION	FACULTY	NOTES
10:30am – 12:00pm Room 123	272	OPTIMIZING MEDICATION-RELATED OUTCOMES IN CKD PATIENTS	Chair: Jerry Yee, MD, FACP, FNKF, FASN	1.5
		Implementing Medication Therapy Management in CKD Patients: New Models of Care	Wendy St. Peter, PharmD, FCCP, FASN, FNKF	
		Strategies to Reduce Polypharmacy in CKD Patients	Nancy Mason, PharmD, FNKF	
		Top 10 Medication-Related Conundrums	Carol Moore, PharmD, BCPS, FNKF	
10:30am – 12:00pm Marquee Ballroom	290	RESIDENTS' POSTER TOUR	Chair: Sylvia E. Rosas, MD, MSCE, FNKF Christina Arce, MD, MS Steven Coca, DO, MS Michal Melamed, MD, MHS, FNKF	
12:00pm – 2:00pm		BREAK IN THE EXHIBIT HALL (LUNCH SERVED 12:15PM – 1:15PM) – VISIT POSTERS/EXHIBITS		1.0*
2:00pm – 3:30pm Room 123	273	CKD-MBD: PHOSPHATE, PTH, AND ACIDOSIS	Chair: Michal Melamed, MD, MHS, FNKF	1.5
		Building the CKD-MBD Guidelines: An Insider's View	Katrin Uhlig, MD, MS	
		PTH Control in CKD: Vitamin D and Cinacalcet – When and How?	Michal Melamed, MD, MHS, FNKF	
		Phosphate: Binders and Beyond	Francesca Tentori, MD	
2:00pm – 3:30pm Room 121	274	AKI ASSOCIATED WITH THERAPEUTICS	Chairs: Chirag Parikh, MD, FNKF, and Claudio Ronco, MD, FNKF	1.5
		AKI Associated with Anti-Microbial Use	Mark Perazella, MD, FNKF	
		AKI Associated with Anti-Neoplastic Agents	Anushree Shirali, MD	
		AKI Associated Volume Resuscitation (Crystalloids, Colloids, and Blood Products)	Chirag Parikh, MD, FNKF	
2:00pm – 3:30pm Room 317	275	STOP THE REVOLVING DOOR: REDUCING READMISSIONS IN HEMODIALYSIS AND PERITONEAL DIALYSIS PATIENTS	Chair: Raymond Hakim, MD, PhD	1.5
		Understanding the Readmission Problem in Dialysis Patients	Daniel Weiner, MD, MS, FNKF	
		Effective Interventions to Reduce Readmissions	Raymond Hakim, MD, PhD	
		Transitioning Back to Dialysis from Hospitalization	Rebecca Wingard, RN, MSN, CNN	
3:30pm – 4:00pm		BREAK		
4:00pm – 5:30pm Room 317	276	DISPARITIES IN KIDNEY DISEASE	Chair: Mark Sarnak, MD, MS	1.5
		Race and CKD: Explaining the Differences in Disease Prevalence and Progression	Bessie Young, MD, MPH	
		Long Distance Nephrology Care: Providing for Native and Remote Populations	Andrew Narva, MD, FACP, FASN	
		Overcoming Disparities: Successful Strategies to Reach Out to Disadvantaged Populations	Diedra Crews, MD, ScM	

● Separate registration and/or fee required ▲ Joint with Councils

TIME/ROOM	SESSION#	SESSION	FACULTY	NOTES
4:00pm – 5:30pm Room 121	277	OBVIOUS BUT OVERLOOKED CARE IN ESRD PATIENTS	Chair: Alfred Cheung, MD, FNKF	1.5
		Cognitive and Psychological Disorders	Daniel Weiner, MD, MS, FNKF	
		Sleep Disorders	Mark Unruh, MD	
		Chronic Pain	Steven Weisbord, MD	
4:00pm – 5:30pm Room 116	278	DON'T BUG ME ON DIALYSIS! HEMODIALYSIS INFECTION UPDATE	Chairs: Charmaine Lok, MD, MSc, FNKF, and Michael Allon, MD	1.5
		Practical Hemodialysis Bloodstream Prevention – A Multidisciplinary Approach	Michael Allon, MD	
		Prevention and Management of Multi-Drug Resistant Infections	William Salzer, MD	
		Preventing Infectious Outbreaks in the Dialysis Unit	Duc Nguyen, MD	
6:00pm – 7:30pm		NETWORKING RECEPTION IN THE EXHIBIT HALL – VISIT POSTERS/EXHIBITS		1.0*
7:30pm – 9:30pm Rooms 318-319	804	NEW INSIGHTS INTO THE ROLE OF PHOSPHORUS BALANCE IN CHRONIC KIDNEY DISEASE	Chair: Myles Wolf, MD, MMSc	1.5
		<i>Supported by an educational grant from Keryx Biopharmaceuticals, Inc.</i>		
		Understanding the Physiology and Therapeutic Targets of Phosphorus Homeostasis in Patients with CKD	Myles Wolf, MD, MMSc	
		Emerging Treatment Options for Serum Phosphorus Levels	Sylvia E. Rosas, MD, MSCE, FNKF	
		Strategies to Improve Care in Patients with Hyperphosphatemia and CKD	Geoffrey Block, MD, CCRI	

FRIDAY, APRIL 25

TIME/ROOM	SESSION#	SESSION	FACULTY	NOTES	CREDIT
6:00am – 7:45am Rooms 318-319	805	EXPERT PERSPECTIVES IN THE MANAGEMENT OF BONE-MINERAL-VASCULAR DISORDERS: A PATHOPHYSIOLOGICAL AND EVIDENCE-BASED APPROACH TO CARE	Chair: Ellie Kelepouris, MD, FAHA	1.5	
		<i>Supported by an educational grant from Sanofi Renal</i>			
		Metabolic and Mineral Disturbances in CKD-MBD: A Discussion of Pathophysiology and Risk	Matthew Weir, MD		
		Dietary Calcium and Phosphorus: A Focus on Cardiovascular Risk in CKD-MBD	Kathleen Hill Gallant, PhD, RD		
		Evolving Clinical Perspectives: Application of Phosphorus and Calcium Management Strategies in Patients With CKD-MBD	Ellie Kelepouris, MD, FAHA		
8:00am – 11:30am		BREAK IN THE EXHIBIT HALL (BREAKFAST SERVED 8:00AM – 9:00AM) – VISIT POSTERS/EXHIBITS		1.0*	

FRIDAY, APRIL 25, *continued*

TIME/ROOM	SESSION#	SESSION	FACULTY	NOTES
9:30am – 11:00am Room 120	279	THE FUTURE OF CKD DETECTION – ROLE FOR THE KIDNEY EARLY EVALUATION PROGRAM	Chairs: Adam Whaley-Connell, DO, MSPH, FAHA, FACP, FNKF, FASN, and Kerri Cavanaugh, MD, MHS, FNKF	1.5
		Strategies for Screening and Detection of Kidney Disease	Georges Saab, MD	
		Using Data from a Focused Community Screening Program to Help Stratify “Risk” for Kidney Disease	Carmen Peralta, MD	
		The Next Generation of Screening of Kidney Disease	Peter McCullough, MD, MPH, FACC, FCCP, FACP, FAHA, FNKF	
9:30am – 11:00am Room 123	280	FALLS AND FRACTURES	Chairs: Wolfgang Winkelmayr, MD, ScD, MPH, FASN, and Bryan Kestenbaum, MD, MS	1.5
		Epidemiology of Fractures in Patients with Kidney Disease	Bryan Kestenbaum, MD, MS	
		Medications that Increase Fracture Risk	Wolfgang Winkelmayr, MD, ScD, MPH, FASN	
		Falls and Fall Prevention in Dialysis Patients	Michael Heung, MD, MS	
9:30am – 11:00am Room 121	291	LATE-BREAKING PRESENTATIONS	Chair: Alfred Cheung, MD, FNKF	1.5
		Zerenex™ (Ferric Citrate) for the Treatment of Iron-Deficiency Anemia and Reduction of Serum Phosphate in Non-Dialysis Dependent CKD	Geoffrey Block, MD, CCRI	
		Estimated GFR Decline and Future Risk of ESRD: A Meta-Analysis from the CKD Prognosis Consortium	Joseph Coresh, MD	
		Individualizing ZS-9 Dosing for Serum Potassium Reduction in Hyperkalemic Patients from a Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial	Philip Lavin, MD Bhupinder Singh, MD	
		Qualification of Total Kidney Volume as a Prognostic Biomarker for Use in Clinical Trials Evaluation Patients with Autosomal Dominant Polycystic Kidney Disease	Ronald Perrone, MD, FNKF	
		Effect of CTP-499 on Renal Function in Patients with Type 2 Diabetes and Kidney Disease	Bhupinder Singh, MD	
11:00am – 11:30am		BREAK		
11:30am – 1:00pm Rooms 210-211	237	WORKSHOP: CONTROVERSIES IN THE MANAGEMENT OF HYPERTENSION IN DIALYSIS PATIENTS	Chair: Wendy St. Peter, PharmD, FCCP, FASN, FNKF	● 1.5
		Controversies of Blood Pressure Targets in Dialysis Patients	Tara Chang, MD, MS	
		RAS Agents in Hypertension Management in Dialysis Patients	Aldo Peixoto, MD	
		Diuretic Agents in Hypertension Management in Dialysis Patients	Wendy St. Peter, PharmD, FCCP, FASN, FNKF	

● Separate registration and/or fee required ▲ Joint with Councils

TIME/ROOM	SESSION#	SESSION	FACULTY	NOTES	
11:30am – 1:00pm Rooms 204-205	238	WORKSHOP: KEY TOPICS IN HEMODIALYSIS MANAGEMENT	Chair: Alfred Cheung, MD, FNKF, and Timmy Lee, MD, MSPH, FACP, FASN, FNKF	●	1.5
		Assessment and Management of Dry Weight and Intradialytic Blood Pressure Changes	Raymond Hakim, MD, PhD		
		Cannulation Practices: Buttonhole or Standard Needling?	Deborah Zimmerman, MD, MSc		
		Improving Hemodialysis Survival: Volume or Solute Control?	Daniel Coyne, MD		
11:30am – 1:00pm Rooms 201-202	239	WORKSHOP: PD PRIMER	Chairs: Claudio Ronco, MD, FNKF, and Joni Hansson, MD, FNKF	●	1.5
		The Peritoneal Membrane, Ultrafiltration, and the PET	Matthew Oliver, MD, MHS, FRCPC		
		Innovative Approaches to Individualizing PD Prescriptions	Joni Hansson, MD, FNKF		
		Treating Peritonitis	William Salzer, MD		
11:30am – 1:00pm Room 309	240	WORKSHOP: MANAGING THE PRE-ESRD PATIENT	Chairs: Michal Melamed, MD, MHS, FNKF	●	1.5
		Ensuring Medication-Related Safety in Late CKD	Jerry Yee, MD, FACP, FNKF, FASN		
		Nutrition Interventions to Delay Progression of CKD—Is There Evidence?	Carolyn Cochran, RD, MS, LD, CDE		
		Renal Replacement Therapy Discussions	Jeffrey Berns, MD, FNKF		
11:30am – 1:00pm Rooms 304-305	241	WORKSHOP: PALLIATIVE CARE AND INITIATION OF DIALYSIS IN THE ELDERLY: CAN “OPPOSITES” ATTRACT?	Chairs: Dena Rifkin, MD, MS, FNKF, and Manjula Kurella Tamura, MD, MPH	●	1.5
			Alvin Moss, MD, FAAHPM		
			Tracy Greene-Mintz, MA, MSW, LCSW		
			Manjula Kurella Tamura, MD, MPH		
11:30am – 1:00pm Room 311	242	WORKSHOP: KIDNEY STONE UPDATE FOR NEPHROLOGISTS	Chair: Kamel Kamel, MD, FRCPC	●	1.5
		Do Kidney Stones Lead to GFR Loss?	Andrew Rule, MD, MSc		
		Strategies to Prevent and Treat Kidney Stones	Kamel Kamel, MD, FRCPC		
		What Should Nephrologists Know About Non-Medical Treatments of Nephrolithiasis?	Benjamin Chung, MD		
11:30am – 1:00pm Room 209	243	WORKSHOP: NUTS ‘N’ BOLTS OF HOME HD: PART II – MAINTENANCE	Chair: Charmaine Lok, MD, MSc, FNKF	●	1.5
		Prevention and Treatment of Vascular Access Complications	Robert Lockridge, MD		
		Keeping Your Patient Home: Integration of Home PD and HD	Joanne Bargman, MD, FRCPC		
		Caregiver Burden and Psychosocial Aspects of Home HD	Mark Unruh, MD		
1:00pm – 1:30pm		BREAK			

FRIDAY, APRIL 25, *continued*

TIME/ROOM	SESSION#	SESSION	FACULTY	NOTES
1:30pm – 3:00pm Room 121	281	MANAGING DIABETES AND CKD: WHAT'S NEW AND WHAT CAN YOU DO?	Chair: David Cherney, MD, PhD, FNKF	1.5
		The Kidney, Glucose Homeostasis, and SGLT2 Inhibition in Diabetes	David Cherney, MD, PhD, FNKF	
		From Bench to Bedside: The Effects of Maternal Diabetes on Kidney Function and Blood Pressure in Offspring	Shaoling Zhang, PhD	
		Renal Protection in Patients with Diabetes: How to Augment RAS Blockade in the Era of ONTARGET, ALTITUDE, and NEPHRON-D	Linda Fried, MD, MPH, FNKF	
1:30pm – 3:00pm Room 123	282	DIFFICULT-TO-TREAT HYPERTENSION	Chairs: Sylvia E. Rosas, MD, MSCE, FNKF, and George Bakris, MD	1.5
		Epidemiology and Treatment of Resistant Hypertension	Raymond Townsend, MD, FAHA, FCHBPR	
		Case Studies of Difficult-to-Treat Hypertension in CKD	Debbie Cohen, MD	
		Emerging Therapies for Treating Resistant Hypertension	George Bakris, MD	
1:30pm – 3:00pm Room 116	283	TRENDY TOPICS FROM DOPPS	Chairs: Alfred Cheung, MD, FNKF, and Friedrich Port, MD, MS, FACP	1.5
		Impact of Payment Changes and Guidelines in Anemia Management in ESRD	David Goodkin, MD, FASN	
		International Trends in Vascular Access Use and Procedures: Implications for Access Management	Francesca Tentori, MD	
		Patient-Centered Outcomes (PRO): What We Already Know and What We Need to Learn	Bill Peckham, BA	
3:00pm – 3:30pm		BREAK		
3:00pm – 4:00pm Room 109		LOCAL MEDICAL ADVISORY BOARDS MEETING		
3:30pm – 5:00pm Room 116	284	IMPROVING THE TRANSITION FROM CKD TO ESRD	Chairs: Charmaine Lok, MD, MSc, FNKF, and Timmy Lee, MD, MSPH, FACP, FASN, FNKF	1.5
		Patient-Centered Decision Making on Treatment Options for Renal Replacement Therapy	Louise Moist, MD, MSc, FRCP	
		Preparing Patients and Their Families for Dialysis (HD and PD)	Jane Schell, MD	
		Deciding Against Chronic Dialysis – Now What?	Alvin Moss, MD, FAAHPM	
3:30pm – 5:00pm Room 121	285	ANNUAL LITERATURE UPDATE	Chair: Sylvia E. Rosas, MD, MSCE, FNKF	1.5
		Hypertension	Raymond Townsend, MD, FAHA, FCHBPR	
		AKI	Chirag Parikh, MD, FNKF	
		Dialysis	Daniel Weiner, MD, MS, FNKF	

● Separate registration and/or fee required ▲ Joint with Councils

SATURDAY, APRIL 26



TIME/ROOM	SESSION#	SESSION	FACULTY	NOTES	CREDITS
8:00am – 9:30am Rooms 314-315	286	BUNDLE UP! U.S. DIALYSIS POLICY	Chair: Friedrich Port, MD, MS, FACP		1.5
		ESCOs and ACOs: Accountable Care and Nephrology	Daniel Weiner, MD, MS, FNKF		
		The Prospective Payment System	Jeffrey Berns, MD, FNKF		
		The Quality Incentive Program: An Update on ESRD Quality Metrics	Rajnish Mehrotra, MD, MBBS, FNKF		
8:00am – 9:30am Room 310	287	GUIDELINES AND THE OLDER PATIENT WITH CKD: DO THE SAME RULES APPLY?	Chairs: Katrin Uhlig, MD, MS, and Paul Stevens, MBBS, BSc, FRCP		1.5
		Integrating Multiple Guidelines: Geriatric Perspective	Paul Stevens, MBBS, BSc, FRCP		
		Hypertension in Older CKD Patients (KDIGO)	Mark Sarnak, MD, MS		
		CKD Care for Older Adults	Dena Rifkin, MD, MS, FNKF		
9:30am – 10:00am		BREAK			
10:00am – 11:30am Room 318	288	MEASURES OF HYPERTENSION: BEYOND THE OFFICE	Chairs: Dena Rifkin, MD, MS, FNKF, and Carmen Peralta, MD		1.5
		Moving Target for Blood Pressure Goals in CKD: Pros vs. Cons	Raymond Townsend, MD, FAHA, FCHBPR		
		Alternative Measures for Blood Pressure	Carmen Peralta, MD		
		When Should Non-Office Blood Pressure Monitoring Be Used in 2014?	Aldo Peixoto, MD		
10:00am – 11:30am Rooms 314-315	289	INTEGRATION OF GENETICS INTO THE NEPHROLOGY CLINIC	Chairs: Debbie Gipson, MD, MS, FNKF, and Xueqing Yu, PhD, MBBS		1.5
		Genetics of Glomerular Disease: What Do We Know?	Jeffrey Kopp, MD		
		Genetics of Non-Glomerular Disease	Ronald Perrone, MD, FNKF		
		Integrating the Discovery of Genetic Findings into the Clinic	Matthew Sampson, MD, MSCE		
11:30am		MEETING ADJOURNS			

* A maximum of 1.0 credit only will be awarded for poster sessions.



Kidney Cars



4 Reasons why you should donate your car

- ✓ Saves Lives
- ✓ Free Pickup
- ✓ No Hassle
- ✓ Tax Deduction*

Donate your car online today at kidneycars.org

*For Those Who Itemize Their Taxes

PHARMACIST PROGRAM

Accreditation Statement



The University of Illinois at Chicago, College of Pharmacy, is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Attendance at the

entire knowledge-based program and completion of the evaluation are pre-requisites for receiving a statement of continuing education credit for up to 31.0 contact hours (3.1 CEUs).

Within 30 days of the program date, all ACPE credit awarded to participants will be uploaded to CPE Monitor.

All ACPE credit awarded to participants must be uploaded to CPE Monitor and ACPE-accredited providers will not be required to distribute paper statements of credit. CPE Monitor will be the only way for state boards of pharmacy to authenticate the CPE units completed by their licensees.

If the pharmacist and/or technician do not submit their NABP e-profile number to the NKF as requested, then NKF cannot award the credit. It is the responsibility of the pharmacist and/or technician to obtain and submit the correct ID to NKF, as well as to ensure that the information in their profile is accurate (much like one checks their credit card bills online to verify proper records). Pharmacists and pharmacy technicians may visit www.MyCPEmonitor.net to set up their e-Profiles.

For more information about CPE Monitor, please visit: <http://www.acpe-accredit.org/pharmacists/cpemonitor.asp>

PRE-CONFERENCE COURSES

Kidney Transplantation 2014

Tuesday, April 22, 7:30am – 6:00pm

Session 220, 8.5 contact hours (0.85 CEUs)
ACPE# 0016-9999-14-016-L01-P

See page 49 for course details. Separate registration and fee required.

CKD Management Along the Continuum: From Predialysis to Policy

Tuesday, April 22, 7:30am – 4:30pm

Session 222, 7.25 contact hours (0.725 CEUs)
ACPE# 0016-9999-14-017-L01-P

See page 52 for course details. Separate registration and fee required.

Glomerular Diseases: Updates on Pathogenesis and Treatment

Tuesday, April 22, 8:00am – 6:00pm

Session 223, 8.5 contact hours (0.85 CEUs)
ACPE# 0016-9999-14-018-L01-P

See page 53 for course details. Separate registration and fee required.

LUNCH WORKSHOPS

Separate registration and an additional fee of \$50 per workshop is required. Includes a box lunch and ACPE credits. Tickets for these workshops may be purchased at the NKF Ticket Sales Booth in the Registration Area. Space is limited, so participation is available on a first-come, first-served basis.

WEDNESDAY, APRIL 23, 12:00PM – 2:00PM

NEPHROTIC SYNDROME IN 2014; SESSION 233

See page 54 for course details

ELECTROLYTES/ACID-BASE; SESSION 235

See page 55 for course details

FRIDAY, APRIL 25, 11:30AM – 1:00PM

CONTROVERSIES IN THE MANAGEMENT OF HYPERTENSION IN DIALYSIS PATIENTS; SESSION 237

See page 55 for course details

MANAGING THE PRE-ESRD PATIENT; SESSION 240

See page 56 for course details

PHARMACIST PROGRAM

TUESDAY, APRIL 22

TIME/ROOM	SESSION#	SESSION	COURSE DIRECTOR (S)	ACPE #	CREDITS
7:30am – 6:00pm Room 112	220	KIDNEY TRANSPLANTATION 2014 ●	Fuad Shihab, MD, FNKF	0016-9999-14-016-L01-P	8.5
7:30am – 4:30pm Room 114	222	CKD MANAGEMENT ALONG THE CONTINUUM: FROM PREDIALYSIS TO POLICY ●	Charmaine Lok, MD, MSc, FNKF Christopher Chan, MD, FRCPC	0016-9999-14-017-L01-P	7.25
8:00am – 6:00pm Room 115	223	GLOMERULAR DISEASES: UPDATES ON PATHOGENESIS AND TREATMENT ●	Fernando Fervenza, MD, PhD, FNKF Michael Choi, MD, FNKF	0016-9999-14-018-L01-P	8.5

WEDNESDAY, APRIL 23

TIME/ROOM	SESSION#	SESSION	FACULTY	ACPE #	CREDITS
6:00am – 7:45am Rooms 318-319	800	CLINICAL ASPECTS OF FIBROBLAST GROWTH FACTOR 23 IN CHRONIC KIDNEY DISEASE <i>Supported by an educational donation provided by Amgen</i>	Chair: Csaba Kovesdy, MD, FASN	0016-9999-14-057-L01-P	1.5
		A Clinician's Perspective on Fibroblast Growth Factor 23	Csaba Kovesdy, MD, FASN		
		FGF23 and Clinical Outcomes in Chronic Kidney Disease	Myles Wolf, MD, MMSc		
		Dietary and Pharmacologic Modifiers of FGF23	Orlando Gutierrez, MD, MMSc		
6:00am – 7:45am Rooms 310-311	807	HIGH-DOSE IRON: TAKING TREATMENT OF IRON DEFICIENCY ANEMIA TO A NEW LEVEL <i>Supported by an educational grant from AMAG Pharmaceuticals, Inc. and American Regent, Inc.</i>	Chair: Jay Wish, MD	0016-9999-14-059-L01-P	1.5
		Iron Deficiency Anemia in ND-CKD: Mechanisms and Treatment Implications	Jay Wish, MD		
		Iron Therapy in ND-CKD Patients: Oral or Intravenous?	Wajeh Qunibi, MD, FACP		
		The Role of IV Iron Therapy in ND-CKD: Newest Evidence	Daniel Coyne, MD		

WEDNESDAY, APRIL 23, *continued*

TIME/ROOM	SESSION#	SESSION	FACULTY	ACPE #	CREDITS
8:00am – 9:30am Room 317	261	NEW APPROACHES TO IMMUNOSUPPRESSION: IS LESS BETTER?	Chairs: Fuad Shihab, MD, FNKF, and Milagros Samaniego, MD, FACP, FASN	0016-9999 14-019-L01-P	1.5
		Corticosteroid Minimization and Avoidance Strategies	Donald Hricik, MD		
		Calcineurin Inhibitor Minimization and Avoidance Strategies	Flavio Vincenti, MD		
		Tolerance Induction in the Real World: Are We Ready for It?	Kenneth Newell, MD, PhD		
8:00am – 9:30am Room 117	661	PUS, BUGS, AND OTHER BAD THINGS		0016-9999 14-020-L01-P	1.5
		Pus and Bugs	Elizabeth Evans, RN, MSN, DNP		
		What is that Cough?	Carl Boethel, MD, FCCP, FAASM		
9:30am – 10:00am		BREAK			
10:00am – 11:30am Room 118	264	LUPUS NEPHRITIS	Chairs: Michael Choi, MD, FNKF, and Xueqing Yu, PhD, MBBS	0016-9999 14-021-L01-P	1.5
		Biomarkers from Bench to Bedside in Lupus Nephritis	Brad Rovin, MD		
		The Future of Steroids in Lupus Nephritis Therapy	Joanne Bargman, MD, FRCPC		
		Recent Trials of B Cell Depletion in Lupus Nephritis	Gerald Appel, MD		
10:00am – 11:30am Room 111	662	INTERDISCIPLINARY TRANSPLANT FROM THE PROS	Bobby Nibhanupudy, MD	0016-9999 14-022-L01-P	1.5
			Lara Tushla, MSW, LCSW, NSW-C		
			Wendy Escobedo, RN, MSN, PHN, CCTN		
			Angella Perez, CCHT-A		
			Maureen McCarthy, MPH, RD, CSR, LD		
10:00am – 11:30am Room 123	563	AMUSED AND AMAZED: HOW TO SURVIVE AND THRIVE AS A HEALTHCARE PROFESSIONAL	Karen Buxman, RN, MS, CSP, CPAE	0016-9999 14-023-L04-P	1.5
11:30am – 12:00pm		BREAK			
12:00pm – 2:00pm Room 318-319	801	REVISITING PHOSPHATE MANAGEMENT IN CHRONIC KIDNEY DISEASE	Chair: Kamyar Kalantar-Zadeh, MD, MPH, PhD, FNKF	0016-9999-14-024-L01-P	1.5
		<i>Supported by an educational grant from Fresenius Medical Care</i>			
		Overview of Phosphate Homeostasis, GI Absorption, and Dietary Sources	Kamyar Kalantar-Zadeh, MD, MPH, PhD, FNKF		
		Traditional and Newer Phosphate Binders	Bruce Spinowitz, MD, FACP		
		Integrating Dietary Restrictions and Therapeutic Agents to Control Phosphate	Stuart Sprague, DO, FNKF		

● Separate registration and/or fee required

TIME/ROOM	SESSION#	SESSION	FACULTY	ACPE #	CREDITS
12:00pm – 2:00pm Room 112	233	WORKSHOP: NEPHROTIC SYNDROME IN 2014 ●	Chairs: Daniel Cattran, MD, FRCP, FACP, and Debbie Gipson, MD, MS, FNKF	0016-9999-14-025-L01-P	2.0
		Epidemiology of Nephrotic Syndrome	Debbie Gipson, MD, MS, FNKF		
		Present and Future Role of Histopathology in Nephrotic Syndrome Classification	Cynthia Nast, MD		
		Nephrotic Syndrome Therapy: Guidelines, Practice, and Outcomes	Daniel Cattran, MD, FRCP, FACP		
12:00pm – 2:00pm Rooms 109-110	235	WORKSHOP: ELECTROLYTES/ACID-BASE ●	Chair: Kamel Kamel, MD, FRCP	0016-9999-14-026-L01-P	2.0
		Acid-Base Abnormalities and Toxic Ingestions: A Case-Based Discussion	Mark Perazella, MD, FNKF		
		Is There a Role for Vasopressin Receptor Antagonists in the Management of Chronic Hyponatremia and Kidney Diseases?	Joseph Verbalis, MD		
		Electrolyte Disturbances, Nephrotoxicity, and Recreational Drugs	Kamel Kamel, MD, FRCP		
2:00pm – 2:30pm		BREAK			
2:30pm – 3:30pm Room 115	265	NKF PRESIDENTIAL ADDRESS: BUILDING CKD AWARENESS	Beth Piraino, MD, FNKF	0016-9999-14-027-L01-P	1.0
		SHAUL G. MASSRY DISTINGUISHED LECTURE: VASCULAR DISEASE IN CHRONIC KIDNEY DISEASE: PROGRESS AND CHALLENGES	Mark Sarnak, MD, MS		
3:30pm – 4:00pm		BREAK			
4:00pm – 5:30pm Room 123	266	KDOQI – ROLES, CONTROVERSIES, AND GUIDELINES IN CKD	Chair: Jeffrey Berns, MD, FNKF	0016-9999-14-028-L01-P	1.5
		KDOQI – Merging Old and New Roles	Jeffrey Berns, MD, FNKF		
		Thresholds for 25(OH)D Supplementation in CKD	Holly Kramer, MD, MPH		
		KDOQI Commentary on KDIGO Clinical Practice Guidelines for CKD	Tamara Isakova, MD, MMSc		
6:00pm – 7:30pm		OPENING CEREMONIES AND RECEPTION IN THE EXHIBIT HALL – VISIT POSTERS/ EXHIBITS		0016-9999-14-053-L01-P	1.0*
7:30pm – 9:30pm Rooms 318-319	802	HEART-KIDNEY INTERACTION AND THE ROLE OF VASOPRESSIN AND HYPONATREMIA IN HEART FAILURE	Chair: Matthew Weir, MD	0016-9999-14-029-L01-P	1.5
		<i>Supported by an educational grant from Otsuka America Pharmaceutical, Inc.</i>			
		The Heart-Kidney Interaction in Heart Failure and the Pathogenesis of Hyponatremia	Matthew Weir, MD		
		The Utility of Current Treatment Options in the Management of Hyponatremia in the Heart Failure Patient with Impaired Kidney Function	Joseph Verbalis, MD		
		Lessons from Clinical Trials of Vasopressin Receptor Antagonists in Heart Failure	James Udelson, MD		

WEDNESDAY, APRIL 23, *continued*

TIME/ROOM	SESSION#	SESSION	FACULTY	ACPE #	CREDITS
7:30pm – 9:30pm Rooms 310-311	808	PERSISTENT HYPERURICEMIA: A MULTI-PRONGED APPROACH TO THE MANAGEMENT OF SERUM URATE LEVELS <i>Supported by an educational grant from Takeda Pharmaceuticals North America, Inc.</i>	Chair: Robert Terkeltaub, MD	0016-9999- 14- 060-L01-P	1.5
		Renal Dysfunction and the Management of Hyperuricemia	Jay Wish, MD		
		Managing Risk Factors and Comorbid Conditions in the Hyperuricemic Patient	Louis Kuritzky, MD		
		Application of Guidelines for Long-Term Treatment of Gout	Robert Terkeltaub, MD		

THURSDAY, APRIL 24

TIME/ROOM	SESSION#	SESSION	FACULTY	ACPE #	CREDITS
6:00am – 7:45am Rooms 318-319	803	CHANGING PROFILE OF CHRONIC HYPERKALEMIA <i>Supported by an educational grant from ZS Pharma, Inc.</i>	Chair: Peter McCullough, MD, MPH, FACC, FCCP, FACP, FAHA, FNKF	0016-9999- 14- 030-L01-P	1.5
		Frequency and Clinical Significance of Hyperkalemia in CKD	Robert Toto, MD		
		Risks of Hyperkalemia in Special Kidney Disease Populations	Michael Emmett, MD		
		Emerging Therapies for Treating Hyperkalemia	John Middleton, MD		
6:00am – 7:45am Rooms 310-311	806	THE ROLE OF BIOSIMILARS IN CHRONIC KIDNEY DISEASE <i>Supported by an educational grant from Hospira, Inc.</i>	Chair: Francesco Locatelli, MD	0016-9999- 14- 054-L01-P	1.5
		The State of Biosimilar Regulation and Development in the United States	Edward Li, PharmD, BCOP		
		Review of Biosimilars vs. Reference Biologics	Graham Jones, PhD, DIC		
		The Potential Role of Biosimilars in Chronic Kidney Disease	Francesco Locatelli, MD		
7:00am – 8:00am		CONTINENTAL BREAKFAST IN THE EXHIBIT HALL – VISIT POSTERS/EXHIBITS		0016-9999- 14- 053-L01-P	1.0*
8:30am – 10:00am Room 116	268	CHANGING THE COURSE OF DIABETIC NEPHROPATHY	Chairs: Adam Whaley- Connell, DO, MSPH, FAHA, FACP, FASN, FNKF, and Sylvia E. Rosas, MD, MSCE, FNKF	0016-9999- 14- 031-L01-P	1.5
		Management of Hyperglycemia and General Diabetes Care in CKD	Katherine Tuttle, MD, FASN, FACP		
		Management of Dyslipidemia in Diabetes and CKD	Linda Fried, MD, MPH, FNKF		
		Primary Prevention of Diabetic Nephropathy	Robert Stanton, MD		

● Separate registration and/or fee required

TIME/ROOM	SESSION#	SESSION	FACULTY	ACPE #	CREDITS
10:00am – 10:30am		BREAK			
10:30am – 12:00pm Room 123	272	OPTIMIZING MEDICATION-RELATED OUTCOMES IN CKD PATIENTS	Chair: Jerry Yee, MD, FACP, FNKF, FASN	0016-9999-14-	1.5
		Implementing Medication Therapy Management in CKD Patients: New Models of Care	Wendy St. Peter, PharmD, FCCP, FASN, FNKF	033-L01-P	
		Strategies to Reduce Polypharmacy in CKD Patients	Nancy Mason, PharmD		
		Top 10 Medication-Related Conundrums	Carol Moore, PharmD, BCPC, FNKF		
10:30am – 12:00pm Room 113	668	WINNING THE BATTLE AND LOSING THE WAR – PSYCHOTROPIC MEDICATIONS		0016-9999-14-	1.5
		Medical Complications of Psychotropic Drugs	Timothy Lineberry, MD	034-L01-P	
		Stump the Chump: Case Studies in Depression Meds	Kim Zuber, MS, PA-C, FNKF Amma Sewaah-Bonsu, MSN, DNP, NP-C		
12:00pm – 2:00pm		BREAK IN THE EXHIBIT HALL (LUNCH SERVED 12:15PM – 1:15PM) – VISIT POSTERS/EXHIBITS		0016-9999-14-	1.0*
				053-L01-P	
2:00pm – 3:30pm Room 123	273	CKD-MBD: PHOSPHATE, PTH, AND ACIDOSIS	Chair: Michal Melamed, MD, MHS, FNKF	0016-9999-14-	1.5
		Building the CKD-MBD Guidelines: An Insider’s View	Katrin Uhlig, MD, MS	035-L01-P	
		PTH Control in CKD: Vitamin D and Cinacalcet – When and How?	Michal Melamed, MD, MHS, FNKF		
		Phosphate: Binders and Beyond	Francesca Tentori, MD		
2:00pm – 3:30pm Room 121	274	AKI ASSOCIATED WITH THERAPEUTICS	Chairs: Chirag Parikh, MD, FNKF, and Claudio Ronco, MD, FNKF	0016-9999-14-	1.5
		AKI Associated with Anti-Microbial Use	Mark Perazella, MD, FNKF	036-L01-P	
		AKI Associated with Anti-Neoplastic Agents	Anushree Shirali, MD		
		AKI Associated Volume Resuscitation (Crystalloids, Colloids and Blood Products)	Chirag Parikh, MD, FNKF		
2:00pm – 3:30pm Room 317	275	STOP THE REVOLVING DOOR: REDUCING READMISSIONS IN HEMODIALYSIS AND PERITONEAL DIALYSIS PATIENTS	Chair: Raymond Hakim, MD, PhD	0016-9999-14-	1.5
		Understanding the Readmission Problem in Dialysis Patients	Daniel Weiner, MD, MS, FNKF	037-L01-P	
		Effective Interventions to Reduce Readmissions	Raymond Hakim, MD, PhD		
		Transitioning Back to Dialysis from Hospitalization	Rebecca Wingard, RN, MSN, CNN		
3:30pm – 4:00pm		BREAK			

THURSDAY, APRIL 24, *continued*

TIME/ROOM	SESSION#	SESSION	FACULTY	ACPE #	CREDITS
4:00pm – 5:30pm Room 121	277	OBVIOUS BUT OVERLOOKED CARE IN ESRD PATIENTS	Chair: Alfred Cheung, MD, FNKF	0016-9999-14-038-L01-P	1.5
		Cognitive and Psychological Disorders	Daniel Weiner, MD, MS, FNKF		
		Sleep Disorders	Mark Unruh, MD		
		Chronic Pain	Steven Weisbord, MD		
4:00pm – 5:30pm Room 116	278	DON'T BUG ME ON DIALYSIS! HEMODIALYSIS INFECTION UPDATE	Chairs: Charmaine Lok, MD, MSc, FNKF, and Michael Allon, MD	0016-9999-14-039-L01-P	1.5
		Practical Hemodialysis Bloodstream Prevention – A Multidisciplinary Approach	Michael Allon, MD		
		Prevention and Management of Multi-Drug Resistant Infections	William Salzer, MD		
		Preventing Infectious Outbreaks in the Dialysis Unit	Duc Nguyen, MD		
6:00pm – 7:30pm		NETWORKING RECEPTION IN THE EXHIBIT HALL-VISIT POSTERS/EXHIBITS		0016-9999-14-053-L01-P	1.0*
7:30pm – 9:30pm Rooms 318-319	804	NEW INSIGHTS INTO THE ROLE OF PHOSPHORUS BALANCE IN CHRONIC KIDNEY DISEASE	Chair: Myles Wolf, MD, MMSc	0016-9999-14-040-L01-P	1.5
		<i>Supported by an educational grant from Keryx Biopharmaceuticals, Inc.</i>			
		Understanding the Physiology and Therapeutic Targets of Phosphorus Homeostasis in Patients with CKD	Myles Wolf, MD, MMSc		
		Emerging Treatment Options for Serum Phosphorus Levels	Sylvia E. Rosas, MD, MSCE, FNKF		
		Strategies to Improve Care in Patients with Hyperphosphatemia and CKD	Geoffrey Block, MD, CCRI		

FRIDAY, APRIL 25

TIME/ROOM	SESSION#	SESSION	FACULTY	ACPE #	CREDITS
6:00am – 7:45am Rooms 318-319	805	EXPERT PERSPECTIVES IN THE MANAGEMENT OF BONE-MINERAL-VASCULAR DISORDERS: A PATHOPHYSIOLOGICAL AND EVIDENCE-BASED APPROACH TO CARE	Chair: Ellie Kelepouris, MD, FAHA	0016-9999-14-041-L01-P	1.5
		<i>Supported by an educational grant from Sanofi Renal</i>			
		Metabolic and Mineral Disturbances in CKD-MBD: A Discussion of Pathophysiology and Risk	Matthew Weir, MD		
		Dietary Calcium and Phosphorus: A Focus on Cardiovascular Risk in CKD-MBD	Kathleen Hill Gallant, PhD, RD		
		Evolving Clinical Perspectives: Application of Phosphorus and Calcium Management Strategies in Patients With CKD-MBD	Ellie Kelepouris, MD, FAHA		
8:00am – 11:30am		BREAK IN THE EXHIBIT HALL (BREAKFAST SERVED 8:00AM – 9:00AM) – VISIT POSTERS/EXHIBITS		0016-9999-14-053-L01-P	1.0*

● Separate registration and/or fee required

TIME/ROOM	SESSION#	SESSION	FACULTY	ACPE #	CREDITS
9:30am – 11:00am Room 123	280	FALLS AND FRACTURES	Chairs: Wolfgang Winkelmayr, MD, ScD, MPH, FASN, and Bryan Kestenbaum, MD, MS	0016-9999-14-042-L01-P	1.5
		Epidemiology of Fractures in Patients with Kidney Disease	Bryan Kestenbaum, MD, MS		
		Medications that Increase Fracture Risk	Wolfgang Winkelmayr, MD, ScD, MPH, FASN		
		Falls and Fall Prevention in Dialysis Patients	Michael Heung, MD, MS		
9:30am – 11:00am Room 113	674	PAIN AND THE KIDNEY PATIENT		0016-9999-14-043-L01-P	1.5
		I Hurt and I Don't Know Why	Lynn Hornick, NP, BSN, MSN		
		Hot to Trot: The Chronically Inflamed Patient	Susan Busch, MSN, CNP		
11:00am – 11:30am		BREAK			
11:30am – 1:00pm Rooms 210-211	237	WORKSHOP: CONTROVERSIES IN THE MANAGEMENT OF HYPERTENSION IN DIALYSIS PATIENTS ●	Chair: Wendy St. Peter, PharmD, FCCP, FASN, FNKF	0016-9999-14-044-L01-P	1.5
		Controversies of Blood Pressure Targets in Dialysis Patients	Tara Chang, MD, MS		
		RAS Agents in Hypertension Management in New Dialysis Patients	Aldo Peixoto, MD		
		Diuretic Agents in Hypertension Management in New Dialysis Patients	Wendy St. Peter, PharmD, FCCP, FASN, FNKF		
11:30am – 1:00pm Room 309	240	WORKSHOP: MANAGING THE PRE-ESRD PATIENT ●	Chair: Michal Melamed, MD, MHS, FNKF	0016-9999-14-045-L01-P	1.5
		Ensuring Medication-Related Safety in Late CKD	Jerry Yee, MD, FACP, FNKF, FASN		
		Nutrition Interventions to Delay Progression of CKD – Is There Evidence?	Carolyn Cochran, RD, MS, LD, CDE		
		Renal Replacement Therapy Discussions	Jeffrey Berns, MD, FNKF		
1:00pm – 1:30pm		BREAK			
1:30pm – 3:00pm Room 123	282	DIFFICULT-TO-TREAT HYPERTENSION	Chairs: Sylvia E. Rosas, MD, MSCE, FNKF, and George Bakris, MD	0016-9999-14-046-L01-P	1.5
		Epidemiology and Treatment of Resistant Hypertension	Raymond Townsend, MD, FAHA, FCHBPR		
		Case Studies of Difficult-to-Treat Hypertension in CKD	Debbie Cohen, MD		
		Emerging Therapies for Treating Resistant Hypertension	George Bakris, MD		
1:30pm – 3:00pm Room 116	283	TRENDY TOPICS FROM DOPPS	Chairs: Alfred Cheung, MD, FNKF, and Friedrich Port, MD, MS, FACP	0016-9999-14-047-L01-P	1.5
		Impact of Payment Changes and Guidelines in Anemia Management in ESRD	David Goodkin, MD, FASN		
		International Trends in Vascular Access Use and Procedures: Implications for Access Management	Francesca Tentori, MD		
		Patient-Centered Outcomes (PRO): What We Already Know and What We Need to Learn	Bill Peckham, BA		

FRIDAY, APRIL 25, *continued*

TIME/ROOM	SESSION#	SESSION	FACULTY	ACPE #	CREDITS
1:30pm – 3:00pm Room 113	676	IATROGENIC KIDNEY MURDER		0016-9999-14-048-L01-P	1.5
		The Top 10 Ways to Kill a Kidney	Harvey Feldman, MD, FACP		
		Shades of Grey: Protecting the AARP Member	Anne Marie Lilies, PharmD, BCPS		
3:00pm – 3:30pm		BREAK			
3:30pm – 5:00pm Room 121	285	ANNUAL LITERATURE UPDATE	Chair: Sylvia E. Rosas, MD, MSCE, FNKF	0016-9999-14-049-L01-P	1.5
		Hypertension	Raymond Townsend, MD, FAHA, FCHBPR		
		AKI	Chirag Parikh, MD, FNKF		
		Dialysis	Daniel Weiner, MD, MS, FNKF		

SATURDAY, APRIL 26

TIME/ROOM	SESSION#	SESSION	FACULTY	ACPE #	CREDITS
8:00am – 9:30am Rooms 314-315	286	BUNDLE UP! U.S. DIALYSIS POLICY	Chair: Friedrich Port, MD, MS, FACP	0016-9999-14-050-L01-P	1.5
		ESCOs and ACOs: Accountable Care and Nephrology	Daniel Weiner, MD, MS, FNKF		
		The Prospective Payment System	Jeffrey Berns, MD, FNKF		
		The Quality Incentive Program: An Update on ESRD Quality Metrics	Rajnish Mehrotra, MD, MBBS, FNKF		
8:00am – 9:30am Room 310	287	GUIDELINES AND THE OLDER PATIENT WITH CKD: DO THE SAME RULES APPLY?	Chairs: Katrin Uhlig, MD, MS, and Paul Stevens, MBBS, BSc, FRCP	0016-9999-14-055-L01-P	1.5
		Integrating Multiple Guidelines: Geriatric Perspective	Paul Stevens, MBBS, BSc, FRCP		
		Hypertension in Older CKD Patients (KDIGO)	Mark Sarnak, MD, MS		
		CKD Care for Older Adults	Dena Rifkin, MD, MS, FNKF		
9:30am – 10:00am		BREAK			
10:00am – 11:30am Room 318	288	MEASURES OF HYPERTENSION: BEYOND THE OFFICE	Chairs: Dena Rifkin, MD, MS, FNKF, and Carmen Peralta, MD	0016-9999-14-051-L01-P	1.5
		Moving Target for Blood Pressure Goals in CKD: Pros vs. Cons	Raymond Townsend, MD, FAHA, FCHBPR		
		Alternative Measures for Blood Pressure	Carmen Peralta, MD		
		When Should Non-Office Blood Pressure Monitoring be Used in 2014?	Aldo Peixoto, MD		
10:00am – 11:30am Room 319	680	THE TAO OF POO: HUMOR AND STRESS	Margarita Gurri, PhD	0016-9999-14-052-L04-P	1.5
11:30am		MEETING ADJOURNS			

* A maximum of 1.0 credit only will be awarded for poster sessions.

ADVANCED PRACTITIONER PROGRAM

Planning Committee

Kim Zuber, MS, PA-C, FNKF

Program Chair

Metropolitan Nephrology, Alexandria, VA

Amma Sewaah-Bonsu, MSN, DNP, NP-C

Program Co-Chair

Nephrology Associates of Central Florida, Orlando, FL

Stephanie Mahooty, MSN, ANP-C, CNN

Desert Kidney Associates, Mesa AZ

Mandy Trolinger MS, RD, PA-C

Denver Nephrology, Denver, CO

Program Goal

To improve patient outcomes by enhancing the advanced practitioner's knowledge base and skills that will have a direct impact on clinical practice in a variety of settings.

Continuing Education Information

Physician Assistants

The National Kidney Foundation is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AAPA accepts Category I credit from AOACME, prescribed credit from AAFP, and AMA *Category I Credit(s)*TM from organizations accredited by ACCME. Physician assistants may receive a maximum of 30.5 hours of Category I credit for completing this program.

Nurse Practitioners

This program is approved for 30.5 contact hours of continuing education (which includes 9.05 hours pharmacology) by the American Association of Nurse Practitioners. Program ID 1403129.

This program was planned in accordance with AANP CE Standards and Policies and AANP Commercial Support Standards.

Pre-Conference Course	Credits/ Contact Hours	Pharmacology Credits	Program ID
CKD Basics	4.0	1.25	1401057
The Hospitalist AP	4.0	2.0	1401060
CKD Advanced	4.0	1.0	1401059
Renal Replacement Therapy	4.0	1.0	1401056
Kidney Transplantation 2014	8.25	1.5	1401061
Integrated Hemodialysis/Peritoneal Dialysis	8.0	2.5	1401058
CKD Management Along the Continuum: From Predialysis to Policy	7.3	0.3	1402096
Glomerular Diseases: Updates on Pathogenesis and Treatment	8.5	4.2	1402069

ADVANCED
PRACTITIONER

PRE-CONFERENCE COURSES

REQUIRED: SEPARATE REGISTRATION.

Includes: Syllabus, light breakfast, boxed lunch, and CME credits/contact hours. Participation is limited, so register early.

PRICING

Half-Day Courses: \$60 NKF Members, \$75 Non-Members

Full-Day Courses: \$200 NKF Members, \$225 Non-Members

CKD Basics

Tuesday, April 22, 7:30am – 12:00pm

Course Directors: Mandy Trolinger, MS, RD, PA-C, and Kim Zuber, MS, PA-C, FNKF

Session 620, 4.0 credits/contact hours

TARGET AUDIENCE

Advanced Practitioners who are new to nephrology (within 5 years), new to practice or moving into the CKD clinic from other aspects of their practices.

COURSE DESCRIPTION

This course will provide the fundamental tools needed to practice in the CKD clinic. It will focus on CKD staging (including the new KDIGO Guidelines), hypertension management, diabetes management in the CKD patient, and preserving residual renal function in the failing CKD patient.

COURSE OBJECTIVES

Upon completion of this course, participants will be able to:

- Explain the renal labs with concentration on those significant for CKD, including but not limited to: urinalysis, hematology, chemistry and specialty labs
- Discuss HTN management of the CKD 3/4 vs. 5/5D patient and review of commonly used medications and JNC VII vs. KDIGO Guidelines
- Discuss the risks of diabetes mellitus in regards to CKD, while comparing and contrasting the medications used (identified by CKD stage) in CKD case studies
- Review the common medications, diagnostic tests and other “insults” to the kidney, along with methods to decrease exposure, with a further discussion of methods to preserve renal function

TIME	TOPIC	FACULTY
7:30am – 8:00am	Breakfast and Staging Your Kidney	Mandy Trolinger, MS, RD, PA-C
8:00am – 8:45am	Na, Ca, PO ₄ , Oh My! The Renal Lab	James Van Rhee, MS, PA-C
8:45am – 9:00am	Break	
9:00am – 9:45am	The Pressure Conundrum—HTN in CKD	Alexis Chettiar, MSN, ACNP
9:45am – 10:30am	Sugar, Sugar, You are My Candy Girl – Diabetes in CKD	Micheal Cronyn, PA-C, MPAS, CDE
10:30am – 10:45am	Break	
10:45am – 11:30am	The Function Junction-Preserving Residual Renal Function	Connie Jo Hemeyer, MSN, ARNP
11:30am – 12:00pm	Wrap-up and Questions	Kim Zuber, MS, PA-C, FNKF Mandy Trolinger, MS, RD, PA-C

The Hospitalist AP

Tuesday, April 22, 7:30am – 12:15pm

Course Directors: Barbara Weis Malone, MSN, RN, CFNP, and Amma Sewaah-Bonsu, MSN, DNP, NP-C
Session 621, 4.0 credits/contact hours

TARGET AUDIENCE

Designed for the experienced AP who is functioning in the acute care setting, or for the AP who wishes to move into acute care.

COURSE DESCRIPTION

Recognizing that the Nephrology AP wears many hats, including functions in the acute care setting, this 4-hour course is designed for that practitioner. This course will review causes of AKI in the CKD population, leading causes of sepsis in the ICU along with a discussion of the new international sepsis guidelines, pharmacology in the hospital setting, and choice of acute RRT (when and what) will be highlighted.

COURSE OBJECTIVES:

Upon completion of this course, participants will be able to:

- Review the iatrogenic and non-iatrogenic causes of AKI, along with suggestions on acute management
- Apply the new international sepsis guidelines to acutely ill CKD/ESRD patients in the ICU
- Discuss renal medication dosing in the ICU for the AKI, AKI on CKD, CKD and crashing ICU patient, including what we can do to solve the question of dosing the rapidly changing patient
- Identify the types of continuous therapies used in the ICU, along with a discussion of the pros and cons of each type, and the basis of patient selection

TIME	TOPIC	FACULTY
7:30am – 8:00am	Breakfast and Introductions	Barbara Weis Malone, MSN, RN, CFNP
8:00am – 8:45am	The Bump: AKI on CKD	Charles Foulks, MD
8:45am – 9:30am	Killing Me Slowly—Sepsis in the ICU	Paul Szczybor, PA-C
9:30am – 10:15am	Lucy in the Sky with Dosing: Advanced Pharmacology in the ICU	Anne Marie Liles, PharmD, BCPS
10:15am – 11:00am	Break	
11:00am – 11:45am	The Alphabet that AKI Built—CRRT and Close Relatives	Catherine Wells, DNP, ACNP-BC, CNN-NP
11:45am – 12:15pm	Wrap-up and Questions	Barbara Weis Malone, MSN, RN, CFNP Amma Sewaah-Bonsu, MSN, DNP, NP-C

CKD Advanced

Tuesday, April 22, 12:30pm – 5:15pm

Course Directors: Barbara Weis Malone, MSN, RN, CFNP, and Amma Sewaah-Bonsu, MSN, DNP, NP-C

Session 622, 4.0 credits/contact hours

TARGET AUDIENCE

Designed for the experienced AP who wants a deeper understanding of CKD and management of the challenging CKD patient.

COURSE DESCRIPTION

This course will cover hypertension and hypotension management, decipher the kidney biopsy with details on how to use the information obtained, discuss management of cardio-renal patients, and give a bird's eye view of hematology-oncology topics commonly seen in the CKD/ESRD patient.

COURSE OBJECTIVES:

Upon completion of this course, participants will be able to:

- Discuss the chronic hypotensive patient with advanced cardiac disease and the resistant hypertensive patient, using patient examples, and discuss echo and ambulatory BP monitoring
- Discuss the biopsy result and initiating treatment on disorders from AIN to ATN through patient examples
- Assess and discuss various treatment options for thrombocytopenia, leucopenia, and resistant anemia in the CKD/ESRD patient (myeloma, MGUS), including patient examples
- Review the diagnosis, medical and symptom management of the cardio-renal patient, and review the liver/kidney failure patient in the outpatient setting

TIME	TOPIC	FACULTY
12:30pm – 1:00pm	Lunch and Welcome	Barbara Weis Malone, MSN, RN, CFNP
1:00pm – 1:45pm	The BP is What?!!!!	Susan Busch, MSN, CNP
1:45pm – 2:30pm	Breaking the Biopsy Code	Alexis Snead, MD
2:30pm – 3:15pm	Curbside Hem/Onc Consult	Glen Peterson, ACNP
3:15pm – 4:00pm	Break	
4:00pm – 4:45pm	The Heart of the Matter	Claudio Ronco, MD, FNKF
4:45pm – 5:15pm	Wrap-up and Questions	Amma Sewaah-Bonsu, MSN, DNP, NP-C

Renal Replacement Therapy

Tuesday, April 22, 12:30pm – 5:15pm

Course Directors: Mandy Trolinger, MS, RD, PA-C,
and Kim Zuber, MS, PA-C, FNKF

Session 623, 4.0 credits/contact hours

TARGET AUDIENCE

Designed for the new (less than 5 years, or new to RRT) AP to give a solid basic understanding of hemodialysis, peritoneal dialysis, and transplantation.

COURSE DESCRIPTION

This course will delve into all aspects of RRT and discuss the pros and cons of each. We will meet the practitioners involved in the care of RRT patients, followed by pearls in hemodialysis. We will follow with an introduction to PD, answering the most important question—who to refer, and then roll into access and transplantation. The goal is to give a solid, basic understanding of RRT.

COURSE OBJECTIVES

Upon completion of this course, participants will be able to:

- Define the AP, RN, PCT, SW and dietitian, and describe their education and job descriptions.
- Demonstrate and discuss the hemodialysis machine; RX—including types of baths, sodium modeling, UF profiles; and complications that can occur with hemodialysis and strategies to prevent them
- Review selection of patients for PD, types, RX, adequacy, complications, and methods to increase adequacy, decrease infections, and manage fluid balance
- Describe the placement of the AVF, AVG, PD and central hemo catheter along with pros and cons of each type of access.
- Review the 3 surgical approaches (pro and con) to placement of a PD catheter
- Review the evaluation process for TX, discuss risks of surgery and immunosuppressant medications, and address the importance of communication between providers in the transplant process

TIME	TOPIC	FACULTY
12:30pm – 1:00pm	Lunch and Introductions	Mandy Trolinger, MS, RD, PA-C
1:00pm – 2:00pm	The Crashing HD Patient – Pearls from the Pros	Angella Perez, CCHT-A
2:00pm – 3:00pm	Tips to Make PD Work for You	Brigitte Schiller, MD
3:00pm – 3:45pm	The Right Patient, The Right Access, The Right Time	Lynn Poole, FNP-BC, CNN Kim Zuber, MS, PA-C, FNKF
3:45pm – 4:00pm	Break	
4:00pm – 4:45pm	I Left My Heart in San Francisco: Transplant Update	Barbara Weis Malone, MSN, RN, CFNP
4:45pm – 5:15pm	Wrap-up and Questions	Mandy Trolinger, MS, RD, PA-C Kim Zuber, MS, PA-C, FNKF

Kidney Transplantation 2014

Tuesday, April 22, 7:30am – 6:00pm

Session 220, 8.25 credits/contact hours

See page 49 for course details. Separate registration and fee required.

Integrated Hemodialysis/Peritoneal Dialysis

Tuesday, April 22, 7:00am – 5:00pm

Session 221, 8.0 credits/contact hours

See page 51 for course details. Separate registration and fee required.

CKD Management Along the Continuum: From Pre-dialysis to Policy

Tuesday, April 22, 7:30am – 4:30pm

Session 222, 7.3 credits/contact hours

See page 52 for course details. Separate registration and fee required.

Glomerular Diseases: Updates on Pathogenesis and Treatment

Tuesday, April 22, 8:00am – 6:00pm

Session 223, 8.5 credits/contact hours

See page 53 for course details. Separate registration and fee required.

LUNCH WORKSHOPS

Separate registration and an additional fee of \$50 per workshop is required. Includes a box lunch and CME Credits/Contact Hours. Tickets for these workshops may be purchased at the NKF Ticket Sales Booth in the Registration Area. Space is limited, so participation is available on a first-come, first-served basis.

FRIDAY, APRIL 25, 11:30AM – 1:00PM

ACCESS ISSUES; SESSION 630

Presenters: Lynn Poole, NP, FNP-BC, CNN, and Tushar Vachharajani, MD, FASN, FACP

Workshop Description: Join our experts for a discussion of access issues across the continuum. Starting with an overview of the surgery, have our experts walk you through evaluation and monitoring, with a special emphasis on trouble-shooting the difficult patient.

CONTROVERSIES IN THE MANAGEMENT OF HYPERTENSION IN DIALYSIS PATIENTS; SESSION 237

See page 55 for course details.

ADVANCED PRACTITIONER PROGRAM

TUESDAY, APRIL 22

TIME/ROOM	SESSION#	SESSION	COURSE DIRECTOR(S)	NOTES	CREDITS
7:30am – 12:00pm Room 122	620	CKD BASICS	Mandy Trolinger, MS, RD, PA-C Kim Zuber, MS, PA-C, FNKF	▲ ●	4.0 (1.25 Pharm)
7:30am – 12:15pm Room 123	621	THE HOSPITALIST AP	Barbara Weis Malone, MSN, RN, CFNP Amma Sewaah-Bonsu, MSN, DNP, NP-C	●	4.0 (2.0 Pharm)
12:30pm – 5:15pm Room 124	622	CKD ADVANCED	Barbara Weis Malone, MSN, RN, CFNP Amma Sewaah-Bonsu, MSN, DNP, NP-C	●	4.0 (1.0 Pharm)
12:30pm – 5:15pm Rooms 304-305	623	RENAL REPLACEMENT THERAPY	Mandy Trolinger, MS, RD, PA-C Kim Zuber, MS, PA-C, FNKF	●	4.0 (1.0 Pharm)
6:30pm – 8:00pm Premier Ballroom Lobby	101	HEALTHCARE PROFESSIONALS WELCOME RECEPTION		▲	

ADVANCED
PRACTITIONER

WEDNESDAY, APRIL 23

TIME/ROOM	SESSION#	SESSION	FACULTY	NOTES	CREDITS
6:00am – 7:45am Rooms 318-319	800	CLINICAL ASPECTS OF FIBROBLAST GROWTH FACTOR 23 IN CHRONIC KIDNEY DISEASE <i>Supported by an educational donation provided by Amgen</i>	Chair: Csaba Kovesdy, MD, FASN	■	1.5 (0.33 Pharm)
		A Clinician's Perspective on Fibroblast Growth Factor 23	Csaba Kovesdy, MD, FASN		
		FGF23 and Clinical Outcomes in Chronic Kidney Disease	Myles Wolf, MD, MMSc		
		Dietary and Pharmacologic Modifiers of FGF23	Orlando Gutierrez, MD, MMSc		
6:00am – 7:45am Rooms 310-311	807	HIGH-DOSE IRON: TAKING TREATMENT OF IRON DEFICIENCY ANEMIA TO A NEW LEVEL <i>Supported by an educational grant from AMAG Pharmaceuticals, Inc. and American Regent, Inc.</i>	Chair: Jay Wish, MD	■	1.5 (0.8 Pharm)
		Iron Deficiency Anemia in ND-CKD: Mechanisms and Treatment Implications	Jay Wish, MD		
		Iron Therapy in ND-CKD Patients: Oral or Intravenous?	Wajeh Qunibi, MD, FACP		
		The Role of IV Iron Therapy in ND-CKD: Newest Evidence	Daniel Coyne, MD		
8:00am – 9:30am Room 122	660	NEPHROLOGY MYSTERIES AND THE PATH THAT SOLVES THEM	Miriam Michael, MD Alexis Sneed, MD		1.5 (0.25 Pharm)
8:00am – 9:30am Room 117	661	PUS, BUGS, AND OTHER BAD THINGS			1.5
		Pus and Bugs	Elizabeth Evans, RN, MSN, DNP		(0.5 Pharm)
		What is that Cough?	Carl Boethel, MD, FCCP, FAASM		

WEDNESDAY, APRIL 23, *continued*

TIME/ROOM	SESSION#	SESSION	FACULTY	NOTES	CREDITS
9:30am – 10:00am		BREAK			
10:00am – 11:30am Room 111	662	INTERDISCIPLINARY TRANSPLANT FROM THE PROS	Bobby Nibhanupudy, MD Lara Tushla, MSW, LCSW, NSW-C Wendy Escobedo, RN, MSN, PHN, CCTN Angella Perez, CCHT-A Maureen McCarthy, MPH, RD, CSR, LD	▲	1.5
10:00am – 11:30am Room 122	663	THE FORGOTTEN HEAD OF THE KIDNEY PATIENT			1.5 (0.5 Pharm)
		The Eye of the Kidney: Ophthalmology	Kristine Wyatt, PA-C		
		The Other Rhyoid	Michael Cronyn, PA-C, MPAS, CDE		
10:00am – 11:30am Room 118	264	LUPUS NEPHRITIS	Chairs: Michael Choi, MD, FNKF, and Xueqing Yu, PhD, MBBS Biomarkers from Bench to Bedside in Lupus Nephritis The Future of Steroids in Lupus Nephritis Therapy Recent Trials of B Cell Depletion in Lupus Nephritis	■	1.5 (0.5 Pharm)
			Brad Rovin, MD		
			Joanne Bargman, MD, FRCPC		
			Gerald Appel, MD		
11:30am – 12:00pm		BREAK			
12:00pm – 2:00pm Room 316	664	COUNCIL OF ADVANCED PRACTITIONERS' LUNCHEON – ALL ARE WELCOME!			
12:00pm – 2:00pm Rooms 318-319	801	REVISITING PHOSPHATE MANAGEMENT IN CHRONIC KIDNEY DISEASE <i>Supported by an educational grant from Fresenius Medical Care</i>	Chair: Kamyar Kalantar-Zadeh, MD, MPH, PhD, FNKF Overview of Phosphate Homeostasis, GI Absorption, and Dietary Sources Traditional and Newer Phosphate Binders Integrating Dietary Restrictions and Therapeutic Agents to Control Phosphate	■	1.5 (0.6 Pharm)
			Kamyar Kalantar-Zadeh, MD, MPH, PhD, FNKF		
			Bruce Spinowitz, MD, FACP		
			Stuart Sprague, DO, FNKF		
2:00pm – 2:30pm		BREAK			
2:30pm – 3:30pm Room 115	265	NKF PRESIDENTIAL ADDRESS: BUILDING CKD AWARENESS SHAUL G. MASSRY DISTINGUISHED LECTURE: VASCULAR DISEASE IN CHRONIC KIDNEY DISEASE: PROGRESS AND CHALLENGES	Beth Piraino, MD, FNKF Mark Sarnak, MD, MS	■▲	1.0
3:30pm – 4:00pm		BREAK			
4:00pm – 5:30pm Room 123	266	KDOQI – ROLES, CONTROVERSIES, AND GUIDELINES IN CKD	Chair: Jeffrey Berns, MD, FNKF KDOQI – Merging Old and New Roles Thresholds for 25(OH)D Supplementation in CKD KDOQI Commentary on KDIGO Clinical Practice Guidelines for CKD	■▲	1.5 (0.2 Pharm)
			Jeffrey Berns, MD, FNKF		
			Holly Kramer, MD, MPH		
			Tamara Isakova, MD, MMSc		

Joint with Physicians
 Separate registration and/or fee required
 Joint with Councils

TIME/ROOM	SESSION#	SESSION	FACULTY	NOTES	CREDITS
4:00pm – 5:30pm Room 118	665	LOST IN TRANSLATION OF THE LAB RESULT		▲	1.5 (0.5 Pharm)
		CBC on a Slide	Janie McDaniel, BSMT		
		The Alphabet Soup of Rheumatology Labs	James Van Rhee, MS, PA-C		
4:00pm – 5:30pm Room 317	267	ACHIEVING GREAT RESULTS IN PERITONEAL DIALYSIS	Chairs: Beth Piraino, MD, FNKF, and David Johnson, PhD, FRACP, MBBS	■	1.5
		Working to Decrease Peritonitis Rates: Focus on Training	David Johnson, PhD, FRACP, MBBS		
		Appropriate and Timely Transition from PD to HD	Rajnish Mehrotra, MD, MBBS, FNKF		
		Urgent Start PD	Joni Hansson, MD, FNKF		
6:00pm – 7:30pm		OPENING CEREMONIES AND RECEPTION IN THE EXHIBIT HALL – VISIT POSTERS/EXHIBITS			1.0*
7:30pm – 9:30pm Rooms 318-319	802	HEART-KIDNEY INTERACTION AND THE ROLE OF VASOPRESSIN AND HYONATREMIA IN HEART FAILURE	Chair: Matthew Weir, MD	■	1.5 (0.4 Pharm)
		<i>Supported by an educational grant from Otsuka America Pharmaceutical, Inc.</i>			
		The Heart-Kidney Interaction in Heart Failure and the Pathogenesis of Hyponatremia	Matthew Weir, MD		
		The Utility of Current Treatment Options in the Management of Hyponatremia in the Heart Failure Patient with Impaired Kidney Function	Joseph Verbalis, MD		
		Lessons from Clinical Trials of Vasopressin Receptor Antagonists in Heart Failure	James Udelson, MD		
7:30pm – 9:30pm Rooms 310-311	808	PERSISTENT HYPERURICEMIA: A MULTI-PRONGED APPROACH TO THE MANAGEMENT OF SERUM URATE LEVELS	Chair: Robert Terkeltaub, MD	■	1.5 (0.4 Pharm)
		<i>Supported by an educational grant from Takeda Pharmaceuticals North America, Inc.</i>			
		Renal Dysfunction and the Management of Hyperuricemia	Jay Wish, MD		
		Managing Risk Factors and Comorbid Conditions in the Hyperuricemic Patient	Louis Kuritzky, MD		
		Application of Guidelines for Long-Term Treatment of Gout	Robert Terkeltaub, MD		

THURSDAY, APRIL 24

TIME/ROOM	SESSION#	SESSION	FACULTY	NOTES	CREDITS
6:00am – 7:45am Rooms 318-319	803	CHANGING PROFILE OF CHRONIC HYPERKALEMIA	Chair: Peter McCullough, MD, MPH, FACC, FCCP, FACP, FAHA, FNKF	■	1.5 (0.5 Pharm)
		<i>Supported by an educational grant from ZS Pharma, Inc.</i>			
		Frequency and Clinical Significance of Hyperkalemia in CKD	Robert Toto, MD		
		Risks of Hyperkalemia in Special Kidney Disease Populations	Michael Emmett, MD		
		Emerging Therapies for Treating Hyperkalemia	John Middleton, MD		

THURSDAY, APRIL 24, *continued*

TIME/ROOM	SESSION#	SESSION	FACULTY	NOTES	CREDITS
6:00am – 7:45am Rooms 310-311	806	THE ROLE OF BIOSIMILARS IN CHRONIC KIDNEY DISEASE <i>Supported by an educational grant from Hospira, Inc.</i>	Chair: Francesco Locatelli, MD	■	1.5 (0.4 Pharm)
		The State of Biosimilar Regulation and Development in the United States	Edward Li, PharmD, BCOP		
		Review of Biosimilars vs. Reference Biologics	Graham Jones, PhD, DIC		
		The Potential Role of Biosimilars in Chronic Kidney Disease	Francesco Locatelli, MD		
7:00am – 8:00am		CONTINENTAL BREAKFAST IN THE EXHIBIT HALL – VISIT POSTERS/EXHIBITS			1.0*
8:30am – 10:00am Room 113	666	CYSTS AND THEIR CLOSE RELATIVES			1.5 (0.25 Pharm)
		PKD: An Update on Diagnostic Criteria and Therapy	Dana Rizk, MD		
		RADS of Cysts	Ronald Perrone, MD, FNKF		
8:30am – 10:00am Room 111	667	MISBEHAVING LABS			1.5 (0.33 Pharm)
		Blood Dyscrazia	Alan Platt, PA-C, MMSc		
		ABCs of the ABGs	Paul Szczybor, PA-C		
10:00am – 10:30am		BREAK			
10:30am – 12:00pm Room 113	668	WINNING THE BATTLE AND LOSING THE WAR – PSYCHOTROPIC MEDICATIONS			1.5 (1.5 Pharm)
		Medical Complications of Psychotropic Drugs	Timothy Lineberry, MD		
		Stump the Chump: Case Studies in Depression Meds	Kim Zuber, MS, PA-C, FNKF Amma Sewaah-Bonsu, MSN, DNP, NP-C		
10:30am – 12:00pm Room 115	669	TO PEE OR NOT TO PEE			1.5 (0.25 Pharm)
		Burning Desire	Robert Toto, MD		
		Peeing Out Protein	Denise Link, MPAS, PA-C		
12:00pm – 2:00pm		BREAK IN THE EXHIBIT HALL (LUNCH SERVED 12:15PM – 1:15PM) – VISIT POSTERS/EXHIBITS			1.0*
2:00pm – 3:30pm Room 113	670	TRANSPLANT FROM A TO Z			1.5 (0.5 Pharm)
			Bobby Nibhanupudy, MD Amma Sewaah-Bonsu, MSN, DNP, NP-C Mandy Trolinger, MS, RD, PA-C		
2:00pm – 3:30pm Room 112	671	THE NON-MI CHEST PAIN			1.5 (0.5 Pharm)
		Non-Cardiac Chest Pain – Conditions that Kill	Carl Boethel, MD, FCCP, FAASM		
		PVC Pipes: The Hyper-Coag Patient	Alan Platt, PA-C, MMSc		
2:00pm – 3:30pm Room 123	273	CKD-MBD: PHOSPHATE, PTH, AND ACIDOSIS	Chair: Michal Melamed, MD, MHS, FNKF	■	1.5 (0.5 Pharm)
		Building the CKD-MBD Guidelines: An Insider's View	Katrin Uhlig, MD, MS		
		PTH Control in CKD: Vitamin D and Cinacalcet – When and How?	Michal Melamed, MD, MHS, FNKF		
		Phosphate: Binders and Beyond	Francesca Tentori, MD		
3:30pm – 4:00pm		BREAK			

Joint with Councils

Joint with Physicians



Separate registration and/or fee required

TIME/ROOM	SESSION#	SESSION	FACULTY	NOTES	CREDITS
4:00pm – 5:30pm Room 123	672	YOU BE THE JUDGE: NEPHROLOGY MALPRACTICE CASES	Della Connor, PhD, FNP-BC, RN Jane Davis, DNP, CRNP, MSN, FNKF Sharon Johnson, JD, RD, LD	▲	1.5
6:00pm – 7:30pm		NETWORKING RECEPTION IN THE EXHIBIT HALL – VISIT POSTERS/EXHIBITS			1.0*
7:30pm – 9:30pm Rooms 318-319	804	NEW INSIGHTS INTO THE ROLE OF PHOSPHORUS BALANCE IN CHRONIC KIDNEY DISEASE <i>Supported by an educational grant from Keryx Biopharmaceuticals, Inc.</i>	Chair: Myles Wolf, MD, MMSc	■	1.5 (0.4 Pharm)
		Understanding the Physiology and Therapeutic Targets of Phosphorus Homeostasis in Patients with CKD	Myles Wolf, MD, MMSc		
		Emerging Treatment Options for Serum Phosphorus Levels	Sylvia E. Rosas, MD, MSCE, FNKF		
		Strategies to Improve Care in Patients with Hyperphosphatemia and CKD	Geoffrey Block, MD, CCRI		

FRIDAY, APRIL 25

TIME/ROOM	SESSION#	SESSION	FACULTY	NOTES	CREDITS
6:00am – 7:30pm Rooms 318-319	805	EXPERT PERSPECTIVES IN THE MANAGEMENT OF BONE-MINERAL-VASCULAR DISORDERS: A PATHOPHYSIOLOGICAL AND EVIDENCE-BASED APPROACH TO CARE <i>Supported by an educational grant from Sanofi Renal</i>	Chair: Ellie Kelepouris, MD, FAHA	■	1.5 (0.33 Pharm)
		Metabolic and Mineral Disturbances in CKD-MBD: A Discussion of Pathophysiology and Risk	Matthew Weir, MD		
		Dietary Calcium and Phosphorus: A Focus on Cardiovascular Risk in CKD-MBD	Kathleen Hill Gallant, PhD, RD		
		Evolving Clinical Perspectives: Application of Phosphorus and Calcium Management Strategies in Patients With CKD-MBD	Ellie Kelepouris, MD, FAHA		
8:00am – 11:30am		BREAK IN THE EXHIBIT HALL (BREAKFAST SERVED 8:00AM – 9:00AM) – VISIT POSTERS/EXHIBITS			1.0*
9:30am – 11:00am Room 112	673	MONEY MATTERS			1.5
		Dollars and Sense: Calculating Your Productivity	Michael Powe, BS		
		2014 NKF Salary and Benefits Survey Prelims	Sean George, PA-C		
9:30am – 11:00am Room 113	674	PAIN AND THE KIDNEY PATIENT			1.5 (0.6 Pharm)
		I Hurt and I Don't Know Why	Lynn Hornick, NP, BSN, MSN		
		Hot to Trot: The Chronically Inflamed Patient	Susan Busch, MSN, CNP		
11:00am – 11:30am		BREAK			
11:30am – 1:00pm Rooms 301-302	630	WORKSHOP: ACCESS ISSUES	Lynn Poole, FNP-BC, CNN Tushar Vachharajani, MD, FASN, FACP	●	1.5

FRIDAY, APRIL 25, *continued*

TIME/ROOM	SESSION#	SESSION	FACULTY	NOTES	CREDITS
11:30am – 1:00pm Rooms 210-211	237	WORKSHOP: CONTROVERSIES IN THE MANAGEMENT OF HYPERTENSION IN DIALYSIS PATIENTS	Chair: Wendy St. Peter, PharmD, FCCP, FASN, FNKF	● ■	1.5 (0.41 Pharm)
		Controversies of Blood Pressure Targets in Dialysis Patients	Tara Chang, MD, MS		
		RAS Agents in Hypertension Management in Dialysis Patients	Aldo Peixoto, MD		
		Diuretic Agents in Hypertension Management in Dialysis Patients	Wendy St. Peter, PharmD, FCCP, FASN, FNKF		
1:00pm – 1:30pm		BREAK			
1:30pm – 3:00pm Room 112	675	HOT BELLIES AND THE O.R.			1.5 (0.5 Pharm)
		The Bellyaching Patient	Jerry Simons, PA-C		
		The Surgical Clearance of the Kidney Patient	Kevin Hall, MHSc, AA-C, PA-C		
1:30pm – 3:00pm Room 113	676	IATROGENIC KIDNEY MURDER			1.5 (0.9 Pharm)
		The Top 10 Ways to Kill a Kidney	Harvey Feldman, MD, FACP		
		Shades of Grey: Protecting the AARP Member	Anne Marie Lilies, PharmD, BCPS		
3:00pm – 3:30pm		BREAK			
3:30pm – 5:00pm Room 123	677	THE HITCHHIKERS GUIDE TO NEPHROLOGY- FROM POSTERS TO PRINT AND BACK	Jane Davis, DNP, CRNP, MSN, FNKF Peter Juergensen, PA-C		1.5 (0.25 Pharm)
3:30pm – 5:00pm Room 116	284	IMPROVING THE TRANSITION FROM CKD TO ESRD	Chairs: Charmaine Lok, MD, MSc, FNKF, and Timmy Lee, MD, MSPH, FACP, FASN, FNKF	■	1.5
		Patient-Centered Decision Making on Treatment Options for Renal Replacement Therapy.	Louise Moist, MD, MSc, FRCPC		
		Preparing Patients and Their Families for Dialysis (HD and PD)	Jane Schell, MD		
		Deciding Against Chronic Dialysis – Now What?	Alvin Moss, MD, FAAHPM		

SATURDAY, APRIL 26

TIME/ROOM	SESSION #	SESSION	FACULTY	NOTES	CREDITS
8:00am – 9:30am Room 319	678	THE HEART OF THE MATTER			1.5 (0.5 Pharm)
		Management of the Cardio-Renal Patient	Peter Juergensen, PA-C		
		He's Clicking Away – Valvular Disease	Lynn Beaulieu, RN, MSN, ANP-BC		
8:00am – 9:30am Room 318	679	KIDNEY DISEASE EDUCATION			1.5
		Kidney Education: Who, What, Where, When, and How	Della Connor, PhD, FNP-BC, RN		
		Stories From the Trenches: What Works	Barbara Weis Malone, MSN, RN, CFNP		
9:30am – 10:00am		BREAK			
10:00am – 11:30am Room 319	680	THE TAO OF POO: HUMOR AND STRESS	Margarita Gurri, PhD	▲	1.5
11:30am		MEETING ADJOURNS			

* A maximum of 1.0 credit only will be awarded for poster sessions.

Joint with Physicians ● Separate registration and/or fee required ▲ Joint with Councils

NEPHROLOGY NURSE AND TECHNICIAN PROGRAM

Planning Committee

Cintia Perez, RN, BSN, CNN

Program Chair

Saint Joseph's Hospital, Orange, CA

Kim Deaver, RN, MSN, CNN

Program Co-Chair

University of Virginia Health System, Charlottesville, VA

Carolyn Atkins, RN, BSN, CCTC

Children's Medical Center, Dallas, TX

Melinda Martin-Lester, RN, BA, CNN, CHC

Renal Ventures Management, Phoenix, AZ

Stuart Mott, LVN

Mercy Medical Center, Cedar Rapids, IA

Erma Rainey, RN, BSN

Liberty Dialysis, St. George, UT

Ken Renel, CCHT-A, CBNT

University of Virginia Health System, Charlottesville, VA

Helen Williams, RN, MSN, CNN

Fresenius Medical Care, Elizabeth, CO

PROGRAM GOAL

To improve patient outcomes by enhancing nephrology nurses' and technicians' knowledge base and skills that will have a direct impact on clinical practice in a variety of settings.

CONTINUING EDUCATION INFORMATION

The National Kidney Foundation is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Awarded 30.5 contact hours of continuing nursing education (includes 4.03 contact hours in the area of pharmacology).

The following pre-conference courses have been approved:

Pre-Conference Course	Contact Hours	Pharmacology Contact Hours
CKD Basics	4.0	1.25
Water Treatment: A Clinical Approach to a Technical Matter	3.75	—
Kidney Transplantation 2014	8.25	1.5
Integrated Hemodialysis/ Peritoneal Dialysis	8.0	2.5
CKD Management Along the Continuum: From Predialysis to Policy	7.3	0.3

PRE-CONFERENCE COURSES

REQUIRED: SEPARATE REGISTRATION

Includes syllabus, light breakfast, boxed lunch, and CE contact hours. Participation is limited.

PRICING

Half-Day Courses: \$60 NKF Members, \$75 Non-Members

Full-Day Courses: \$200 NKF Members, \$225 Non-Members

Water Treatment: A Clinical Approach to a Technical Matter

Tuesday, April 22, 1:00pm – 5:00pm

Course Director:

Danilo Concepcion, CCHT, CHT, CBNT

Session 320, 3.75 contact hours

TARGET AUDIENCE

Nephrology technicians, registered nurses, and other healthcare professionals interested in dialysis facility water treatment and its clinical implications.

COURSE DESCRIPTION

This course will provide a comprehensive review of the typical dialysis water treatment system, the importance of an effective monitoring program, safe judgment to perform dialysis with water issues, and the significance of a Quality Performance Improvement water treatment program.

COURSE OBJECTIVES

Upon the completion of this course, participants will be able to:

- List components and functions of the typical dialysis water treatment system
- Discuss the methods of monitoring water treatment
- Describe the role of clinical and technical staff in monitoring an effective program
- Explain how to make a safe judgment to do dialysis with water issues
- Identify strategies for an effective Water Treatment Quality Assessment Performance Improvement

TIME	TOPIC	FACULTY
1:00pm – 2:00pm	Source Water/Pre-Treatment Components and Function	Danilo Concepcion, CCHT, CHT, CBNT
2:00pm – 2:45pm	Primary Treatment/Post-Treatment Components and Function	Alex Karmaszin, CBNT
2:45pm – 3:00pm	Break	
3:00pm – 3:45pm	Methods of Monitoring the Water System and Role of the Clinical/Technical Staff	Alex Karmaszin, CBNT
3:45pm – 5:00pm	Trending/Determining If the Water System is Safe for Use/Strategies and Regulatory Issues for Water Systems	Danilo Concepcion, CCHT, CHT, CBNT

CKD Basics

Tuesday, April 22, 7:30am – 12:00pm

Session 620, 4.0 contact hours

See page 80 for course details.

Kidney Transplantation 2014

Tuesday, April 22, 7:30am – 6:00pm

Session 220, 8.25 contact hours

See page 49 for course details.

Integrated Hemodialysis/ Peritoneal Dialysis

Tuesday, April 22, 7:00am – 5:00pm

Session 221, 8.0 contact hours

See page 51 for course details.

CKD Management Along the Continuum: From Pre-dialysis to Policy

Tuesday, April 22, 7:30am – 4:30pm

Session 222, 7.3 contact hours

See page 52 for course details.

Back by Popular Demand! Technician Day

Wednesday, April 23, 8:00am – 5:30pm

Technicians are invited to attend a full day of interactive sessions that will discuss the importance of their role in the kidney healthcare team. Topics include: water, fluid management, cannulation techniques, the role of the technician as an IDT member, and much more. Sessions noted with a “❖” denote a Technician Day sessions.

LUNCH WORKSHOP

REQUIRED:

Separate registration fee of \$50; includes a box lunch and CE contact hours.

Participation is limited to 75, so register early.

FRIDAY, APRIL 25, 11:30AM – 1:00PM

USING CRITICAL THINKING TO SOLVE DAILY PROBLEMS IN THE DIALYSIS UNIT – ASK THE EXPERTS! ; SESSION 330

This workshop will offer a lively discussion of areas that cause frequent issues in the hemodialysis facility. The workshop will be led by a panel of experts in a variety of roles who will provide suggestions about difficult areas to provide safe, quality patient care.

NEPHROLOGY NURSE AND TECHNICIAN PROGRAM

TUESDAY, APRIL 22

TIME/ROOM	SESSION#	SESSION	COURSE DIRECTOR(S)	NOTES	CREDITS
7:30am – 12:00pm Room 122	620	CKD BASICS	Mandy Trolinger, MS, RD, PA-C Kim Zuber, MS, PA-C, FNKF	●▲	4.0 (1.25 Pharm)
7:30am – 6:00pm Room 112	220	KIDNEY TRANSPLANTATION 2014	Fuad Shihab, MD, FNKF	●■	8.25 (1.5 Pharm)
7:00am – 5:00pm Room 113	221	INTEGRATED HEMODIALYSIS/PERITONEAL DIALYSIS COURSE	Joanne Bargman, MD, FRCPC	●■	8.0 (2.5 Pharm)
7:30am – 4:30pm Room 114	222	CKD MANAGEMENT ALONG THE CONTINUUM: FROM PREDIALYSIS TO POLICY	Charmaine Lok, MD, MSc, FNKF Christopher Chan, MD, FRCPC	●■	7.3 (0.3 Pharm)
1:00pm – 5:00pm Rooms 301-302	320	WATER TREATMENT: A CLINICAL APPROACH TO A TECHNICAL MATTER	Danilo Concepcion, CCHT, CHT, CBNT	●	3.75
6:30pm – 8:00pm Premier Ballroom Lobby	101	HEALTHCARE PROFESSIONALS WELCOME RECEPTION		▲	

WEDNESDAY, APRIL 23

TIME/ROOM	SESSION#	SESSION	FACULTY	NOTES	CREDITS
6:00am – 7:45am Rooms 318-319	800	CLINICAL ASPECTS OF FIBROBLAST GROWTH FACTOR 23 IN CHRONIC KIDNEY DISEASE <i>Supported by an educational donation provided by Amgen</i>	Chair: Csaba Kovesdy, MD, FASN	■	1.5 (0.33 Pharm)
		A Clinician's Perspective on Fibroblast Growth Factor 23	Csaba Kovesdy, MD, FASN		
		FGF23 and Clinical Outcomes in Chronic Kidney Disease	Myles Wolf, MD, MMSc		
		Dietary and Pharmacologic Modifiers of FGF23	Orlando Gutierrez, MD, MMSc		
6:00am – 7:45am Rooms 310-311	807	HIGH-DOSE IRON: TAKING TREATMENT OF IRON DEFICIENCY ANEMIA TO A NEW LEVEL <i>Supported by an educational grant from AMAG Pharmaceuticals, Inc. and American Regent, Inc.</i>	Chair: Jay Wish, MD	■	1.5 (0.8 Pharm)
		Iron Deficiency Anemia in ND-CKD: Mechanisms and Treatment Implications	Jay Wish, MD		
		Iron Therapy in ND-CKD Patients: Oral or Intravenous?	Wajeh Qunibi, MD, FACP		
		The Role of IV Iron Therapy in ND-CKD: Newest Evidence	Daniel Coyne, MD		
8:00am – 9:30am Room 112	360	CANNULATION TECHNIQUES	Stuart Mott, LVN	❖	1.5
8:00am – 9:30am Room 121	562	EUVOLEMIA: WHO CARES AND WHY?	Anne Diroll, RN, CNN Sheila Deziel, BSN, RN, CNN	▲	1.5
8:00am – 9:30am Room 317	261	NEW APPROACHES TO IMMUNOSUPPRESSION: IS LESS BETTER?	Chairs: Fuad Shihab, MD, FNKF, and Milagros Samaniego, MD, FACP, FASN	■	1.5 (0.5 Pharm)
		Corticosteroid Minimization and Avoidance Strategies	Donald Hricik, MD		
		Calcineurin Inhibitor Minimization and Avoidance Strategies	Flavio Vincenti, MD		
		Tolerance Induction in the Real World: Are We Ready for It?	Kenneth Newell, MD, PhD		

Technician Day Session ❖ Joint with Physicians ● Separate registration and/or fee required ▲ Joint with Councils

TIME/ROOM	SESSION#	SESSION	FACULTY	NOTES	CREDITS
8:00am – 9:30am Room 120	561	TEACHING VS. LEARNING: CREATIVE APPROACHES TO EDUCATING PATIENTS	Janelle Gonyea, BS, RD, LD Judith Beto, PhD, RD, FADA	▲	1.5
9:30am – 10:00am		BREAK			
10:00am – 11:30am Room 112	361	WATER TREATMENTS: COMPONENTS AND FUNCTIONS	Danilo Concepcion, CCHT, CHT, CBNT Alex Karmazsin, CBNT	❖	1.5
10:00am – 11:30am Room 123	563	AMUSED AND AMAZED: HOW TO SURVIVE AND THRIVE AS A HEALTHCARE PROFESSIONAL	Karyn Buxman, RN, MS, CSP, CPAE	▲	1.5
10:00am – 11:30am Room 111	662	INTERDISCIPLINARY TRANSPLANT FROM THE PROS	Bobby Nibhanupudy, MD Lara Tushla, MPH, MSW, LCSW, NSW-C Maureen McCarthy, MPH, RD, CSR, LD Wendy Escobedo, RN, MSN, PHN, CCTN Angella Perez, CCHT-A	▲	1.5
11:30am – 12:00pm		BREAK			
12:00pm – 2:00pm Rooms 113-114	362	COUNCIL OF NEPHROLOGY NURSES AND TECHNICIANS' LUNCHEON – ALL ARE WELCOME			
12:00pm – 2:00pm Rooms 318-319	801	REVISITING PHOSPHATE MANAGEMENT IN CHRONIC KIDNEY DISEASE <i>Supported by an educational grant from Fresenius Medical Care</i>	Chair: Kamyar Kalantar-Zadeh, MD, MPH, PhD, FNKF	■	1.5 (0.6 Pharm)
		Overview of Phosphate Homeostasis, GI Absorption, and Dietary Sources	Kamyar Kalantar-Zadeh, MD, MPH, PhD, FNKF		
		Traditional and Newer Phosphate Binders	Bruce Spinowitz, MD, FACP		
		Integrating Dietary Restrictions and Therapeutic Agents to Control Phosphate	Stuart Sprague, DO, FNKF		
2:00pm – 2:30pm		BREAK			
2:30pm – 3:30pm Room 115	265	NKF PRESIDENTIAL ADDRESS: BUILDING CKD AWARENESS SHAUL G. MASSRY DISTINGUISHED LECTURE: VASCULAR DISEASE IN CHRONIC KIDNEY DISEASE: PROGRESS AND CHALLENGES	Beth Piraino, MD, FNKF Mark Sarnak, MD, MS	■▲	1.0
3:30pm – 4:00pm		BREAK			
4:00pm – 5:30pm Room 118	665	LOST IN TRANSLATION OF THE LAB RESULT CBC on a Slide The Alphabet Soup of Rheumatology Labs	Janie McDaniel, BSMT James Van Rhee, MS, PA-C	▲	1.5 (0.5 Pharm)
4:00pm – 5:30pm Room 122	364	THE TECHNICIAN'S CORNER Importance of Certification The Role of the Technician as an IDT Member	Kim Deaver, RN, BSN, CNN Angella Perez, CCHT-A	❖	1.5
4:00pm – 5:30pm Room 123	266	KDOQI – ROLES, CONTROVERSIES, AND GUIDELINES IN CKD KDOQI – Merging Old and New Roles Thresholds for 25(OH)D Supplementation in CKD KDOQI Commentary on KDIGO Clinical Practice Guidelines for CKD	Chair: Jeffrey Berns, MD, FNKF Jeffrey Berns, MD, FNKF Holly Kramer, MD, MPH Tamara Isakova, MD, MMSc	■	1.5 (0.2 Pharm)

WEDNESDAY, APRIL 23, *continued*

TIME/ROOM	SESSION#	SESSION	FACULTY	NOTES	CREDITS
4:00pm – 5:30pm Room 317	267	ACHIEVING GREAT RESULTS IN PERITONEAL DIALYSIS	Chairs: Beth Piraino, MD, FNKF, and David Johnson, PhD, FRACP, MBBS	■	1.5
		Working to Decrease Peritonitis Rates: Focus on Training	David Johnson, PhD, FRACP, MBBS		
		Appropriate and Timely Transition from PD to HD	Rajnish Mehrotra, MD, MBBS, FNKF		
		Urgent Start PD	Joni Hansson, MD, FNKF		
6:00pm – 7:30pm		OPENING CEREMONIES AND RECEPTION IN THE EXHIBIT HALL – VISIT POSTERS/EXHIBITS			1.0*
7:30pm – 9:30pm Rooms 318-319	802	HEART-KIDNEY INTERACTION AND THE ROLE OF VASOPRESSIN AND HYPONATREMIA IN HEART FAILURE	Chair: Matthew Weir, MD	■	1.5 (0.4 Pharm)
		<i>Supported by an educational grant from Otsuka America Pharmaceutical, Inc.</i>			
		The Heart-Kidney Interaction in Heart Failure and the Pathogenesis of Hyponatremia	Matthew Weir, MD		
		The Utility of Current Treatment Options in the Management of Hyponatremia in the Heart Failure Patient with Impaired Kidney Function	Joseph Verbalis, MD		
7:30pm – 9:30pm Rooms 310-311	808	PERSISTENT HYPERURICEMIA: A MULTI-PRONGED APPROACH TO THE MANAGEMENT OF SERUM URATE LEVELS	Chair: Robert Terkeltaub, MD	■	1.5 (0.4 Pharm)
		<i>Supported by an educational grant from Takeda Pharmaceuticals North America, Inc.</i>			
		Renal Dysfunction and the Management of Hyperuricemia	Jay Wish, MD		
		Managing Risk Factors and Comorbid Conditions in the Hyperuricemic Patient	Louis Kuritzky, MD		
		Application of Guidelines for Long-Term Treatment of Gout	Robert Terkeltaub, MD		

THURSDAY, APRIL 24

TIME/ROOM	SESSION#	SESSION	FACULTY	NOTES	CREDITS
6:00am – 7:45am Rooms 318-319	803	CHANGING PROFILE OF CHRONIC HYPERKALEMIA	Chair: Peter McCullough, MD, MPH, FACC, FCCP, FACP, FAHA, FNKF	■	1.5 (0.5 Pharm)
		<i>Supported by an educational grant from ZS Pharma, Inc.</i>			
		Frequency and Clinical Significance of Hyperkalemia in CKD	Robert Toto, MD		
		Risks of Hyperkalemia in Special Kidney Disease Populations	Michael Emmett, MD		
		Emerging Therapies for Treating Hyperkalemia	John Middleton, MD		
6:00am – 7:45am Rooms 310-311	806	THE ROLE OF BIOSIMILARS IN CHRONIC KIDNEY DISEASE	Chair: Francesco Locatelli, MD	■	1.5 (0.4 Pharm)
		<i>Supported by an educational grant from Hospira, Inc.</i>			
		The State of Biosimilar Regulation and Development in the United States	Edward Li, PharmD, BCOP		
		Review of Biosimilars vs. Reference Biologics	Graham Jones, PhD, DIC		
		The Potential Role of Biosimilars in Chronic Kidney Disease	Francesco Locatelli, MD		
7:00am – 8:00am		CONTINENTAL BREAKFAST IN THE EXHIBIT HALL – VISIT POSTERS/EXHIBITS			1.0*

◆ Technician Day Session ■ Joint with Physicians ● Separate registration and/or fee required ▲ Joint with Councils

TIME/ROOM	SESSION#	SESSION	FACULTY	NOTES	CREDITS
8:30am – 10:00am Room 122	365	INSPECTION READINESS: EVERY DAY, EVERY WAY	Glenda Payne, MS, RN, CNN		1.5
8:30am – 10:00am Room 309	366	UNDERSTANDING THE CARDIO-KIDNEY-DIABETES (CKD) CONNECTION			1.5
		Diabetes – The Main Comorbid for CKD: What Should I Know?	Jeff Giullian, MD, MBA		
		Cardiac Renal: Cardiac Stunning, Arrhythmias During Treatment	Jeff Giullian, MD, MBA		
8:30am – 10:00am Room 317	269	LESSONS TO BE LEARNED IN PERITONEAL DIALYSIS FROM AROUND THE WORLD	Chairs: David Johnson, PhD, FRACP, MBBS, and Xueqing Yu, PhD, MBBS	■	1.5
		PD Utilization: Global Practice Patterns	Rajnish Mehrotra, MD, MBBS, FNKF		
		Home Assisted Peritoneal Dialysis	Matthew Oliver, MD, MHS, FRCPC		
		New Peritoneal Dialysis Solutions	David Johnson, PhD, FRACP, MBBS		
10:00am – 10:30am		BREAK			
10:30am – 12:00pm Room 117	367	THE CONTINUUM OF CARE FOR THE DIALYSIS PATIENT			1.5
		Importance of the First 90 Days of Dialysis for the Dialysis Patient	Stuart Mott, LVN		
		Inpatient to Outpatient and Vice Versa	Rebecca Wingard, RN, MSN, CNN		
10:30am – 12:00pm Room 116	271	DIALYSIS ACCESS: STRENGTHENING THE ACHILLES HEEL	Chairs: Michael Allon, MD, and Charmaine Lok, MD, MSc, FNKF	■	1.5
		Barriers and Solutions for Vascular Access Placement: A Patient-Centered Approach	Louise Moist, MD, MSc, FRCPC		
		When a PD Catheter is the Most Appropriate Access	Rajnish Mehrotra, MD, MBBS, FNKF		
		Therapies for Vascular Access Dysfunction: Myth or Reality?	Timmy Lee, MD, MSPH, FACP, FASN, FNKF		
10:30am – 12:00pm Room 121	467	END-OF-LIFE ISSUES, INTERVENTIONS, AND DOCUMENTATION: ACCEPTANCE DOESN'T MEAN GIVING UP	Mary Beth Callahan, MSSW, ACSW, LCSW	▲	1.5
12:00pm – 2:00pm		BREAK IN THE EXHIBIT HALL (LUNCH SERVED 12:15PM – 1:15PM) – VISIT POSTERS/EXHIBITS			1.0*
2:00pm – 3:30pm Room 117	368	THE INS AND OUTS OF CHOOSING A DIALYSIS MODALITY	Cathy Wilson Bates, RN, CDN, CPDN		1.5
2:00pm – 3:30pm Room 111	470	ETHICS: CURRENT ESRD ACCESS-TO-TREATMENT DILEMMAS IN AN HISTORICAL CONTEXT	Paula Goodman-Crews, MSW, LCSW Aaron Wightman, MD	▲	1.5
3:30pm – 4:00pm		BREAK			
4:00pm – 5:30pm Room 114	369	WHAT'S NEW IN INFECTION CONTROL	Deborah Cote, MSN, RN, CNN Kim Deaver, RN, BSN, CNN		1.5
4:00pm – 5:30pm Room 117	370	THE CHALLENGES OF CARING FOR THE ELDERLY	Christine Chmielewski, MS, CRNP, ANP-BC, CNN-NP		1.5

THURSDAY, APRIL 24, *continued*

TIME/ROOM	SESSION#	SESSION	FACULTY	NOTES	CREDITS
4:00pm – 5:30pm Room 116	278	DON'T BUG ME ON DIALYSIS! HEMODIALYSIS INFECTION UPDATE	Chairs: Charmaine Lok, MD, MSc, FNKF, and Michael Allon, MD	■	1.5
		Practical Hemodialysis Bloodstream Prevention – A Multidisciplinary Approach	Michael Allon, MD		
		Prevention and Management of Multi-Drug Resistant Infections	William Salzer, MD		
		Preventing Infectious Outbreaks in the Dialysis Unit	Duc Nguyen, MD		
6:00pm – 7:30pm		NETWORKING RECEPTION IN THE EXHIBIT HALL – VISIT POSTERS/EXHIBITS			1.0*
7:30pm – 9:30pm Rooms 318-319	804	NEW INSIGHTS INTO THE ROLE OF PHOSPHORUS BALANCE IN CHRONIC KIDNEY DISEASE <i>Supported by an educational grant from Keryx Biopharmaceuticals, Inc.</i>	Chair: Myles Wolf, MD, MMSc	■	1.5 (0.4 Pharm)
		Understanding the Physiology and Therapeutic Targets of Phosphorus Homeostasis in Patients with CKD	Myles Wolf, MD, MMSc		
		Emerging Treatment Options for Serum Phosphorus Levels	Sylvia E. Rosas, MD, MSCE, FNKF		
		Strategies to Improve Care in Patients with Hyperphosphatemia and CKD	Geoffrey Block, MD, CCRI		

FRIDAY, APRIL 25

TIME/ROOM	SESSION#	SESSION	FACULTY	NOTES	CREDITS
6:00am – 7:45am Rooms 318-319	805	EXPERT PERSPECTIVES IN THE MANAGEMENT OF BONE-MINERAL-VASCULAR DISORDERS: A PATHOPHYSIOLOGICAL AND EVIDENCE-BASED APPROACH TO CARE <i>Supported by an educational grant from Sanofi Renal</i>	Chair: Ellie Kelepouris, MD, FAHA	■	1.5 (0.33 Pharm)
		Metabolic and Mineral Disturbances in CKD-MBD: A Discussion of Pathophysiology and Risk	Matthew Weir, MD		
		Dietary Calcium and Phosphorus: A Focus on Cardiovascular Risk in CKD-MBD	Kathleen Hill Gallant, PhD, RD		
		Evolving Clinical Perspectives: Application of Phosphorus and Calcium Management Strategies in Patients With CKD-MBD	Ellie Kelepouris, MD, FAHA		
8:00am – 11:30am		BREAK IN THE EXHIBIT HALL (BREAKFAST SERVED 8:00AM – 9:00AM) – VISIT POSTERS/EXHIBITS			1.0*
9:30am – 11:00am Room 111	573	SOCIAL MEDIA: “DOS” AND “DON'TS”	Sharon Johnson, JD, RD, LD	▲	1.5
9:30am – 11:00am Room 122	371	THE PATIENT CARE EXPERIENCE	Glenda Payne, MS, RN, CNN		1.5
9:30am – 11:00am Room 120	279	THE FUTURE OF CKD DETECTION – ROLE FOR THE KIDNEY EARLY EVALUATION PROGRAM	Chairs: Adam Whaley-Connell, DO, MSPH, FAHA, FACP, FNKF, FASN, and Kerri Cavanaugh, MD, MHS, FNKF	■	1.5
		Strategies for Screening & Detection of Kidney Disease	Georges Saab, MD		
		Using Data from a Focused Community Screening Program to Help Stratify “Risk” for Kidney Disease	Carmen Peralta, MD		
		The Next Generation of Screening for Kidney Disease	Peter McCullough, MD, MPH, FACC, FCCP, FACP, FAHA, FNKF		

Technician Day Session ■ Joint with Physicians ● Separate registration and/or fee required ▲ Joint with Councils

TIME/ROOM	SESSION#	SESSION	FACULTY	NOTES	CREDITS
11:00am – 11:30am		BREAK			
11:30am – 1:00pm Room 208	330	WORKSHOP: USING CRITICAL THINKING TO SOLVE DAILY PROBLEMS IN THE DIALYSIS UNIT—ASK THE EXPERTS!	Kim Deaver, RN, MSN, CNN Stuart Mott, LVN Danilo Concepcion, CCHT, CHT, CBNT Christine Chmielewski, MS, CRNP, ANP-BC, CNN-NP Deborah Cote, MSN, RN, CNN	●▲	1.5
11:30am – 12:30pm Room 116	372	TRANSPLANT CLINIC	Kim Alleman, MS, RN, FNP-C, CNN, APRN		1.0
1:00pm – 1:30pm		BREAK			
1:30pm – 3:00pm Room 122	373	NUTS AND BOLTS OF CKD			1.5
		Early Stages of CKD	Christine Chmielewski, MS, CRNP, ANP-BC, CNN-NP		
		CKD and Pre-Dialysis Clinics	Christine Chmielewski, MS, CRNP, ANP-BC, CNN-NP		
1:30pm – 3:00pm Room 118	579	CHRONIC DIABETIC WOUNDS IN THE DIALYSIS PATIENT	Elizabeth Evans, RN, MSN, DNP		1.5
3:00pm – 3:30pm		BREAK			
3:30pm – 5:00pm Room 122	374	PD FROM START TO FINISH	Joanne Bargman, MD, FRCPC		1.5
3:30pm – 5:00pm Room 114	375	QAPI: HOW TO DO IT EFFECTIVELY	Barbara Landreth, RN, BSN, CNN, CPHQ		1.5

SATURDAY, APRIL 26

TIME/ROOM	SESSION#	SESSION	FACULTY	NOTES	CREDITS
8:00am – 9:30am Room 311	582	TRAVELING COMPANIONS: POVERTY AND CHRONIC ILLNESS	Diane McRae, MSW, LICSW	▲	1.5
8:00am – 9:30am Room 320	376	HEMODIALYSIS AND VENTRICULAR ASSIST DEVICES AND CARE IN THE OUTPATIENT DIALYSIS UNIT	Eileen Lischer, MA, BSN, RN, CNN		1.5
8:00am – 9:30am Room 314-315	286	BUNDLE UP! U.S. DIALYSIS POLICY	Chair: Friedrich Port, MD, MS, FACP	■	1.5
		ESCOs and ACOs: Accountable Care and Nephrology	Daniel Weiner, MD, MS, FNKF		
		The Prospective Payment System	Jeffrey Berns, MD, FNKF		
		The Quality Incentive Program: An Update on ESRD Quality Metrics	Rajnish Mehrotra, MD, MBBS, FNKF		
9:30am – 10:00am		BREAK			
10:00am – 11:30am Room 319	680	THE TAO OF POO: HUMOR AND STRESS	Margarita Gurri, PhD	▲	1.5
11:30am		MEETING ADJOURNS			

RENAL AND CLINICAL DIETITIAN PROGRAM

Planning Committee

Marie Becker, MS, RD, LDN

Program Chair

Central Orlando Dialysis, Orlando, FL

Kristine D'Angelo David, RD

Program Co-Chair

Sigma-Tau Pharmaceuticals, Inc., Gaithersburg, MD

Louise Clement, MS, RD, CSR, LD

South Plains Kidney Disease Center, Lubbock, TX

Aimee Jarenowicz, RD, LDN

Chicago Ridge, IL

Irene Rosario, RD, LD

DaVita Inc., Winter Park, FL

Beth Shanaman, RD

Northwest Kidney Centers, Seattle, WA

Mary Sundell, RD, LDN, CCRP

Vanderbilt Dialysis Program, Nashville, TN

Jana Zimmer, RD, LD, BS

DaVita Weslaco, Weslaco, TX

Continuing Education Information



The National Kidney Foundation is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and Dietetic Technicians, Registered (DTRs) will receive 37.5 continuing professional education units (CPEUs) for completion of this program/material.

PRE-CONFERENCE COURSES

REQUIRED: SEPARATE REGISTRATION

Includes: Syllabus, light breakfast, box lunch and CPEU credits. Participation is limited, so register early.

PRICING

Fee of \$150 for NKF Members, \$175 for Non-Members

Foundations of Nutrition Practice for Kidney Disease (Strategies I)

Tuesday, April 22

7:30am – 5:00pm

Course Director: Louise Clement, MS, RD, CSR, LD
Session 520, 7.75 CPEUs

TARGET AUDIENCE

Designed for registered dietitians and advanced practitioners who wish to strengthen their overall knowledge of the complex nutritional requirements of people with chronic kidney disease, and CKD Stage 5 in particular.

COURSE DESCRIPTION

This course will focus on learning and building on the basics of renal nutrition. Topics will include medical nutrition therapy for hemodialysis and peritoneal dialysis, bone disease, treating malnutrition, and anemia presented by nationally-recognized

leaders. This course will also focus on guidelines regarding vitamin requirements, programs and resources available for CKD stage 5, urea kinetic adequacy, and nutrition assessment. This workshop will conclude with a number of case studies to help practically apply solutions to common issues facing professionals who treat people with kidney disease.

COURSE OBJECTIVES

Upon completion of this course, participants will be able to:

- Review the treatment of protein energy malnutrition, including its assessment and nutritional requirements
- Describe normal bone metabolism and resulting alterations in CKD; discuss treatment options appropriate for this population
- Discuss physiology and transport in peritoneal dialysis, the guidelines to meet the nutrient requirements in PD, and special considerations
- List available CKD programs and resources, including CMS, quality initiatives, and ESRD Networks
- Review kinetic modeling in hemodialysis, including factors related to clearance, Kt/V, and the identification and treatment of problems
- Explain the process of anemia management regarding: RBC development, the role of ESAs, and the nutrients required to enhance this process
- Discuss the unique vitamin requirements of patients in CKD Stage 5 by status assessment, recommendations, and knowledge of available products
- Describe the process of nutrition assessment in the dialysis population; discuss pertinent rules and standards, the RD role in patient assessment, and the patient Plan of Care

TIME	TOPIC	FACULTY
7:30am – 8:00am	Breakfast, Welcome, and Introductions	Louise Clement, MS, RD, CSR, LD
8:00am – 9:00am	Nutrition Guidelines for Hemodialysis	Janelle Gonyea, BS, RD, LD
9:00am – 10:00am	Overview of Bone and Mineral Disease	Linda McCann, RD, CSR, LD
10:00am – 10:15am	Break	
10:15am – 11:15am	Treating Malnutrition in CKD Stage 5	Kamyar Kalantar-Zadeh, MD, MPH, PhD, FNKF
11:15am – 12:00pm	MNT in Peritoneal Dialysis	Karen Wiesen, MS, RD, LDN
12:00pm – 12:45pm	Lunch	
12:45pm – 1:15pm	Introduction to CKD Programs	Karen Wiesen, MS, RD, LDN
1:15pm – 2:00pm	Kinetic Modeling	Lisa Gutekunst, MEd, RD, CSR, CDN
2:00pm – 2:30pm	Anemia Management	Louise Clement, MS, RD, CSR, LD
2:30pm – 3:00pm	Vitamin Requirements in CKD Stage 5	Joy Lutz, MS, RD
3:00pm – 3:15pm	Break	
3:15pm – 4:00pm	Nutrition Assessment	Joy Lutz, MS, RD
4:00pm – 5:00pm	Case Studies	Louise Clement, MS, RD, CSR, LD

Advanced Practice in Renal Nutrition: Update 2014 (Strategies II)

Tuesday, April 22, 7:30am – 5:00pm

Course Director: Kathy Schiro-Harvey, MS, RD, CSR, CD

Session 521, 7.25 CPEUs

TARGET AUDIENCE

Advanced practice renal dietitians

COURSE DESCRIPTION

This course is designed to teach the advanced practice renal dietitian how to identify complex clinical and management issues, foster critical thinking to identify best practice strategies, and utilize interactive learning that will result in changes in practice, to improve nephrology care.

COURSE OBJECTIVES

Upon completion of this course, participants will be able to:

- Describe the pathogenesis, epidemiology, risk factors, clinical manifestations, and diagnosis of calciphylaxis
- Formulate nutrition strategies to impact the development of calciphylaxis and affect therapy outcomes
- Discuss altered glucose metabolism and interpret clinical manifestations of diabetes in CKD and how they are affected by dialysis therapies
- Design appropriate and effective medical nutrition therapy plans, with realistic treatment goals for CKD patients
- Identify and differentiate normal fluid, electrolyte, and acid base balance compared to CKD. Recognize how this balance changes before, during, and after dialysis, and evaluate the affect of diet, activity and medications on fluid, electrolyte and acid-base balance
- Define how working in a “bundled” environment affects the dietitian. Discuss CMS budget constraints and their impact on the CKD community, including strategies and goals for maintaining quality nutrition care
- Create strategies to improve working relationships within the healthcare team. Identify tools for thinking “outside the box” to implement change, solve problems, and become invaluable to the organization

TIME	TOPIC	FACULTY
7:30am – 8:00am	Breakfast	
8:00am – 8:30am	Welcome and Introductions	Kathy Schiro-Harvey, MS, RD, CSR, CD
8:30am – 9:30am	Calciphylaxis in Five Easy Pieces: A Good Mineral Gone Bad	Sagar Nigwekar, MD, MMSc
9:30am – 10:30am	Understanding Diabetes in Kidney Disease	Deb McGrath, RD, CD, CDE
10:30am – 10:45am	Break	
10:45am – 11:45am	Fluid and Electrolyte Balance and Imbalance in CKD	Suhail Ahmad, MD
11:45am – 1:00pm	Lunch	
1:00pm – 1:15pm	Regroup and Review	Kathy Schiro-Harvey, MS, RD, CSR, CD
1:15pm – 2:15pm	Working in a Bundled Environment: What Does This Mean to the Dietitian?	Kathy Schiro-Harvey, MS, RD, CSR, CD
2:15pm – 3:15pm	Team Dynamics – Dealing with Difficult People	Monica Wofford, CSP
3:15pm – 3:30pm	Break	
3:30pm – 4:30pm	Outside the Box – Creative Strategies to Implement Change	Judith Beto, PhD, RD, FADA
4:30pm – 5:00pm	Questions, Answers, Discussion, Evaluations	

LUNCH WORKSHOP

REQUIRED:

Separate registration fee of \$50; includes a box lunch and CPEU credits.
Participation is limited to 75, so register early.

FRIDAY, APRIL 25, 11:30AM – 1:00PM

PUTTING THE PUZZLE PIECES TOGETHER WITH SGA: SCREENING FOR MALNUTRITION; SESSION 530

Presenter: Linda McCann, BS, RD, CSR, LD

Workshop Description: Spend time with the expert in a more intimate setting. Go beyond the scope of your current knowledge and learn about ways dietitians can assess their patients' nutritional deficiencies. This is an interactive workshop with hands-on experience!

You inspire us with your
passion for teaching, Katy!

2013 SUSAN KNAPP EXCELLENCE IN EDUCATION AWARD RECIPIENT



**Congratulations to Katy Wilkens,
our nutrition and fitness manager!**

*"I have always felt the primary role of the
renal dietitian is that of a teacher."*

-Katy Wilkens

 **NORTHWEST
Kidney Centers**

Live. Learn. Hope.
206-292-2771 | www.nwkidney.org

RENAL AND
CLINICAL DIETITIAN

RENAL AND CLINICAL DIETITIAN PROGRAM

TUESDAY, APRIL 22

TIME/ROOM	SESSION#	SESSION	COURSE DIRECTOR(S)	NOTES	CREDITS
7:30am – 5:00pm Rooms 206-207	520	FOUNDATIONS OF NUTRITION PRACTICE FOR KIDNEY DISEASE (STRATEGIES I)	Louise Clement, MS, RD, CSR, LD	●	7.75
7:30am – 5:00pm Rooms 208-209	521	ADVANCED PRACTICE IN RENAL NUTRITION: UPDATE 2014 (STRATEGIES II)	Kathy Schiro-Harvey, MS, RD, CSR, CD	●	7.25
6:30pm – 8:00pm Premier Ballroom Lobby	101	HEALTHCARE PROFESSIONALS WELCOME RECEPTION		▲	

WEDNESDAY, APRIL 23

TIME/ROOM	SESSION#	SESSION	FACULTY	NOTES	CREDITS
6:00am – 7:45am Rooms 318-319	800	CLINICAL ASPECTS OF FIBROBLAST GROWTH FACTOR 23 IN CHRONIC KIDNEY DISEASE <i>Supported by an educational donation provided by Amgen</i>	Chair: Csaba Kovesdy, MD, FASN	■	1.5
		A Clinician's Perspective on Fibroblast Growth Factor 23	Csaba Kovesdy, MD, FASN		
		FGF23 and Clinical Outcomes in Chronic Kidney Disease	Myles Wolf, MD, MMSc		
		Dietary and Pharmacologic Modifiers of FGF23	Orlando Gutierrez, MD, MMSc		
6:00am – 7:45am Rooms 310-311	807	HIGH-DOSE IRON: TAKING TREATMENT OF IRON DEFICIENCY ANEMIA TO A NEW LEVEL <i>Supported by an educational grant from AMAG Pharmaceuticals, Inc. and American Regent, Inc.</i>	Chair: Jay Wish, MD	■	1.5
		Iron Deficiency Anemia in ND-CKD: Mechanisms and Treatment Implications	Jay Wish, MD		
		Iron Therapy in ND-CKD Patients: Oral or Intravenous?	Wajeh Qunibi, MD, FACP		
		The Role of IV Iron Therapy in ND-CKD: Newest Evidence	Daniel Coyne, MD		
8:00am – 9:30am Room 111	560	THE BENEFITS OF EATING DURING HEMODIALYSIS TREATMENT IN THE LIST OF PRIORITIES	Kamyar Kalantar-Zadeh, MD, MPH, PhD, FNKF		1.5
8:00am – 9:30am Room 120	561	TEACHING VS. LEARNING: CREATIVE APPROACHES TO EDUCATING PATIENTS	Janelle Gonyea, BS, RD, LD Judith Beto, PhD, RD, FADA	▲	1.5
8:00am – 9:30am Room 121	562	EUVOLEMIA: WHO CARES AND WHY?	Anne Diroll, RN, CNN Sheila Deziel, BSN, RN, CNN	▲	1.5
9:30am – 10:00am		BREAK			

■ Joint with Physicians ● Separate registration and/or fee required ▲ Joint with Councils

TIME/ROOM	SESSION#	SESSION	FACULTY	NOTES	CREDITS
10:00am – 11:30am Room 111	662	INTERDISCIPLINARY TRANSPLANT FROM THE PROS	Bobby Nibhanupudy, MD Lara Tushla, MSW, LCSW, NSW-C Wendy Escobedo, RN, MSN, PHN, CCTN, Angella Perez, CCHT-A Maureen McCarthy, MPH, RD, CSR, LD	▲	1.5
10:00am – 11:30am Room 123	563	AMUSED AND AMAZED: HOW TO SURVIVE AND THRIVE AS A HEALTHCARE PROFESSIONAL	Karyn Buxman, RN, MS, CSP, CPAE	▲	1.5
10:00am – 11:30am Room 120	263	WALK THIS WAY...IN CKD	Chairs: Daniel Weiner, MD, MS, FNKF, and Kirsten Johansen, MD Charmaine Lok, MD, MSc, FNKF Patricia Painter, PhD, FACSM Kirsten Johansen, MD	■	1.5
11:30am – 12:00pm		BREAK			
12:00pm – 2:00pm Rooms 310-311	564	COUNCIL ON RENAL NUTRITION LUNCHEON – ALL ARE WELCOME! THE MUSHROOM HUNTERS: HOW TO TEACH OTHERS WHAT TO FIND	Katy G. Wilkens, MS, RD		0.75
2:00pm – 2:30pm		BREAK			
2:30pm – 3:30pm Room 115	265	NKF PRESIDENTIAL ADDRESS: BUILDING CKD AWARENESS SHAUL G. MASSRY DISTINGUISHED LECTURE: VASCULAR DISEASE IN CHRONIC KIDNEY DISEASE: PROGRESS AND CHALLENGES	Beth Piraino, MD, FNKF Mark Sarnak, MD, MS	■▲	1.0
3:30pm – 4:00pm		BREAK			
4:00pm – 5:30pm Room 123	266	KDOQI – ROLES, CONTROVERSIES, AND GUIDELINES IN CKD KDOQI – Merging Old and New Roles Thresholds for 25(OH)D Supplementation in CKD KDOQI Commentary on KDIGO Clinical Practice Guidelines for CKD	Chair: Jeffrey Berns, MD, FNKF Jeffrey Berns, MD, FNKF Holly Kramer, MD, MPH Tamara Isakova, MD, MMSc	■▲	1.5
4:00pm – 5:30pm Room 120	565	JOEL D. KOPPLE AWARD PRESENTATION: RENAL NUTRITION AND THE ROAD LESS TRAVELLED	Juan Jesus Carrero, PharmD, PhD, MSc, MBA		1.5
6:00pm – 7:30pm		OPENING CEREMONIES AND RECEPTION IN THE EXHIBIT HALL – VISIT POSTERS/EXHIBITS			1.0*

WEDNESDAY, APRIL 23, *continued*

TIME/ROOM	SESSION#	SESSION	FACULTY	NOTES	CREDITS
7:30pm – 9:30pm Rooms 318-319	802	HEART-KIDNEY INTERACTION AND THE ROLE OF VASOPRESSIN AND HYPONATREMIA IN HEART FAILURE <i>Supported by an educational grant from Otsuka America Pharmaceutical, Inc.</i>	Chair: Matthew Weir, MD	■	1.5
		The Heart-Kidney Interaction in Heart Failure and the Pathogenesis of Hyponatremia	Matthew Weir, MD		
		The Utility of Current Treatment Options in the Management of Hyponatremia in the Heart Failure Patient with Impaired Kidney Function	Joseph Verbalis, MD		
		Lessons from Clinical Trials of Vasopressin Receptor Antagonists in Heart Failure	James Udelson, MD		
7:30pm – 9:30pm Rooms 310-311	808	PERSISTENT HYPERURICEMIA: A MULTI-PRONGED APPROACH TO THE MANAGEMENT OF SERUM URATE LEVELS <i>Supported by an educational grant from Takeda Pharmaceuticals North America, Inc.</i>	Chair: Robert Terkeltaub, MD	■	1.5
		Renal Dysfunction and the Management of Hyperuricemia	Jay Wish, MD		
		Managing Risk Factors and Comorbid Conditions in the Hyperuricemic Patient	Louis Kuritzky, MD		
		Application of Guidelines for Long-Term Treatment of Gout	Robert Terkeltaub, MD		

THURSDAY, APRIL 24

TIME/ROOM	SESSION#	SESSION	FACULTY	NOTES	CREDITS
6:00am – 7:45am Rooms 318-319	803	CHANGING PROFILE OF CHRONIC HYPERKALEMIA <i>Supported by an educational grant from ZS Pharma, Inc.</i>	Chair: Peter McCullough, MD, MPH, FACC, FCCP, FACP, FAHA, FNKF	■	1.5
		Frequency and Clinical Significance of Hyperkalemia in CKD	Robert Toto, MD		
		Risks of Hyperkalemia in Special Kidney Disease Populations	Michael Emmett, MD		
		Emerging Therapies for Treating Hyperkalemia	John Middleton, MD		
6:00am – 7:45am Rooms 310-311	806	THE ROLE OF BIOSIMILARS IN CHRONIC KIDNEY DISEASE <i>Supported by an educational grant from Hospira, Inc.</i>	Chair: Francesco Locatelli, MD	■	1.5
		The State of Biosimilar Regulation and Development in the United States	Edward Li, PharmD, BCOP		
		Review of Biosimilars vs. Reference Biologics	Graham Jones, PhD, DIC		
		The Potential Role of Biosimilars in Chronic Kidney Disease	Francesco Locatelli, MD		
7:00am – 8:00am		CONTINENTAL BREAKFAST IN THE EXHIBIT HALL – VISIT POSTERS/EXHIBITS			1.0*
8:30am – 10:00am Room 114	566	EATING AND ENTERAL THERAPY DURING HEMODIALYSIS TREATMENT: AN OVERLOOKED OPPORTUNITY	Raymond Hakim, MD, PhD Daniel Weiner, MD, MS, FNKF		1.5

■ Joint with Physicians ● Separate registration and/or fee required ▲ Joint with Councils

TIME/ROOM	SESSION#	SESSION	FACULTY	NOTES	CREDITS
8:30am – 10:00am Room 116	268	CHANGING THE COURSE OF DIABETIC NEPHROPATHY	Chairs: Adam Whaley-Connell, DO, MSP, FAHA, FACP, FNKF, and Sylvia E. Rosas, MD, MSCE, FNKF	■	1.5
		Management of Hyperglycemia and General Diabetes Care in CKD	Katherine Tuttle, MD, FASN, FACP		
		Management of Dyslipidemia in Diabetes and CKD	Linda Fried, MD, MPH, FNKF		
		Primary Prevention of Diabetic Nephropathy	Robert Stanton, MD		
8:30am – 10:00am Room 317	269	LESSONS TO BE LEARNED IN PERITONEAL DIALYSIS FROM AROUND THE WORLD	Chairs: David Johnson, PhD, FRACP, MBBS, and Xueqing Yu, PhD, MBBS	■	1.5
		PD Utilization: Global Practice Patterns	Rajnish Mehrotra, MD, MBBS, FNKF		
		Home Assisted Peritoneal Dialysis	Matthew Oliver, MD, MHS, FRCPC		
		New Peritoneal Dialysis Solutions	David Johnson, PhD, FRACP, MBBS		
10:00am – 10:30am		BREAK			
10:30am – 12:00pm Room 118	567	BIOAVAILABILITY OF PO₄ CONTENT OF FOODS/ LABELING REGULATIONS	Lisa Gutekunst, MSED, RD, CSR, CDN		1.5
10:30am – 12:00pm Room 123	272	OPTIMIZING MEDICATION-RELATED OUTCOMES IN CKD PATIENTS	Chair: Jerry Yee, MD, FACP, FNKF, FASN	■	1.5
		Implementing Medication Therapy Management to CKD Patients: New Models of Care	Wendy St. Peter, PharmD, FCCP, FASN, FNKF		
		Strategies to Reduce Polypharmacy in CKD Patients	Nancy Mason, PharmD, FNKF		
		Top 10 Medication-Related Conundrums	Carol Moore, PharmD, BCPS, FNKF		
10:30am – 12:00pm Room 114	568	CENTER STAGE: COMPARING NUTRITION CARE IN CKD AND RENAL REPLACEMENT THERAPIES	Carolyn Cochran, RD, LD, MS, CDE		1.5
			Jessie Pavlinac, MS, RD, CSR, LD		
12:00pm – 2:00pm		BREAK IN THE EXHIBIT HALL (LUNCH SERVED 12:15PM – 1:15PM) - VISIT POSTERS/EXHIBITS			1.0*
2:00pm – 3:30pm Room 114	569	RD – SHINING STARS: INNOVATIVE PROGRAMS THAT MAKE A DIFFERENCE	Kirsten Thompson, MPH, RD, CSR		1.5
			Judith Beto, PhD, RD, FADA		
			Darlene Griffin, MS, RD, LDN		
2:00pm – 3:30pm Room 118	570	OMG! MY PATIENT TOLD ME SHE IS PREGNANT – NOW, WHAT?	Miriam Michael, MD Mandy Trolinger, MS, RD, PA-C		1.5
2:00pm – 3:30pm Room 111	470	ETHICS: CURRENT ESRD ACCESS TO TREATMENT DILEMMAS IN AN HISTORICAL CONTEXT	Paula Goodman-Crews, MSW, LCSW	▲	1.5
			Aaron Wightman, MD		
3:30pm – 4:00pm		BREAK			
4:00pm – 5:30pm Room 118	571	SENSATIONS OF TASTE AND SMELL: “MY FOOD TASTES LIKE CARDBOARD”	Sarah Washburn, MS, RD, CSO		1.5

THURSDAY, APRIL 24, *continued*

TIME/ROOM	SESSION#	SESSION	FACULTY	NOTES	CREDITS
4:00pm – 5:30pm Room 123	672	YOU BE THE JUDGE: NEPHROLOGY MALPRACTICE CASES	Della Connor, PhD, FNP-BC, RN Jane Davis, DNP, CRNP, MSN, FNKF Sharon Johnson, JD, RD, LD	▲	1.5
4:00pm – 5:30pm Room 121	277	OBVIOUS BUT OVERLOOKED CARE IN ESRD PATIENTS	Chair: Alfred Cheung, MD, FNKF	■	1.5
		Cognitive and Psychological Disorders	Daniel Weiner, MD, MS, FNKF		
		Sleep Disorders	Mark Unruh, MD		
		Chronic Pain	Steven Weisbord, MD, FNKF		
6:00pm – 7:30pm		NETWORKING RECEPTION IN THE EXHIBIT HALL—VISIT POSTERS/EXHIBITS			1.0*
7:30pm – 9:30pm Rooms 318-319	804	NEW INSIGHTS INTO THE ROLE OF PHOSPHORUS BALANCE IN CHRONIC KIDNEY DISEASE	Chair: Myles Wolf, MD, MMSc	■	1.5
		<i>Supported by an educational grant from Keryx Biopharmaceuticals, Inc.</i>			
		Understanding the Physiology and Therapeutic Targets of Phosphorus Homeostasis in Patients with CKD	Myles Wolf, MD, MMSc		
		Emerging Treatment Options for Serum Phosphorus Levels	Sylvia E. Rosas, MD, MSCE, FNKF		
		Strategies to Improve Care in Patients with Hyperphosphatemia and CKD	Geoffrey Block, MD, CCRI		

FRIDAY, APRIL 25

TIME/ROOM	SESSION#	SESSION	FACULTY	NOTES	CREDITS
6:00am – 7:45am Rooms 318-319	805	EXPERT PERSPECTIVES IN THE MANAGEMENT OF BONE-MINERAL-VASCULAR DISORDERS: A PATHOPHYSIOLOGICAL AND EVIDENCE-BASED APPROACH TO CARE	Chair: Ellie Kelepouris, MD, FAHA	■	1.5
		<i>Supported by an educational grant from Sanofi Renal</i>			
		Metabolic and Mineral Disturbances in CKD-MBD: A Discussion of Pathophysiology and Risk	Matthew Weir, MD		
		Dietary Calcium and Phosphorus: A Focus on Cardiovascular Risk in CKD-MBD	Kathleen Hill Gallant, PhD, RD		
		Evolving Clinical Perspectives: Application of Phosphorus and Calcium Management Strategies in Patients With CKD-MBD	Ellie Kelepouris, MD, FAHA		
8:00am – 11:30am		BREAK IN THE EXHIBIT HALL (BREAKFAST SERVED 8:00AM – 9:00AM) – VISIT POSTERS/ EXHIBITS			1.0*
9:30am – 11:00am Room 118	572	USING QUALITY MEASURES TO IMPROVE OUTCOMES: THE DIETITIAN'S ROLE	Mark Neumann, MS Kathy Schiro-Harvey, MS, RD, CSR, CD		1.5
9:30am – 11:00am Room 111	573	SOCIAL MEDIA: “DOS” AND “DON'TS”	Sharon Johnson, JD, RD, LD	▲	1.5
9:30am – 11:00am Room 117	574	PREVALENT PROBLEMATIC PICA: PUBERTY TO PRIME	Aimee Jaremicz, RD, LDN	▲	1.5
11:00am – 11:30am		BREAK			

■ Joint with Physicians ● Separate registration and/or fee required ▲ Joint with Councils

TIME/ROOM	SESSION#	SESSION	FACULTY	NOTES	CREDITS
11:30am – 12:30pm Room 118	575	WEIGHT LOSS DRUGS AND APPETITE STIMULANTS	Anne Marie Liles, PharmD, BCPS		1.0
11:30am – 12:30pm Room 120	576	A SPEECH PATHOLOGIST'S CONTRIBUTION TO NUTRITIONAL THERAPY	John Nilsson, CCC-SLP/L		1.0
11:30am – 1:00pm Rooms 306-307	530	WORKSHOP: PUTTING THE PUZZLE PIECES TOGETHER WITH SGA: SCREENING FOR MALNUTRITION	Linda McCann, BS, RD, CSR, LD	●	1.5
1:00pm – 1:30pm		BREAK			
1:30pm – 3:00pm Room 117	577	LIVER DISEASE AND CKD-5 HD: CONSIDERATIONS, COMMONALITIES, AND INTERVENTION FOR MALNUTRITION	Eileen Moore, CNSC, RD, LD		1.5
1:30pm – 3:00pm Room 120	578	HOME PROGRAM: CAPD, CCPD, HOME HEMO, AND NOCTURNAL HD IN-CENTER PROGRAM – SO MANY CHOICES! WHAT'S A PERSON TO DO?!	Rachel Fissell, MD Rita Dimmitt, RD, CSR, LDN		1.5
1:30pm – 3:00pm Room 118	579	CHRONIC DIABETIC WOUNDS IN THE DIALYSIS PATIENT	Elizabeth Evans, RN, MSN, DNP		1.5
3:00pm – 3:30pm		BREAK			
3:30pm – 5:00pm Room 120	580	SODIUM GIRL MEETS CHEF DUANE! MAKING LOW SODIUM DIETS SEXY!!	Chef Duane Sunwold Jess Goldman Foug		1.5
3:30pm – 5:00pm Room 118	581	OPTIMIZING NUTRITIONAL STATUS IN INFANTS AND TODDLERS IN PREPARATION FOR TRANSPLANT	Kirsten Thompson, MPH, RD, CSR	▲	1.5
3:30pm – 5:00pm Room 116	284	IMPROVING THE TRANSITION FROM CKD TO ESRD	Chairs: Charmaine Lok, MD, MSc, FNKF, and Timmy Lee, MD, MSPH, FACP, FASN, FNKF	●	1.5
		Patient-Centered Decision Making on Treatment Options for Renal Replacement Therapy	Louise Moist, MD, MSc, FRCP		
		Preparing Patients and Their Families for Dialysis	Jane Schell, MD		
		Deciding Against Chronic Dialysis – Now What?	Alvin Moss, MD, FAAHPM		

SATURDAY, APRIL 26

TIME/ROOM	SESSION#	SESSION	FACULTY	NOTES	CREDITS
8:00am – 9:30am Room 311	582	TRAVELING COMPANIONS: POVERTY AND CHRONIC ILLNESS	Diane McRae, MSW, LICSW	▲	1.5
8:00am – 9:30am Room 313	583	REVOLUTIONIZE YOUR NUTRITION PRACTICE WITH MOBILE APPLICATIONS	Melissa Prest, MS, RD, LDN		1.5
9:30am – 10:00am		BREAK			
10:00am – 11:30am Room 319	680	THE TAO OF POO: HUMOR AND STRESS	Margarita Gurri, PhD	▲	1.5
10:00am – 11:30am Room 311	584	APPLICATION OF MIND-BODY THERAPIES FOR PATIENTS WITH END-STAGE RENAL DISEASE	Gurjeet Birdee, MD, MPH		1.5
11:30am		MEETING ADJOURNS			

* A maximum of 1.0 credit only will be awarded for poster sessions.

NEPHROLOGY SOCIAL WORKER PROGRAM

Planning Committee

Kristin Stockard, MSW, LICSW

Program Chair

Seattle's Children's Hospital and Regional Medical Center,
Seattle, WA

Vernon Silva, LCSW, NSW-C

Program Co-Chair

US Renal Care, Lomita, CA

Andrea DeKam, LMSW, NSW-C

Continuing Education Coordinator

University of Michigan Dialysis, Livonia, MI

Denise Collins, MSSW, LCSW, NSW-C

Kaiser Permanente, Washington, DC

Deborah Collinworth, LAPSW, NSW-C

Dialysis Clinics Inc., Jackson, TN

John Gowan, MSW

Fresenius Medical Care, North America, Clearwater, FL

Kim Gusse, MSW, LMSW, ACSW

Helen DeVos Children's Hospital, Grand Rapids, MI

Jennifer McClain, MSW, LSW

FMC Fire Mesa, Las Vegas, NV

Jessica Zeman, MSW, APSW

Luther Midelfort Mayo Health System, Eau Claire, WI

Continuing Education Information

A maximum of 32.5 continuing education clock hours for social workers (for the entire program) have been approved through the following agencies:

- The National Kidney Foundation Council of Nephrology Social Workers, Provider #1014, is approved as a provider for social work continuing education by the Association of Social Work Boards (ASWB) www.aswb.org, through the Approved Continuing Education (ACE) program. The National Kidney Foundation Council of Nephrology Social Workers maintains responsibility for the program.
- The National Kidney Foundation Council of Nephrology Social Workers, approval number PCE 2410, is approved as a Continuing Education Provider by the California Board of Behavioral Sciences. This course meets the qualifications for continuing education credit for LCSWs as required by the California Board of Behavioral Sciences
- Florida Board of Clinical Social Work, Marriage and Family Therapy, and Mental Health Counseling, Provider Number 50-1414, expires March 31, 2015.

Conference registrants are responsible for making sure their state accepts the ASWB ACE provider as sufficient for CEUs, or if they need to do anything additional to independently receive state CEUs.

Program Goals

At the conclusion of this program, participants will be able to:

- Gain the knowledge and skills for outcomes-oriented clinical nephrology social work practice
- Identify biopsychosocial variables affecting chronic kidney disease patients and their families
- Learn skills to ameliorate and address biopsychosocial variables affecting kidney disease patients and their families
- Address issues of diversity among chronic kidney disease patients and healthcare professionals
- Practice ethical social work with renal, dialysis, and transplant patients and their families

This program is NSW-C approved. All Social Work Ethics courses will be accepted for NSW-C re-certification.

PRE-CONFERENCE COURSES

REQUIRED: Separate registration fee of \$60 for NKF Members, \$75 for Non-Members; includes syllabus, light breakfast or boxed lunch, and CE credits. Participation is limited, so register early.

What Happens in Vegas Awakens You in Vegas: Mindful Leadership Skills for Nephrology Social Workers

Tuesday, April 22, 8:00am – 12:00pm

Course Director: Gary Petingola, MSW, RSW

Session 420, 3.75 clock hours

TARGET AUDIENCE

Designed for nephrology social workers (those who are formal leaders and those who are “quiet” leaders) of all expert levels (novice, experienced, seasoned) and in all nephrology practice settings.

COURSE DESCRIPTION

Mindfulness Meditation is a powerful tool that can help to instill feelings of calmness, improved concentration and focus, a general sense of well-being, less reactivity, reduced anxiety, improved sleep, and increased compassion for others and oneself. Mindfulness meditation can facilitate resilience amidst full-time job responsibilities and employee, patient, and public demands. This half-day course blends both indigenous and Buddhist teachings and explores the intersection of mindfulness training and some of the key qualities of great leaders - clarity, compassion, creativity, and focus. It invites Nephrology Social Workers, those who are formal leaders and those who are quiet leaders, to notice the auto-pilot, habituated reactivity that is often a part of our professional lives. One can then cultivate the mental discipline of mindfulness to be more consistently present, an essential requirement for optimal leadership.

COURSE OBJECTIVES

Upon completion of this course, participants will be able to:

- Increase understanding of mindfulness as it relates to leadership in nephrology social work practice
- Apply mindfulness meditation practice in personal and professional domains
- Recognize the tell-tale signs of slipping into the “sacrifice syndrome” and implement strategies for renewal
- Integrate the indigenous teachings of the Seven Grandfathers and the Four Noble Truths for enhanced leadership

TIME	TOPIC
8:00am – 8:30am	Introduction
8:30am – 9:00am	A Definition of Mindfulness and Seven Pillars
9:00am – 9:15am	Mindfulness and Social Work
9:15am – 9:30am	Auto-Pilot and Ineffective Leadership
9:30am – 10:00am	The Sacrifice Syndrome and Renewal
10:00am – 10:15am	Break
10:15am – 10:45am	Indigenous Teachings of the Seven Grandfathers and the Four Noble Truths— Leadership Lessons
10:45am – 11:00am	The Aikido of Mindful Communication
11:00am – 12:00pm	Mindfulness Practice

**Nephrology Social Work 101:
Learning/Reviewing the Clinical and
Concrete Fundamentals**

Tuesday, April 22, 1:00pm – 5:00pm

Course Directors: Jessica Phipps, MSW, LSW, and
Steve Bogatz, MBA, MSW, LCSW, NSW-C
Session 421, 4.0 clock hours

TARGET AUDIENCE

- Nephrology social workers who are new to the sub-specialty
- Experienced nephrology social workers who would like to review basic skills
- Candidates for Nephrology Social Worker Certification (NSW-C)

COURSE DESCRIPTION

This course doubles as an overview of the knowledge and expertise necessary for the experienced social worker to obtain Nephrology Social Worker Certification (NSW-C).

COURSE OBJECTIVES

Upon completion of this course, participants will be able to:

- Identify the main duties and responsibilities of the nephrology social worker in a fast-paced, time constrained, and culturally diverse treatment setting
- Apply the main duties and responsibilities of nephrology social work in an organized, effective and efficient manner that is compliant with the CMS Conditions for Coverage
- Integrate the competencies for Nephrology Social Work Certification into daily practice

TIME	TOPIC	FACULTY
1:00pm – 3:00pm	NSW 101: Learning the Clinical and Concrete Fundamentals – Part 1	Jessica Phipps, MSW, LSW
3:00pm – 4:00pm	A Day at the Dialysis Center: Developing and Utilizing the NSW-C Competencies	Steve Bogatz, MBA, MSW, LCSW, NSW-C
4:00pm – 5:00pm	NSW 101: Learning the Clinical and Concrete Fundamentals – Part 2	Jessica Phipps, MSW, LSW

Suicide Assessment Skill Building for Nephrology Social Workers

Tuesday, April 22, 1:00pm – 5:00pm

Course Directors: Jane Kwatcher, MSW, LCSW, and Matt Stricherz, EdD

Session 422, 3.75 clock hours

TARGET AUDIENCE

Designed for nephrology social workers of all expert levels (novice, experienced, seasoned) who practice in a dialysis facility or those who supervise those practitioners.

COURSE DESCRIPTION

Suicide takes on an added significance in the world of renal replacement therapy where the treatment in itself is intrinsically life-preserving. The incidence of depression

and related mood disorders remains critically high among ESRD patients, sometimes resulting in crisis situations. This 4-hour course will incorporate: identifying suicidal ideation and behavior, methods of completing an effective suicide assessment, and developing appropriate interventions within the nephrology social worker role. Skill acquisition based upon best practices, will be accomplished through lecture and case discussion activities.

COURSE OBJECTIVES

Upon completion of this course, participants will be able to:

- Define incidence and parameters of suicidal ideation and behavior in the dialysis setting
- Increase understanding of the components of a suicide assessment and the role of the nephrology social worker
- Identify interventions and a plan of care for patients with suicidal ideation and/or behaviors.

TIME	TOPIC
1:00pm – 1:15pm	Defining Suicide in the ESRD Population
1:15pm – 1:30pm	Group Interaction: Defining Participant Experiences and Confidence
1:30pm – 2:15pm	Internal and External Dynamics within the Suicidal Continuum
2:15pm – 3:00pm	Assessing Suicidal Risk
3:00pm – 3:15pm	Break
3:15pm – 4:00pm	Intervention
4:00pm – 5:00pm	Case Discussion/Activity

WORKSHOP

REQUIRED

Separate complimentary registration required. Space is limited, so register early.

Guided Tour of the Posters; Session 430

Thursday, April 24, 4:00pm – 5:30pm

1.5 clock hours

Presenters: Teri Browne PhD, MSW, NSW-C, and Joseph Merighi, PhD, MSW

Workshop Description: An experiential, hand-on tour of abstracts featuring psychosocial content. What makes for a good poster? How do you identify key findings? Veteran instructors will help participants hone skills in assessing and digesting (and building!) posters.

NEPHROLOGY SOCIAL WORKER PROGRAM

TUESDAY, APRIL 22

TIME/ROOM	SESSION#	SESSION	COURSE DIRECTOR(S)	NOTES	CREDITS
8:00am – 12:00pm Room 203	420	WHAT HAPPENS IN VEGAS AWAKENS YOU IN VEGAS: MINDFUL LEADERSHIP SKILLS FOR NEPHROLOGY SOCIAL WORKERS	Gary Petingola, MSW, RSW	●	3.75
1:00pm – 5:00pm Rooms 306-307	421	NEPHROLOGY SOCIAL WORK 101: LEARNING/ REVIEWING THE CLINICAL AND CONCRETE FUNDAMENTALS	Jessica Phipps, MSW, LSW Steve Bogatz, MBA, MSW, LCSW, NSW-C	●	4.0
1:00pm – 5:00pm Room 202	422	SUICIDE ASSESSMENT SKILL BUILDING FOR NEPHROLOGY SOCIAL WORKERS	Jane Kwatcher, MSW, LCSW Matt Stricherz, EdD	●	3.75
6:30pm – 8:00pm Premier Ballroom Lobby	101	HEALTHCARE PROFESSIONALS WELCOME RECEPTION		▲	

WEDNESDAY, APRIL 23

TIME/ROOM	SESSION#	SESSION	FACULTY	NOTES	CREDITS
6:00am – 7:45am Rooms 318-319	800	CLINICAL ASPECTS OF FIBROBLAST GROWTH FACTOR 23 IN CHRONIC KIDNEY DISEASE <i>Supported by an educational donation provided by Amgen</i>	Chair: Csaba Kovesdy, MD, FASN	■	1.5
		A Clinician's Perspective on Fibroblast Growth Factor 23	Csaba Kovesdy, MD, FASN		
		FGF23 and Clinical Outcomes in Chronic Kidney Disease	Myles Wolf, MD, MMSc		
		Dietary and Pharmacologic Modifiers of FGF23	Orlando Gutierrez, MD, MMSc		
6:00am – 7:45am Rooms 310-311	807	HIGH-DOSE IRON: TAKING TREATMENT OF IRON DEFICIENCY ANEMIA TO A NEW LEVEL <i>Supported by an educational grant from AMAG Pharmaceuticals, Inc. and American Regent, Inc.</i>	Chair: Jay Wish, MD	■	1.5
		Iron Deficiency Anemia in ND-CKD: Mechanisms and Treatment Implications	Jay Wish, MD		
		Iron Therapy in ND-CKD Patients: Oral or Intravenous?	Wajeh Qunibi, MD, FACP		
		The Role of IV Iron Therapy in ND-CKD: Newest Evidence	Daniel Coyne, MD		
8:00am – 9:30am Rooms 314-315	460	PROFESSIONAL EFFECTIVENESS: BUILDING ENERGY, STRATEGY, AND CLARITY OF PURPOSE FOR NEPHROLOGY SOCIAL WORK TOOLS	Megan Prescott, LCSW, NSW-C		1.5
9:30am – 10:00am		BREAK			
10:00am – 11:30am Room 117	461	PLAN OF CARE: STRATEGIES FOR SETTING AND ACHIEVING PATIENT-CENTERED QUALITY OF LIFE GOALS	Stephanie Johnstone, LCSW, NSW-C Beth Witten, MSW, ACSW, LSCSW		1.5

♦ Ethics Session ■ Joint with Physicians ● Separate registration and/or fee required ▲ Joint with Councils

TIME/ROOM	SESSION#	SESSION	FACULTY	NOTES	CREDITS
10:00am – 11:30am Room 123	563	AMUSED AND AMAZED: HOW TO SURVIVE AND THRIVE AS A HEALTHCARE PROFESSIONAL	Karyn Buxman, RN, MS, CSP, CPAE	▲	1.5
10:00am – 11:30am Room 111	662	INTERDISCIPLINARY TRANSPLANT FROM THE PROS	Bobby Nibhanupudy, MD Lara Tushla, MSW, LCSW, NSW-C Wendy Escobedo RN, MSN, PHN, CCTN Angella Perez, CCHT-A Maureen McCarthy, MPH, RD, CSR, LD	▲	1.5
11:30am – 12:00pm		BREAK			
12:00pm – 2:00pm Room 119	462	COUNCIL OF NEPHROLOGY SOCIAL WORKERS LUNCHEON – ALL ARE WELCOME!			
2:00pm – 2:30pm		BREAK			
2:30pm – 3:30pm Room 115	265	NKF PRESIDENTIAL ADDRESS: BUILDING CKD AWARENESS	Beth Piraino, MD, FNKF	■▲	1.0
		SHAUL G. MASSRY DISTINGUISHED LECTURE: VASCULAR DISEASE IN CHRONIC KIDNEY DISEASE: PROGRESS AND CHALLENGES	Mark Sarnak, MD, MS		
3:30pm – 4:00pm		BREAK			
4:00pm – 5:30pm Room 123	266	KDOQI – ROLES, CONTROVERSIES, AND GUIDELINES IN CKD	Chair: Jeffrey Berns, MD, FNKF	■▲	1.5
		KDOQI – Merging Old and New Roles	Jeffrey Berns, MD, FNKF		
		Thresholds for 25(OH)D Supplementation in CKD	Holly Kramer, MD, MPH		
		KDOQI Commentary on KDIGO Clinical Practice Guidelines for CKD	Tamara Isakova, MD, MMSc		
4:00pm – 5:30pm Room 111	463	CLINICAL EYE: DEMENTIA AND DECISION MAKING	Kristen Fischer, MSW, LCSW, NSW-C	◆	1.5
4:00pm – 5:30pm Room 309	464	SURVIVING A CMS TRANSPLANT AUDIT	Jennifer Bruns, MSW, LMSW, CCTSW		1.5
6:00pm – 7:30pm		OPENING CEREMONIES AND RECEPTION IN THE EXHIBIT HALL – VISIT POSTERS/EXHIBITS			1.0*
7:30pm – 9:30pm Rooms 318-319	802	HEART-KIDNEY INTERACTION AND THE ROLE OF VASOPRESSIN AND HYPONATREMIA IN HEART FAILURE	Chair: Matthew Weir, MD	■	1.5
		<i>Supported by an educational grant from Otsuka America Pharmaceutical, Inc.</i>			
		The Heart-Kidney Interaction in Heart Failure and the Pathogenesis of Hyponatremia	Matthew Weir, MD		
		The Utility of Current Treatment Options in the Management of Hyponatremia in the Heart Failure Patient with Impaired Kidney Function	Joseph Verbalis, MD		
		Lessons from Clinical Trials of Vasopressin Receptor Antagonists in Heart Failure	James Udelson, MD		

WEDNESDAY, APRIL 23, *continued*

TIME/ROOM	SESSION#	SESSION	FACULTY	NOTES	CREDITS
7:30pm – 9:30pm Rooms 310-311	808	PERSISTENT HYPERURICEMIA: A MULTI-PRONGED APPROACH TO THE MANAGEMENT OF SERUM URATE LEVELS <i>Supported by an educational grant from Takeda Pharmaceuticals North America, Inc.</i>	Chair: Robert Terkeltaub, MD	■	1.5
		Renal Dysfunction and the Management of Hyperuricemia	Jay Wish, MD		
		Managing Risk Factors and Comorbid Conditions in the Hyperuricemic Patient	Louis Kuritzky, MD		
		Application of Guidelines for Long-Term Treatment of Gout	Robert Terkeltaub, MD		

THURSDAY, APRIL 24

TIME/ROOM	SESSION#	SESSION	FACULTY	NOTES	CREDITS
6:00am – 7:45am Rooms 318-319	803	CHANGING PROFILE OF CHRONIC HYPERKALEMIA <i>Supported by an educational grant from ZS Pharma, Inc.</i>	Chair: Peter McCullough, MD, MPH, FACC, FCCP, FACP, FAHA, FNKF	■	1.5
		Frequency and Clinical Significance of Hyperkalemia in CKD	Robert Toto, MD		
		Risks of Hyperkalemia in Special Kidney Disease Populations	Michael Emmett, MD		
		Emerging Therapies for Treating Hyperkalemia	John Middleton, MD		
7:00am – 8:00am		CONTINENTAL BREAKFAST IN THE EXHIBIT HALL – VISIT POSTERS/EXHIBITS			1.0*
8:30am – 10:00am Room 117	465	QAPI: NEPHROLOGY SOCIAL WORK PRACTICES AND TOOLS	Jessica Phipps, MSW, LSW		1.5
8:30am – 10:00am Room 115	466	TRANSPLANT ISSUES FOR MINORITIES	Akinlolu Ojo, MD, MPH, PhD Rebecca Hays, MSW, APSW, NSW-C		1.5
10:00am – 10:30am		BREAK			
10:30am – 12:00pm Room 121	467	END-OF-LIFE ISSUES, INTERVENTIONS, AND DOCUMENTATION: ACCEPTANCE DOESN'T MEAN GIVING UP	Mary Beth Callahan, MSSW, ACSW, LCSW	▲	1.5
10:30am – 12:00pm Room 317	468	RESEARCH SKILL BUILDING: ANALYSIS OF NEPHROLOGY SOCIAL WORK SALARY AND CASELOAD SURVEY RESULTS	Joseph Merighi, PhD, MSW Teri Browne, PhD, MSW, NSW-C		1.5
12:00pm – 2:00pm		BREAK IN THE EXHIBIT HALL (LUNCH SERVED 12:15PM – 1:15PM) – VISIT POSTERS/EXHIBITS			1.0*
2:00pm – 3:30pm Room 115	469	ADDICTION AND THE ESRD PATIENT	Steve Kelley, MSW, MDIV		1.5
2:00pm – 3:30pm Room 111	470	ETHICS: CURRENT ESRD ACCESS TO TREATMENT DILEMMAS IN AN HISTORICAL CONTEXT	Paula Goodman-Crews, MSW, LCSW Aaron Wightman, MD	▲❖	1.5
3:30pm – 4:00pm		BREAK			

❖ Ethics Session ■ Joint with Physicians ● Separate registration and/or fee required ▲ Joint with Councils

TIME/ROOM	SESSION#	SESSION	FACULTY	NOTES	CREDITS
4:00pm – 5:30pm Room 111	471	ADDRESSING MENTAL HEALTH IN THE DIALYSIS UNIT WITH DSM-5	Melissa Fry, MSW, CAPSW, NSW-C Paul Gasser, MS, LMFT		1.5
4:00pm – 5:30pm Room 115	472	NEPHROLOGY SOCIAL WORK MANAGEMENT SKILLS: CLINICAL STAFF AND INTERNS	Felipe Amaya, LCSW Debbie Brady, LCSW, ACSW, NSW-C		1.5
4:00pm – 5:30pm Marquee Ballroom	430	GUIDED TOUR OF THE POSTERS	Teri Browne, PhD, MSW, NSW-C Joseph Merighi, PhD, MSW	●	1.5
6:00pm – 7:30pm		NETWORKING RECEPTION IN THE EXHIBIT HALL –VISIT POSTERS/EXHIBITS			1.0*
7:30pm – 9:30pm Rooms 318-319	804	NEW INSIGHTS INTO THE ROLE OF PHOSPHORUS BALANCE IN CHRONIC KIDNEY DISEASE <i>Supported by an educational grant from Keryx Biopharmaceuticals, Inc.</i>	Chair: Myles Wolf, MD, MMSc	■	1.5
		Understanding the Physiology and Therapeutic Targets of Phosphorus Homeostasis in Patients with CKD	Myles Wolf, MD, MMSc		
		Emerging Treatment Options for Serum Phosphorus Levels	Sylvia E. Rosas, MD, MSCE, FNKF		
		Strategies to Improve Care in Patients with Hyperphosphatemia and CKD	Geoffrey Block, MD, CCRI		

FRIDAY, APRIL 25

TIME/ROOM	SESSION#	SESSION	FACULTY	NOTES	CREDITS
6:00am – 7:45am Rooms 318-319	805	EXPERT PERSPECTIVES IN THE MANAGEMENT OF BONE-MINERAL-VASCULAR DISORDERS: A PATHOPHYSIOLOGICAL AND EVIDENCE-BASED APPROACH TO CARE <i>Supported by an educational grant from Sanofi Renal</i>	Chair: Ellie Kelepouris, MD, FAHA	■	1.5
		Metabolic and Mineral Disturbances in CKD-MBD: A Discussion of Pathophysiology and Risk	Matthew Weir, MD		
		Dietary Calcium and Phosphorus: A Focus on Cardiovascular Risk in CKD-MBD	Kathleen Hill Gallant, PhD, RD		
		Evolving Clinical Perspectives: Application of Phosphorus and Calcium Management Strategies in Patients With CKD-MBD	Ellie Kelepouris, MD, FAHA		
8:00am – 11:30am		BREAK IN THE EXHIBIT HALL (BREAKFAST SERVED 8:00AM – 9:00AM) – VISIT POSTERS/EXHIBITS			1.0*
9:30am – 11:00am Room 115	473	ADHERENCE: THE USE OF ACCEPTANCE AND COMMITMENT THERAPY (ACT)	Mary Rzeszut, MSW, LCSW		1.5
9:30am – 11:00am Room 114	474	EXPLORING ETHICAL ISSUES IN DISCONTINUATION OF DIALYSIS	Mary Beth Callahan, MSSW, ACSW, LCSW Jane Kwatcher, MSW, LCSW	❖	1.5
9:30am – 11:00am Room 117	574	PREVALENT PROBLEMATIC PICA: PUBERTY TO PRIME	Aimee Jaremowicz, RD, LDN	▲	1.5
11:00am – 11:30am		BREAK			

FRIDAY, APRIL 25, *continued*

TIME/ROOM	SESSION#	SESSION	FACULTY	NOTES	CREDITS
11:30am – 12:30pm Room 114	475	CONFLICT MANAGEMENT	Lisa Hall, MSSW, LICSW Lois Kelley, MSW, ACSW, NSW-C		1.0
11:30am – 12:30pm Room 115	476	WHEN THE END IS AT THE BEGINNING: DEALING WITH DEATH AND LOSS IN THE PEDIATRIC SETTING	Lynn Puma, LCSW Allison Shukraft, MSW, MAT		1.0
12:30pm – 1:30pm		BREAK			
1:30pm – 3:00pm Room 115	477	CARE TRANSITIONS: THE NEPHROLOGY SOCIAL WORK ROLE WITH ESRD PATIENT PROVIDERS	Elanderia Rowe, LMSW-IPR, NSW-C		1.5
1:30pm – 3:00pm Room 111	478	ADHERENCE WITH ADOLESCENTS	Paula Goodman-Crews, MSW, LCSW Kim Gusse, MSW, LMSW, ACSW	❖	1.5
3:00pm – 3:30pm		BREAK			
3:30pm – 5:00pm Room 111	479	BEYOND TOLERANCE: PROMOTING AN EQUAL DIALYSIS UNIT FOR LGBT PATIENTS AND STAFF	Jeff Jin, MSW		1.5
3:30pm – 5:00pm Room 115	480	AFFORDABLE CARE ACT IMPLEMENTATION IMPLICATIONS	Troy Zimmerman, BA Denise Collins, MSSW, LCSW-C, LICSW, NSW-C Deborah Barnett, MSW, LCSW		
3:30pm – 5:00pm Room 118	581	OPTIMIZING NUTRITIONAL STATUS IN INFANTS AND TODDLERS IN PREPARATION FOR TRANSPLANT	Kirsten Thompson, MPH, RD, CSR	▲	1.5

SATURDAY, APRIL 26

TIME/ROOM	SESSION#	SESSION	FACULTY	NOTES	CREDITS
8:00am – 9:30am Room 309	481	TRANSPLANT: PEER EDUCATION PROGRAM FOR HISPANICS ON DIALYSIS	Nicole Pinkerton, MFT		1.5
8:00am – 9:30am Rooms 301-302	482	PEDIATRIC TRANSITIONS: ADULT CARE AND TRANSPLANT	Debbie Brady, LCSW, ACSW, NSW-C Kristin Stockard, MSW, LICSW Camille Yuscak, LCSW-R, NSW-C		1.5
8:00am – 9:30am Room 311	582	TRAVELING COMPANIONS: POVERTY AND CHRONIC ILLNESS	Diane McRae, MSW, LICSW	▲	1.5
9:30am – 10:00am		BREAK			
10:00am – 11:30am Room 320	483	DOMESTIC VIOLENCE IN THE DIALYSIS UNIT	Jennifer Geiger, MSW, LSW, NSW-C		1.5
10:00am – 11:30am Room 313	484	ADVOCATING FOR THE FUTURE OF NEPHROLOGY SOCIAL WORK: CHOOSE YOUR OWN ADVENTURE	Leanne Peace, MSW, LCSW, MHA		1.5
11:30am		MEETING ADJOURNS			

* A maximum of 1.0 credit only will be awarded for poster sessions.

Ethics Session ■ Joint with Physicians ● Separate registration and/or fee required ▲ Joint with Councils


FELLOWSHIP OF THE NATIONAL KIDNEY FOUNDATION INDUCTEES

CONGRATULATIONS AND THANK YOU FOR ALL YOU DO TO IMPROVE THE LIVES OF PATIENTS WITH KIDNEY DISEASE:

Konstantin Abramov, MD, FNKF	Chester Fox, MD, FNKF	Peter McCullough, MD, MPH, FNKF	Amit Sharma, MD, FNKF
Anjali Acharya, MD, FNKF	Linda Fried, MD, FNKF	Rita McGill, MD, FNKF	Fuad Shihab, MD, FNKF
Alok Agrawal, MD, FNKF	Masafumi Fukagawa, MD, FNKF	Rajnish Mehrotra, MD, FNKF	Michael Shlipak, MD, FNKF
Anil Agarwal, MD, FNKF	Susan Furth, MD, PhD, FNKF	Michal Melamed, MD, FNKF	Mawya Shocair, MD, FNKF
Ayoola Akinbamowo, MD, FNKF	Kumar Gaurav, MD, FNKF	Tina Melanson, MD, FNKF	Bhupinder Singh, MD, FNKF
Fadel Alrowaie, MD, FNKF	Charles George, MD, FNKF	Sergio Mezzano, MD, FNKF	Sandeep Soman, MD, FNKF
Jose Arruda, MD, FNKF	Deb Gipson, MD, FNKF	Neal Mittman, MD, FNKF	Stephen Sozio, MD, FNKF
Arif Asif, MD, FNKF	David Goldfarb, MD, FNKF	Carol Moore, PharmD, FNKF	Matthew Sparks, MD, FNKF
Abdo Asmar, MD, FNKF	Stuart Goldstein, MD, FNKF	Tariq Mubin, MD, FNKF	John Sperati, MD, FNKF
Rasheed Balogun, MD, FNKF	Larry Greenbaum, MD, PhD, FNKF	Bruce Mueller, PharmD, FNKF	Stuart Sprague, DO, FNKF
George Bayliss, MD, FNKF	Mark Greenwell, MD, FNKF	Fareha Nawaz, MD, FNKF	Leslie Spry, MD, FNKF
Bryan Becker, MD, FNKF	Joni Hansson, MD, FNKF	Allen Nissenson, MD, FNKF	Wendy St. Peter, PharmD, FNKF
Gavin Becker, MD, FNKF	Azzour Hazzan, MD, FNKF	Vandana Niyyar, MD, FNKF	Gerald Stephanz, MD, FNKF
May Behren, MD, FNKF	Nasser Hebah, MD, FNKF	Paul Olson, MD, FNKF	Leonard Stern, MD, FNKF
Laurie Benton, PA-C, FNKF	Joanna Hudson, PharmD, FNKF	David Owshalimpur, MD, FNKF	Giovanni Strippoli, MD, FNKF
Jeffrey Berns, MD, FNKF	Kunitoshi Iseki, MD, FNKF	Paul Palevsky, MD, FNKF	Rachel Sturdivant, MD, FNKF
Anthony Bleyer, MD, FNKF	Bernard Jaar, MD, FNKF	Saurabh Pande, MD, FNKF	Lynda Szczech, MD, FNKF
Geoffrey Block, MD, FNKF	Bertrand Jaber, MD, FNKF	Chirag Parikh, MD, FNKF	Harold Szerlip, MD, FNKF
Joseph Bonventre, MD, PhD, FNKF	Tazeen Jafar, MD, FNKF	Dipen Parikh, MD, FNKF	Ahmad Tarakji, MD, FNKF
Jonathan Bress, MD, FNKF	Pankaj Jawa, MD, FNKF	Stephen Pastan, MD, FNKF	Charuhas Thakar, MD, FNKF
Robert Brown, MD, FNKF	Kenar Jhaveri, MD, FNKF	Mark Perazella, MD, FNKF	Arshdeep Tindni, MD, FNKF
Kellie Calderon, MD, FNKF	Kamyar Kalantar-Zadeh, MD, FNKF	Jeffrey Perlmutter, MD, FNKF	Nori Uday, MD, FNKF
Katie Cardone, PharmD, FNKF	Ayman Karkar, MD, FNKF	Ronald Perrone, MD, FNKF	Joseph Vassalotti, MD, FNKF
Laurence Carroll, MD, FNKF	Richard Kasama, MD, FNKF	Kashif Piracha, MD, FNKF	John Wang, MD, FNKF
Kerri Cavanaugh, MD, FNKF	Bertram Kasiske, MD, FNKF	Beth Piraino, MD, FNKF	Bradley Warady, MD, FNKF
Micah Chan, MD, FNKF	Federick Kaskel, MD, PhD, FNKF	Jai Radhakrishnan, MD, FNKF	Marc Weber, MD, FNKF
David Cherney, MD, PhD, FNKF	Pranay Kathuria, MD, FNKF	Fernando Raudales, MD, FNKF	Eric Wechsler, MD, FNKF
Alfred K. Cheung, MD, FNKF	Paul Kellerman, MD, FNKF	Giuseppe Remuzzi, MD, FNKF	Daniel Weiner, MD, FNKF
Daraneé Chewaproug, DO, FNKF	Nelson Kopyt, MD, FNKF	Dena Rifkin, MD, FNKF	Wendy Weinstock Brown, MD, MPH, FNKF
Michael Choi, MD, FNKF	Christina Lankhorst, MD, FNKF	Michael Rocco, MD, FNKF	Lawrence Weisberg, MD, FNKF
Woojin James Chon, MD, FNKF	Brian Lee, MD, FNKF	Sylvia Rosas, MD, FNKF	Steven Weisbord, MD, FNKF
Jacques Daoud, MD, FNKF	David Leehey, MD, FNKF	Mario Rubin, MD, FNKF	Miriam Weiss, MD, FNKF
Jane Davis, DNP, CRNP, FNKF	Edgar Lerma, MD, FNKF	Sachin Sachdev, MD, FNKF	Robert Weiss, DO, FNKF
Tejas Desai, MD, FNKF	Andrew Levey, MD, FNKF	Heidi Schaefer, MD, FNKF	Adam Whaley-Connell, DO, FNKF
Shannon Doyle, MD, FNKF	Susie Lew, MD, FNKF	Charles Schleifer, MD, FNKF	David Wheeler, MD, FNKF
Anjum Ehteshamul, MD, FNKF	Philip Li, MD, FNKF	Michael Schwenk, PharmD, FNKF	Jerry Yee, MD, FNKF
Fernando Fervenza, MD, FNKF	Charmaine Lok, MD, FNKF	Adam Segal, MD, FNKF	Melvin Yudis, MD, FNKF
Jeffrey Fink, MD, FNKF	Adit Mahale, MD, FNKF	Jonathan Segal, MD, FNKF	Alfredo Zannier, MD, FNKF
Frederic Finkelstein, MD, FNKF	Samir Mallat, MD, FNKF	Craig Shadur, MD, FNKF	Carmine Zoccali, MD, FNKF
Jurgen Floege, MD, FNKF	Nancy Mason, PharmD, FNKF	Tariq Shafi, MBBS, MHS, FNKF	Kim Zuber, PA-C, FNKF

EXHIBIT HALL MAP

MARQUEE BALLROOM



EXHIBITORS*/BOOTH NUMBERS

Abbott Nutrition.....	522	Frenova	218	Nationwide Laboratory Services.....	126
AbbVie.....	110	Fresenius Medical Care – Physician Practice/Placement.....	119	NephCure Foundation	108
Acumen Physician Solutions.....	223	Fresenius Medical Care – Renal Therapies Group	227	Nephroceuticals, LLC.	512
Alexion Pharmaceuticals, Inc.	100	Fresenius Medical Care – Velphoro..	129	<i>Nephrology News & Issues</i>	115
American Regent, Inc.	515	Fresenius Medical Care – Services ..	123	Nephrology Nursing Certification Commission.....	521
American Society of Nephrology.	122	Genentech	422	Nephropath.....	417
Amgen.....	272	Genzyme, A Sanofi Company	316	Nephro-Tech, Inc.	527
Angelini Pharma, Inc.....	505	Global Health Products	407	Nestlé Health Science	313
Ascend Clinical	413	HiDow.....	128	Nipro Medical Corporation.....	211
Associates of Cape Cod	508	ICU Medical, Inc.....	412	NxStage Medical, Inc.....	114
B. Braun Medical, Inc.....	423	Infian/HII	410	Pentec Health, Inc.	409
Baxter Healthcare	401	Intelomed, Inc.....	319	Polycystic Kidney Disease Foundation	216
Binding Site.....	214	Kaneka Pharma America.....	503	Questcor Pharmaceuticals, Inc.....	472
BONENT	120	Kibow Biotech, Inc.....	416	Reach Kidney Care	320
Center for the Study of Services.....	124	Kidney Ties.....	322	<i>Renal & Urology News.....</i>	321
Commission on Dietetic Registration	118	Kramer Novis.....	323	Rockwell Medical.....	317
CryoLife.....	318	Llorens Pharmaceutical International Division, Inc.....	311	Sanofi Renal.....	516
Daxor Corporation	212	Mayo Clinic Kidney and Pancreas Transplant	117	Sceptre Management Solutions, Inc.	506
DCRX Infusion.....	109	Medical Education Institute.....	519	Smart Mobile LV.....	501
Dialysis Patient Citizens.....	116	Molded Products, Inc.	113	Spectra Laboratories	219
DOPPS/Arbor Research	420	Mom’s Meals NourishCare	217	The Gideons International	418
DSI Renal.....	425	National Kidney and Urologic Diseases Information Clearinghouse (NKUDIC)	517	Treat the Pain	525
Elsevier, Inc.	523	NATIONAL KIDNEY FOUNDATION.....	429	What’s So Funny About...Karyn Buxman.....	507
End Stage Renal Disease Network Coordinating Center.....	509	NATIONAL KIDNEY FOUNDATION PROFESSIONAL COUNCILS.....	327		
Ethicon BIOPATCH	106				
Everidis Health Sciences	524				
Feel Good, Inc.....	511				

**Bolded Companies are Sponsors*

2014 EXHIBITOR PRODUCT/SERVICE DESCRIPTIONS

EXHIBITORS/BOOTH NUMBERS

ABBOTT NUTRITION – 522

Abbott Nutrition is one of the world's leading authorities in science-based nutrition for all stages of life. As your nutrition partner, we invite you to visit us and explore our portfolio of products, including Nepro and Seplena, to help your patients grow and achieve greater well-being.

ABBVIE – 110

AbbVie is a global, research-based biopharmaceutical company which combines the focus of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. AbbVie is committed to using unique approaches to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases.

ACUMEN PHYSICIAN SOLUTIONS – 223

Acumen Physician Solutions is the leading provider of products and solutions designed to assist nephrologists in the practice of medicine. The Acumen Solution was designed by nephrologists and made available under an internet-based service model. Our products include Acumen Nephrology: nEHR, Practice Management, Mobile Charge Capture and the Physician Quality Reporting System (PQRS) Registry.

ALEXION PHARMACEUTICALS, INC. – 100

Alexion Pharmaceuticals is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the innovation, development, and commercialization of life-transforming products.

AMERICAN REGENT, INC. – 515

American Regent, Inc., a subsidiary of Luitpold Pharmaceuticals, Inc., is the leading manufacturer and distributor of IV iron in the U.S. In addition to Venofer® (iron sucrose injection, USP), American Regent now offers Injectafer® (ferric carboxymaltose injection), available in 750 mg/15 mL single-use vials. Please visit us at Booth 515 to learn more!

AMERICAN SOCIETY OF NEPHROLOGY – 122

The American Society of Nephrology (ASN) leads the fight against kidney disease by educating health professionals, sharing new knowledge, advancing research, and advocating the highest quality care for patients. For more information please visit: www.asn-online.org

AMGEN – 272

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing, and delivering innovative human therapeutics. A biotechnology pioneer since 1980, Amgen has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

ANGELINI PHARMA, INC. – 505

Alcavis HDC is dedicated to supporting the renal community through education and aid with innovative and progressive skin cleansers, disinfectants and medical devices. Our core products are electrolytically produced sodium hypochlorite-based solutions for applications that include skin and exit site care, connectivity and dialyzer reprocessing. The clear solutions to your infection control needs in dialysis.

ASCEND CLINICAL – 413

Ascend Clinical is the nation's leader in ESRD laboratory testing for independent dialysis providers. Our multiple, cutting-edge, online and mobile app solutions, harnessing CROWNWeb technologies, empower you with integrated access to real-time results, reporting, workflow, and treatment features, reclaiming your time, and providing you with ultimate flexibility.

ASSOCIATES OF CAPE COD – 508

B. BRAUN MEDICAL, INC. – 423

B. Braun's renal therapies division, Avitum, has been a leading provider of dialysis care products for more than 30 years. As a manufacturer and distributor of hemodialysis equipment and related disposables, we offer the technology and dialysis products you need for therapy from one single source. Customers profit from the expertise of an all-around system supplier with comprehensive knowledge and experience in every aspect of the dialysis situation – from research to manufacturing to therapy. For more information, call 800.848.2066.

BAXTER HEALTHCARE – 401

Baxter enhanced its leadership in renal therapies with the acquisition of Gambro and now offers a comprehensive portfolio of therapeutic options across the home, in-center, and intensive care settings. The portfolio includes innovative technologies and therapies for peritoneal dialysis, in-center and home hemodialysis, continuous renal replacement therapy, multi-organ extracorporeal support therapy, and additional dialysis services.

BINDING SITE – 214

Binding Site is committed to developing special protein assays and automated systems for the improvement of patient care. Our market-leading assay Freelite® for detecting free light chains is widely used in diagnosis and monitoring of myeloma, often complicated by kidney dysfunction. Our patented antibody production technology and medical educators, backed by clinical practice guidelines, provide healthcare professionals tools to significantly improve diagnosis and management of patients. www.thebindingsite.com

BONENT – 120

This is the 40th anniversary of BONENT – We have been certifying nurses and technicians worldwide since 1973, making us the original certifying organization for professionals working in dialysis. We have the Certified Hemodialysis Nurse (CHN), the Certified Hemodialysis Technologist (CHT) and the Certified Peritoneal Dialysis Nurse (CPDN) programs. BONENT has started a continuing education program for our members and the wider dialysis community, including Regional Dialysis Education Seminars. More information about BONENT can be found at BONENT.org

CENTER FOR THE STUDY OF SERVICES – 124

The Center for the Study of Services (CSS) is a nonprofit, 501(c)(3) organization with decades of experience in capturing and improving the experience of healthcare consumers and patients. CSS administers a variety of CAHPS surveys, including the In-Center Hemodialysis CAHPS required by CMS.

COMMISSION ON DIETETIC REGISTRATION – 118

Commission on Dietetic Registration (CDR), the credentialing agency for the Academy of Nutrition and Dietetics, offers Board Certification as a Specialist for Registered Dietitian/Registered Dietitian Nutritionists in Renal Nutrition, as well as Gerontological Nutrition, Pediatric Nutrition, Oncology Nutrition and Sports Dietetics. Coming soon: Specialist in Obesity and Weight Management.

CRYOLIFE – 318

CryoLife® is a leader in the development and implementation of advanced technologies associated with vascular allograft processing and cryopreservation. CryoLife also has the HeRO Graft (Hemodialysis Reliable Outflow). HeRO Graft is the ONLY fully subcutaneous AV access solution clinically proven to maintain long-term access for hemodialysis patients with central venous stenosis.

DAXOR CORPORATION – 212

Daxor Corporation's BVA-100® Blood Volume Analyzer is a semi-automated instrument patented for direct measurement of blood, red cell and plasma volume. The system utilizes the Volumex® injection kit for a multi-sample blood volume. Measurement of blood volume is applicable for hypertension, CHF, transfusion, ICU/CCU, anemia, orthostatic hypotension, and syncope.

DCRX INFUSION – 109

DCRX Infusion is the premier provider of renal nutrition support therapies, Intradialytic Parenteral Nutrition (IDPN), and Intraperitoneal Nutrition (IPN). The highest quality control standards and commitment to continued development of state-of-the-art therapies have made DCRX Infusion a leader in the infusion therapy industry.

DIALYSIS PATIENT CITIZENS – 116

With a membership composed of 30,000 patients, family members, and care providers, DPC works to improve the quality of life for all dialysis patients through education and advocacy.

DOPPS/ARBOR RESEARCH – 420

Arbor Research is a not-for-profit research organization based in Ann Arbor, MI, conducting large studies in epidemiology and public health. With particular expertise in biostatistical analysis, clinical practice, the management and integration of large data sets, economics, and public policy, Arbor Research engages in health outcomes research on chronic disease and end-stage organ failure. Currently including the international Dialysis Outcomes and Practice Patterns Study (DOPPS), Peritoneal Dialysis Outcomes and Practice Patterns Study and the Chronic Kidney Disease Outcomes and Practice Patterns Study. www.DOPPS.org

DSI RENAL – 425

DSI Renal is a leading provider of dialysis services in the U.S., offering state-of-the-art treatment for patients suffering from chronic kidney failure. With its physician partners, DSI owns and operates 90 clinics in 22 states. www.dsi-corp.com

ELSEVIER, INC. – 523

ELSEVIER is a leading publisher of health science publications, advancing medicine by delivering superior reference information and decision support tools to doctors, nurses, health practitioners, and students. With an extensive media spectrum—print, online, and handheld—we are able to supply the information you need in the most convenient format.

END STAGE RENAL DISEASE NETWORK COORDINATING CENTER – 509

The ESRD Network Coordinating Center (NCC) provides support and coordination at the national level for the Medicare ESRD Network Program, emphasizing three core goals: better care for the individual through beneficiary and family-centered care; better health for the ESRD population; and reduced costs of ESRD care by improving care.

ETHICON BIOPATCH – 106

Ethicon BIOPATCH Products: BIOPATCH Protective Disk with CHG is the only IV dressing with an FDA-cleared indication to reduce CRBSIs. Randomized controlled trial data exclusively from studies using BIOPATCH were referenced in the 2011 CDC Guidelines for the Prevention of Intravascular Catheter-Related Bloodstream Infections to support the Category IB recommendation for use of a chlorhexidine-containing sponge.

EVERIDIS HEALTH SCIENCES – 524

Everidis is an innovative health sciences company focused on developing unique approaches to address nutritional and metabolic deficiencies. We strive to translate peer-reviewed research on health and nutrition into products that are safe, therapeutic, and healthful. We are committed to improving patient quality of life.

FEEL GOOD, INC. – 511

Feel Good, Inc. is the premier leading distributor of mini electric massagers intended for temporary relief of minor aches and pains associated with sore and aching muscles as well as stress and tension while relaxing muscles from strains, exercise, or normal household and sport work activities.

FRENOVA – 218

Frenova Renal Research is your only clinical development partner dedicated exclusively to renal research. We offer complete Phase I-IV clinical services and exceptional bioinformatics capabilities, along with a world-class network of resources, and access to 183,000+ active ESRD patients and 390,000+ active CKD patients. Trust the partner that's completely renal—Frenova.

FRESENIUS MEDICAL CARE – PHYSICIAN PRACTICE/ PLACEMENT – 119

Physician Placement Services is dedicated to helping nephrologists find fulfilling and enduring career opportunities in a wide variety of practice settings. Stop by our booth to meet our team and learn more about our new self-service website.

FRESENIUS MEDICAL CARE – RENAL THERAPIES GROUP – 227

The Renal Therapies Group of Fresenius Medical Care continues to provide a wealth of product offerings to the renal industry, including Optiflux® dialyzers, the 2008® series hemodialysis machines, and Crit-Line®. Fresenius Medical Care continues to solidify its position as the only comprehensive home therapy provider through a suite of product offerings, including 2008K@home™, Liberty® cycler, and stay-safe® connectology, as well as a host of services to support the established home therapy education. Our Renal Pharmaceutical Team continues to drive innovation with novel offerings such as Velporo® (sucroferric oxyhydroxide), Venofer® (iron sucrose), and PhosLyra® (calcium acetate oral solution). To learn more, visit us at www.fmcna.com or contact us at 800.662.1237.

FRESENIUS MEDICAL CARE – VELPHORO – 129

Fresenius Medical Care North America (FMCNA) introduces Velporo® (sucroferric oxyhydroxide) chewable tablets, a new iron-based phosphate binder for patients on dialysis. Stop by Booth #129 for a product brochure or to talk to a representative about Velporo tablets and the other products and services provided by FMCNA.

FRESENIUS MEDICAL CARE – SERVICES – 123

At Fresenius Medical Services (FMS), we deliver superior care that improves the quality of life of every patient, every day, setting the standard by which others in the healthcare industry are judged. Come meet our team: Clinical Services, FreseniusRx, Inpatient Services, Patient Admissions, UltraCare® at Home, UltraCare-Dialysis.com, and Recruiting.

GENENTECH – 422

Considered the founder of the biotechnology industry, Genentech has been delivering on the promise of biotechnology for more than 35 years, using human genetic information to discover, develop, manufacture, and commercialize medicines to treat patients with serious or life-threatening medical conditions. Today, Genentech is among the world's leading biotech companies, with multiple products on the market and a promising development pipeline.

GENZYME, A SANOFI COMPANY – 316

Genzyme has pioneered the development and delivery of transformative therapies for patients affected by rare and debilitating diseases for over 30 years. We accomplish our goals through world-class research, collaboration with the global patient community, and with the compassion and commitment of our employees. With a focus on rare diseases and multiple sclerosis, we are dedicated to making a positive impact on the lives of the patients and families we serve. Genzyme's portfolio of transformative therapies, which are marketed in countries around the world, represent groundbreaking and life-saving advances in medicine. As a Sanofi company, Genzyme benefits from the reach and resources of one of the world's largest pharmaceutical companies, with a shared commitment to improving the lives of patients. Learn more at www.genzyme.com

GLOBAL HEALTH PRODUCTS – 407

Global Health Products, Inc. is a family-owned business based in Rochester, NY. We design, manufacture, and distribute a varied line of products to address the needs of hospitals, dialysis centers, nursing homes, bariatric centers, and pharmacies. Products include: LiquaCel, ProCel, ProCel 100, UpCal D, LiquaFiber, and Prep-It Wound Cleanser.

HIDOW – 128

ICU MEDICAL, INC. – 412

ICU Medical, a leader in IV devices has launched its newest connector the TEGO™, specifically designed for use on hemodialysis catheters. The TEGO prevents contamination of the catheter which may otherwise lead to bloodstream infections. The TEGO is also approved for use with a saline flush, which offers substantial cost and clinical benefits.

INFIAN/HII – 410

Infian, formerly known as Health Informatics International (HII), is the leading provider of renal electronic health records (EHR), medical billing services, and billing software for over 25 years. Infian ensures your medical and billing data is secure and accessible, and ultimately improves the care you provide. The TIME System is ONC HIT certified as a Complete EHR for Meaningful Use. Please visit www.infian.com for more information.

INTELOMED, INC. – 319

CVInsight® is a real-time, patient-specific monitor of changes in critical physiologic measures. With CVInsight, the physician or other caregiver can have a non-invasive, pre-symptomatic view into the physiological status of their patient.

KANEKA PHARMA AMERICA – 503

Kaneka's Liposorber is an FDA-approved LDL Apheresis system that is indicated to acutely remove LDL-C in Pediatric Primary FSGS and Familial Hypercholesterolemia patients for whom diet and drug therapies have been ineffective.

KIBOW BIOTECH, INC. – 416

Kibow Biotech specializes in the development of patented probiotic dietary supplements for kidney health. Our flagship product Renadyl™ is a probiotic formulation that promotes healthy kidney function. Ongoing clinical studies further validate that Renadyl™ stabilizes and/or reduces uremic toxin levels in CKD patients, resulting in an improved quality of life.

KIDNEY TIES – 322

A cloud-based software tool to effectively manage your CKD patient education program with proven efficacy. It enables tracking and scoring of each patient's education, clinical progression, care, and preparedness for dialysis. Features include scheduling, EMR integration, educator reports, access timeline, billing documentation, management reports, and analysis.
www.kidneyties.com

KRAMER NOVIS – 323

Kramer Novis offers a wide variety of protein supplements in liquid, powder, and tablets. PRE PROTEIN provides 20 grams of protein per 1 oz., free of fats, carbs, gluten, and sugar. Low sodium, low potassium, and low phosphorus. We offer hydrolyzed collagen and whey protein isolate supplements at affordable prices.

LLORENS PHARMACEUTICAL INTERNATIONAL DIVISION, INC. – 311

A family-owned business, Llorens Pharmaceuticals, was founded in 1985. Llorens Pharmaceutical International Division, Inc. began doing business with the introduction of three products: Nutrivit®, Proteinex®, and Nephronex®. These products received great acceptance and approval among physicians and pharmacists, which motivated the company to flourish. With the ambition of improving human life by marketing quality health-related products, this company strives to become one of the leading pharmaceutical enterprises in dietary supplements, with fiber and tinnitus dietary supplements, and other cost-effective products.

MAYO CLINIC KIDNEY AND PANCREAS TRANSPLANT – 117

Mayo Clinic's Kidney and Pancreas Transplant Programs are among the largest and most innovative in the country. Transplant teams in Arizona, Florida, and Minnesota perform more than 450 kidney transplants and 30 to 40 pancreas transplants each year, while achieving excellent outcomes.

MEDICAL EDUCATION INSTITUTE – 519

Medical Education Institute (MEI) is a nonprofit organization dedicated to helping people with chronic disease learn to manage and improve their health. We conduct health behavior research and develop evidence-based patient education materials. MEI administers Life Options (www.lifeoptions.org), and created Kidney School (www.kidneyschool.org), Home Dialysis Central (www.homedialysis.org), and KDQOL COMPLETE (www.kdqol-complete.org).

MOLDED PRODUCTS, INC. – 113

Molded Products, Inc. provides ancillary dialysis supplies, including access sites, luer lock caps, transducer protectors, tube occluding forceps, recirculation sets, specialty connectors, fistula pressure clamps, safety face-shields, and more! Molded Products is a full-service custom injection molder, providing mold design, engineering services, mold manufacturing, injection molding, and post-molding assembly.

MOM'S MEALS NOURISHCARE – 217

Mom's Meals NourishCare, the leading provider of nutrition solutions delivered to seniors and patients nationwide. We offer up to 70 nutritious, fresh-made meals that are dietitian-designed, and chef-prepared. Menus for leading health conditions include heart-healthy, diabetic, renal, gluten-free, vegetarian, and pureed.
www.MomsMeals.com

NATIONAL KIDNEY AND UROLOGIC DISEASES INFORMATION CLEARINGHOUSE (NKUDIC) – 517

The National Kidney and Urologic Diseases Information Clearinghouse (NKUDIC) is an information and referral service of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), one of the National Institutes of Health. The Clearinghouse responds to inquiries, develops and distributes publications, and provides referrals to kidney and urologic organizations. www.kidney.niddk.nih.gov

NATIONAL KIDNEY FOUNDATION – 429

Awareness. Prevention. Treatment. NKF is the leading organization dedicated to the awareness, prevention, and treatment of kidney disease for hundreds of thousands of healthcare professionals, millions of patients and their families, and tens of millions of Americans at risk.

NKF raises awareness of kidney disease through public service campaigns, a comprehensive website, robust social media initiatives, and community-based kidney health checkups. NKF empowers and educates at-risk individuals to seek testing and treatment for prevention of kidney damage and progression of the disease. The Foundation improves treatment through patient and professional education, clinical practice guidelines, professional memberships, and peer-reviewed journals: *American Journal of Kidney Diseases*, *Advances in Chronic Kidney Disease* and *Journal of Renal Nutrition*. Come learn about our patient and professional programs and materials, and find out how you can become involved! And learn more at www.kidney.org

NATIONAL KIDNEY FOUNDATION PROFESSIONAL COUNCILS – 327

Learn about NKF's four Professional Councils and how you can benefit from membership. Council Executive Committee members will be available to discuss upcoming Council projects and resources, current initiatives in progress, and to answer any membership questions you may have.

The National Kidney Foundation Council of Advanced Practitioners (CAP) provides a diversified, advanced educational curriculum for Nephrology Nurse Practitioners, Physician Assistants, and Clinical Nurse Specialists, and supports the growth of Advanced Practitioners coming to nephrology, as well as those already in practice. Members educate the public about this growing sector of the nephrology team and advocate for health policies

and legislation that support sound practice for kidney health professionals and good outcomes for patients. CAP aims to elevate the voices of PAs, NPs and CNSs in nephrology to better serve their patients, enhance their practices, and educate them about innovations in research and patient care.

The National Kidney Foundation Council of Nephrology Nurses and Technicians (CNNT) is a strong volunteer professional membership organization that promotes and participates in the establishment of public services directed toward prevention, detection, and care of kidney and/or related diseases. Members collaborate in the development of health policies that impact professional practices and the delivery of patient care. CNNT advocates for and contributes to the professional development of members through education, networking and the dissemination of information related to professional practice and quality of patient care.

The National Kidney Foundation Council of Nephrology Social Workers (CNSW) upholds and supports the profession of nephrology social work through advocacy and the creation of patient and professional education materials. Members provide assistance, education, and support to patients and their families in dealing with the psychosocial stresses and lifestyle readjustments encountered by patients in all stages of CKD, and facilitate treatment programs that will maximize rehabilitation potential. CNSW supports the federal regulations governing ESRD reimbursement in regard to standards for social work practice and in the definition of a qualified social worker.

The National Kidney Foundation Council on Renal Nutrition (CRN) is dedicated to promoting quality nutritional care and education for kidney patients. Members impact regulatory and legislative issues, and actively promote the professional education of the renal dietitian. CRN offers frequent opportunities for collaboration and networking with colleagues to improve clinical practice and promote career advancement. The Council supports and disseminates nutrition-related research, and develops patient and professional public education materials encouraging quality nutrition care for CKD patients.

NATIONWIDE LABORATORY SERVICES – 126

NLS is the nation's independent laboratory of choice, the only lab with ISO-17025 and ISO-15189 accreditation providing expertise in ESRD/CKD/SNF/clinical trials and general clinical reference testing. Results are accurate, dependable, with rapid turn-around time and superior client service. Our strong Management Team commits to the pursuit of excellence by building long-lasting partnerships with each customer.

NEPHCURE FOUNDATION – 108

The NephCure Foundation is the only organization committed exclusively to supporting research seeking the cause of two potentially devastating kidney diseases, Nephrotic Syndrome and FSGS, to improve treatment and find a cure.

NEPHROCEUTICALS, LLC – 512

Nephroceuticals is the leader in developing guideline-based supplements designed to promote health in people with chronic kidney disease. Our supplements are the only products that follow recommendations put forth by the National Kidney Foundation to support optimal nutritional health.

NEPHROLOGY NEWS & ISSUES – 115

Nephrology News & Issues is a peer-reviewed news journal that takes a global approach to covering the political, social, and economic issues surrounding the delivery of dialysis and transplantation. Stop by the booth for a complimentary copy of the latest issue of *NN&I* and find the latest news developments in renal care at our website www.NephrologyNews.com

NEPHROLOGY NURSING CERTIFICATION COMMISSION – 521

The Nephrology Nursing Certification Commission (NNCC) exists to establish credentialing mechanisms to promote patient safety and to improve the quality of care provided to nephrology patients. The Nephrology Nursing Certification Commission supports the philosophy that there should be a diversity of examinations that will effectively provide opportunities for certification at various levels of education, experience, and areas of practice within nephrology nursing.

NEPHROPATH – 417

NephroPath is a private renal pathology laboratory offering over 30 years of experience interpreting renal biopsies. We understand the critical effect that time-to-diagnose can have on the outcome of many renal diseases. With this in mind we provide light, immunofluorescence, and electron microscopy results on the same day we receive a biopsy.

NEPHRO-TECH, INC. – 527

Nephro-Tech, Inc. provides high-quality pharmaceuticals at affordable prices. Our newest addition, RENAPLEX-D®, along with VITAL-D Rx®, treats vitamin D (25-OH D) deficiency daily. It contains all the ingredients of a renal multivitamin plus 2000 IU of cholecalciferol. RenaPlex-D® is available at \$12.00/100 through Nephro-Tech, Inc. We also sell CALPHRON® which is 667mg calcium acetate and costs \$15.00/200. Call 800.879.4755 for more information.

NESTLÉ HEALTH SCIENCE – 313

Nestlé Health Science offers nutritional solutions for people with specific needs related to illnesses, disease states, or the special challenges of different life stages. Nestlé Health Science has worldwide headquarters in Vevey, Switzerland, and the North American headquarters of its HealthCare Nutrition business is in Florham Park, NJ.

NIPRO MEDICAL CORPORATION – 211

Nipro Medical Corporation is a subsidiary of Nipro Corporation, a world-leading manufacturer of renal products, including dialyzers, blood tubing sets, safety fistula needles, dull fistula needles, and syringes. The Company is committed to educating customers and delivering innovative, high-quality, and value-added solutions to improve patient care.

NXSTAGE MEDICAL, INC. – 114

NxStage is more than just a company; we are leading the renal revolution. By our own design, we're at the leading edge of a movement to transform renal care. To make it simpler. To make it portable. To expand treatment options for clinicians by overcoming traditional barriers. To enhance patient freedom and fulfillment.

PENTEC HEALTH, INC. – 409

Pentec Health is a specialty infusion services company. The Renal Division provides IDPN and IPN products for dialysis patients. Pentec Health also provides specialized in-home care and pharmaceuticals for patients with spasticity and acute or chronic pain. The renal formulas include: the innovative PROPLETE® IDPN, PROPLETE® PLUS IDPN for malnourished hemodialysis patients, and PROPLETE® IPN for malnourished peritoneal dialysis patients. The formulations are designed to maximize patient response and improve patient tolerance. Developed by a nationally recognized nutrition support renal specialist, they are represented by a team of expert clinicians available to assist with all aspects of therapy provision.

POLYCYSTIC KIDNEY DISEASE FOUNDATION – 216

Polycystic Kidney Disease (PKD) is one of the most common, life-threatening genetic diseases. The PKD Foundation (Kansas City, MO) funds research to find treatments and a cure, and provides information and support to people affected by PKD. Visit our booth at the NKF Spring Clinical Meetings, or our website at www.pkdcure.org for more information about PKD and our programs and services.

QUESTCOR PHARMACEUTICALS, INC. – 472

Questcor Pharmaceuticals is a biopharmaceutical company whose lead product, HP Acthar® Gel (repository corticotropin injection), is used in a variety of serious conditions. The indications include inducing a diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus. Visit www.Acthar.com for full prescribing information.

REACH KIDNEY CARE – 320

Reach Kidney Care, a division of Dialysis Clinic, Inc., is on a mission to help individuals to maintain their kidney function and delay the start of dialysis as long as medically possible, while providing education to help them transition safely and effectively into a treatment option of their choice, if needed.

RENAL & UROLOGY NEWS – 321

Renal & Urology News is a monthly tabloid with a circulation of 17,300 nephrologists, transplantation surgeons, and urologists. The publication's primary editorial mission is to report on new scientific developments of interest to these three specialist groups. News coverage focuses on medical conferences, but also includes reporting on recently published papers in peer-reviewed journals. Various features and departments complement the news coverage.

ROCKWELL MEDICAL – 317

Rockwell offers products for treating iron deficiency, secondary hyperparathyroidism, and hemodialysis. Investigational iron-delivery drug Triferic®, for treating iron-deficient CKD-HD patients; delivered successful Phase-3 clinical results in maintaining hemoglobin and lowering ESA; NDA filed early 2014. Low-cost Calcitriol (active vitamin D) injection available in 2014. New standard-of-care dialysate CitraPure®, the only acetate-free citric-based acid concentrate, offering reduced inflammation and cost savings.

SANOFI RENAL – 516

Sanofi, a global and diversified healthcare leader, discovers, develops, and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health, and the new Genzyme. www.sanofi.us

SCEPTRE MANAGEMENT SOLUTIONS, INC. – 506

Billing specialists for nephrology practices and dialysis facilities. We will help you successfully navigate the change to ICD-10! Improve your cash flow, lower your receivables, and stay in compliance with billing regulations. No software or hardware to buy. We file claims, follow up on unpaid claims, bill patients, and provide detailed reports.

SMART MOBILE LV – 501**SPECTRA LABORATORIES – 219**

Spectra delivers renal-specific testing, analysis, and reporting with the reliability you require to ensure the best outcomes possible for your patients. Our team of clinical experts, paired with our patient-centric tools and resources, help you comply with the latest industry guidelines.

THE GIDEONS INTERNATIONAL – 418

The Gideons International distributes white New Testaments to all medical personnel at no charge in appreciation for what they do in our community.

TREAT THE PAIN – 525

TREAT THE PAIN is a non-profit organization dedicated to empowering people with chronic pain to improve their quality of life, decrease their sense of isolation, and take a more active role in their treatment.

WHAT'S SO FUNNY ABOUT...KARYN BUXMAN – 507

Keynote speaker, neuro-humorist, author. There's more to Karyn Buxman than just a funny lady. She's an accomplished speaker, author and registered nurse who uses humor to help people deal with the issues in their work and lives. Contact Karyn Buxman: 800.848.6679; info@karynbuxman.com

FACULTY

Suhail Ahmad, MD
University of Washington
Seattle, WA

Kim Alleman, MS, RN, FNP-C, CNN, APRN
Hartford Hospital
Lebanon, CT

Michael Allon, MD
University of Alabama at Birmingham
Birmingham, AL

Felipe Amaya, LCSW
Fresenius Medical Care – North America
Fontana, CA

Gerald Appel, MD
Columbia University
New York, NY

Cristina Arce, MD, MS
The Ohio State University
Wexner Medical Center
Columbus, OH

George Bakris, MD
The University of Chicago
Chicago, IL

James Balow, MD
National Institute of Diabetes and
Digestive and Kidney Diseases
Bethesda, MD

Joanne Bargman, MD, FRCPC
University Health Network –
Toronto General Hospital
Toronto, ON, Canada

Deborah Barnett, MSW, LCSW
DaVita Front Royal Dialysis Center
Front Royal, VA

Cathy Wilson Bates, RN, CDN, CPDN
Satellite Healthcare
Anaheim, CA

Lynn Beaulieu, RN, MSN, ANP-BC
Mayo Clinic Rochester Methodist Hospital
Rochester, MN

Jeffrey Berns, MD, FNKF
University of Pennsylvania School of
Medicine
Philadelphia, PA

Judith Beto, PhD, RD, FADA
Loyola University Healthcare System - Dialysis
Kirkland, WA

Cynthia Bhola, BN, MSN
University Health Network – Toronto
General Hospital
Toronto, ON, Canada

Gurjeet Birdee, MD, MPH
Vanderbilt University Medical Center
Nashville, TN

Geoffrey Block, MD, CCRI
Denver Nephrology
Denver, CO

Carl Boethel, MD, FCCP, FAASM
Scott & White Clinic
Temple, TX

Steve Bogatz, MBA, MSW, LCSW, NSW-C
Fresenius Medical Care Central CT Dialysis
Newington, CT

Debbie Brady, LCSW, ACSW, NSW-C
Arkansas Children's Hospital
Little Rock, AR

Teri Browne, PhD, MSW, NSW-C
University of South Carolina College of
Social Work
Columbia, SC

Jennifer Bruns, MSW, LMSW, CCTSW
St. John Hospital and Medical Center
Detroit, MI

Susan Busch, MSN, CNP
Cleveland Clinic Foundation
Cleveland, OH

Karyn Buxman, RN, MS, CSP, CPAE
What's So Funny About...
San Diego, CA

Mary Beth Callahan, MSSW, ACSW, LCSW
Dallas Transplant Institute
Dallas, TX

Juan Jesus Carrero, PharmD, PhD, MSc, MBA
Karolinska Institute
Stockholm, Sweden

Daniel Cattran, MD, FRCPC, FACP
University Health Network – Toronto
General Hospital
Toronto, ON, Canada

Kerri Cavanaugh, MD, MHS, FNKF
Vanderbilt University Medical Center
Nashville, TN

Christopher Chan, MD, FRCPC
University Health Network – Toronto
General Hospital
Toronto, ON, Canada

Tara Chang, MD, MS
Stanford University School of Medicine
Palo Alto, CA

David Cherney, MD, PhD, FNKF
University Health Network – Toronto
General Hospital
Toronto, ON, Canada

Alexis Chettiar, MSN, ACNP
East Bay Nephrology Medical
Oakland, CA

Alfred Cheung, MD, FNKF
University of Utah
Salt Lake City, UT

**Christine Chmielewski, MS, CRNP,
ANP-BC, CNN-NP**
Edward J. Filippone, MD, PC & Associates
Andalusia, PA

Michael Choi, MD, FNKF
Johns Hopkins University
School of Medicine
Baltimore, MD

Benjamin Chung, MD
Stanford University
Palo Alto, CA

Louise Clement, MS, RD, CSR, LD
Fresenius Medical Care
Lubbock, TX

Steven Coca, DO, MS
Yale University School of Medicine
New Haven, CT

Carolyn Cochran, RD, LD, MS, CDE
Dallas Nephrology Associates
Dallas, TX

Debbie Cohen, MD
University of Pennsylvania
Philadelphia, PA

**Denise Collins, MSSW, LCSW-C,
LICSW, NSW-C**
Kaiser Permanente of the
Mid-Atlantic States
North Bethesda, MD

Danilo Concepcion, CCHT, CHT, CBNT
St. Joseph Hospital
Orange, CA

Della Connor, PhD, FNP-BC, RN
Stephen F. Austin State University
Nacogdoches, TX

Joseph Coresh, MD
Johns Hopkins Bloomberg
School of Public Health
Baltimore, MD

Deborah Cote, MSN, RN, CNN
University of Virginia Health System
Charlottesville, VA

Daniel Coyne, MD
Washington University School of Medicine
St. Louis, MO

Deidra Crews, MD, ScM
Johns Hopkins University
School of Medicine
Baltimore, MD

Michael Cronyn, PA-C, MPAS, CDE
Florida Diabetes and Endocrine Center
Orlando, FL

Connie Davis, MD
Skagit Regional Health
Mount Vernon, WA

Jane Davis, DNP, CRNP, MSN, FNKF
University of Alabama at Birmingham
Birmingham, AL

Kim Deaver, RN, BSN, CNN
University of Virginia Health System
Charlottesville, VA

Sheila Deziel, BSN, RN, CNN
Fresenius Renal Technologies
Mesa, AZ

Rita Dimmitt, RD, CSR, LDN
Vanderbilt Dialysis Clinic
Nashville, TN

Anne Diroll, RN, CNN
Rocklin, CA

Michael Emmett, MD
Baylor University Medical Center
Dallas, TX

Wendy Escobedo, RN, MSN, PHN, CCTN
St. Joseph Kidney Transplant Center
Orange, CA

Elizabeth Evans, RN, MSN, DNP
Renal Medicine Associates
Albuquerque, NM

Harvey Feldman, MD, FACP
Nova Southeastern University
Ft. Lauderdale, FL

Fernando Fervenza, MD, PhD, FNKF
Mayo Clinic
Rochester, MN

Kristen Fischer, MSW, LCSW, NSW-C
Sanford Transplant Center
Fargo, ND

Rachel Fissell, MD
Vanderbilt University School of Medicine
Nashville, TN

Agnes Fogo, MD
Vanderbilt University Medical Center
Nashville, TN

Charles Foulks, MD
University of Oklahoma
Tulsa, OK

Linda Fried, MD, MPH, FNKF
VA Pittsburgh Healthcare System
University of Pittsburgh
Pittsburgh, PA

Melissa Fry, MSW, CAPSW, NSW-C
Mile Bluff Medical Center
Mauston, WI

Kathleen Hill Gallant, PhD, RD
Purdue University
West Lafayette, IN

Paul Gasser, MS, LMFT
St. Joseph's Health Care
Tomah, WI

Jennifer Geiger, MSW, LSW, NSW-C
Fresenius Medical Services
Collingswood, NJ

Sean George, PA-C
Chris Sholer MD, PC
Oklahoma City, OK

Debbie Gipson, MD, MS, FNKF
University of Michigan Health System
Ann Arbor, MI

Jeff Giullian, MD, MBA
South Denver Nephrology Associates
Denver, CO

Richard Glassock, MD, MACP
University of California Los Angeles
Geffen School of Medicine
Los Angeles, CA

Jess Goldman Foug
Sodium Girl Blog
San Francisco, CA

Janelle Gonyea, BS, RD, LD
Mayo Clinic
Rochester, MN

David Goodkin, MD, FASN
Goodkin Biopharma Consulting, LLC
Bellevue, WA

Paula Goodman-Crews, MSW, LCSW
Kaiser Permanente
San Diego, CA

Tracy Greene-Mintz, MA, MSW, LCSW
Senior Care Training
Redondo Beach, CA

Darlene Griffin, MS, RD, LDN
DaVita Healthcare Partners, Inc.
Brevard, NC

Margarita Gurri, PhD
Red Shoe Institute
Dania Beach, FL

Kim Gusse, MSW, LMSW, ACSW
Helen DeVos Children's Hospital
Grand Rapids, MI

Lisa Gutekunst, MEd, RD, CSR, CDN
DaVita, Inc.
East Aurora, NY

Orlando Gutierrez, MD, MMSc
University of Alabama at Birmingham
Birmingham, AL

Raymond Hakim, MD, PhD
Vanderbilt University Medical Center
Franklin, TN

Kevin Hall, MHSc, AA-C, PA-C
Emory University Hospital Midtown
Atlanta, GA

Lisa Hall, MSSW, LICSW
Northwest Renal Network 16
Seattle, WA

Joni Hansson, MD, FNKF
Yale University
New Haven, CT

Rebecca Hays, MSW, APSW, NSW-C
University of Wisconsin Hospital
and Clinics
Madison, WI

Connie Jo Hemeyer, MSN, ARNP
Mayo Clinic
Jacksonville, FL

Michael Heung, MD, MS
University of Michigan Health System
Ann Arbor, MI

Michelle Hladunewich, MD
University Health Network –
Toronto General Hospital
Toronto, ON, Canada

Lynn Hornick, NP, BSN, MSN
University of Colorado
Denver, CO

Donald Hricik, MD
Case Western Reserve University
Cleveland, OH

Hassan Ibrahim, MD, MS
University of Minnesota
Minneapolis, MN

Tamara Isakova, MD, MMSc
Northwestern University
Evanston, IL

Ajay Israni, MD
Hennepin County Medical Center
Minneapolis, MN

Aimee Jarenowicz, RD, LDN
Chicago Ridge, IL

Jeff Jin, MSW
Kennedy Health System
Sewell, NJ

Kirsten Johansen, MD
University of California
San Francisco, CA

David Johnson, PhD, FRACP, MBBS
Princess Alexandra Hospital
University of Queensland
Brisbane, Australia

Sharon Johnson, JD, RD, LD
State of Florida and DaVita Healthcare
Orlando, FL

Stephanie Johnstone, LCSW, NSW-C
Fresenius Medical Care – North America
La Jolla, CA

Graham Jones, PhD, DIC
Northeastern University
Boston, MA

Peter Juergensen, PA-C
Metabolism Associates
Cheshire, CT

Kamyar Kalantar-Zadeh, MD, MPH, PhD, FNKF
University of California – Irvine
Orange, CA

Kamel Kamel, MD, FRCPC
St. Michael's Hospital
Toronto, ON, Canada

Alex Karmazsin, CBNT
Fresenius Medical Care – North America
Salt Lake City, UT

Ellie Kelepouris, MD, FAHA
Drexel University College of Medicine
Philadelphia, PA

Lois Kelley, MSW, ACSW, NSW-C
DaVita Harrisonburg Dialysis
Harrisonburg, VA

Steve Kelley, MSW, MDIV
Fresenius Medical Care – North America
Portland, OR

Bryan Kestenbaum, MD, MS
University of Washington
Seattle, WA

Alan Kliger, MD
Yale New Haven Health System
New Haven, CT

Jeffrey Kopp, MD
National Institute of Diabetes and
Digestive and Kidney Diseases
National Institutes of Health
Bethesda, MD

Csaba Kovacs, MD, FASN
University of Tennessee Health
Sciences Center
Memphis, TN

Holly Kramer, MD, MPH
Loyola University Medical Center
Maywood, IL

Louis Kuritzky, MD
University of Florida
Gainesville, FL

Jane Kwatcher, MSW, LCSW
DaVita Health Care Partners, Inc.
Upland, CA

Barbara Landreth, RN, BSN, CNN, CPHQ
BV Consultants
Tyler, TX

Philip Lavin, MD
Boston Biostatistics Research Foundation
Framingham, MA

Timmy Lee, MD, MSPH, FACP, FASN, FNKF
University of Alabama at Birmingham
Birmingham, AL

Nelson Leung, MD
Mayo Clinic
Rochester, MN

Edward Li, PharmD, BCOP
University of New England
College of Pharmacy
Portland, ME

Anne Marie Liles, PharmD, BCPS
Auburn University Harrison
School of Pharmacy
Birmingham, AL

Timothy Lineberry, MD
Mayo Clinic
Rochester, MN

Denise Link, MPAS, PA-C
The University of Texas
Southwestern Medical Center
Dallas, TX

Francesco Locatelli, MD
Alessandro Manzoni Hospital
Lecco, Italy

Eileen Lischer, MA, BSN, RN, CNN
University of California
San Diego Medical Center
San Diego, CA

Robert Lockridge, MD
University of Virginia
Lynchburg Nephrology Physicians
Lynchburg, VA

Charmaine Lok, MD, MSc, FNKF
University Health Network –
Toronto General Hospital
Toronto, ON, Canada

Claudia Lora, MD, MS
University of Illinois at Chicago
College of Medicine
Chicago, IL

Joy Lutz, MS, RD
Fresenius Medical Care – North America
Upland, CA

Barbara Weis Malone, MSN, RN, CFNP
University of Colorado
Denver, CO

Nancy Mason, PharmD, FNKF
University of Michigan
College of Pharmacy
Ann Arbor, MI

Linda McCann, BS, RD, CSR, LD
Satellite Healthcare, Inc.
San Jose, CA

Maureen McCarthy, MPH, RD, CSR, LD
Oregon Health & Science University
Portland, OR

Peter McCullough, MD, MPH, FACC, FACP,
FCCP, FAHA, FNKF
St. John Providence Health System
Southfield, MI

Janie McDaniel, BSMT
Wake Forest School of Medicine
Winston-Salem, NC

Deb McGrath, RD, CD, CDE
Cascade Valley Hospital
Arlington, WA

Diane McRae, MSW, LICSW
Puget Sound Kidney Centers
Arlington, WA

Rajnish Mehrotra, MBBS, MD, FNKF
University of Washington
Seattle, WA

Michal Melamed, MD, MHS, FNKF
Albert Einstein College of Medicine
Bronx, NY

Joseph Merighi, PhD, MSW
University of Minnesota
Saint Paul, MN

Miriam Michael, MD
Howard University
Washington, DC

John Middleton, MD
Duke University
Durham, NC

Louise Moist, MD, MSc, FRCPC
University of Western Ontario
London, ON, Canada

Carol Moore, PharmD, BCPS, FNKF
Henry Ford Health System
Detroit, MI

Eileen Moore, CNSC, RD, LD
Pentec Health
Parma, OH

Alvin Moss, MD, FAAHPM
West Virginia University
Morgantown, WV

Stuart Mott, LVN
Mercy Medical Center
Cedar Rapids, IA

Patrick Nachman, MD, FASN
University of North Carolina
Chapel Hill, NC

Andrew Narva, MD, FACP, FASN
National Institutes of Health
Bethesda, MD

Cynthia Nast, MD
Cedars-Sinai Medical Center
Los Angeles, CA

Mark Neumann, MS
Nephrology News & Issues
Scottsdale, AZ

Kenneth Newell, MD, PhD
Emory University School of Medicine
Atlanta, GA

Duc Nguyen, MD
Centers for Disease Control
and Prevention
Atlanta, GA

Bobby Nibhanupudy, MD
Florida Hospital
Orlando, FL

Sagar Nigwekar, MD, MMSc
Massachusetts General Hospital
Boston, MA

John Nilsson, CCC-SLP/L
Therapy Care Ltd.
Lockport, IL

Douglas Norman, MD
Oregon Health & Science University
Portland, OR

Akinlolu Ojo, MD, MPH, PhD
University of Michigan
Ann Arbor, MI

Matthew Oliver, MD, MHS, FRCPC
Sunnybrook Health Sciences Centre
Toronto, ON, Canada

Patricia Painter, PhD, FACSM
The University of Utah
Salt Lake City, UT

Chirag Parikh, MD, FNKF
Yale University School of Medicine
VA Medical Center
West Haven, CT

Jessie Pavlinac, MS, RD, CSR, LD
Oregon Health & Science University
Portland, OR

Glenda Payne, MS, RN, CNN
Nephrology Clinical Solutions
Duncanville, TX

Leanne Peace, MSW, LCSW, MHA
Missouri Kidney Program
Columbia, MO

Bill Peckham, BA
Triumph Expo & Events
Seattle, WA

Aldo Peixoto, MD
Yale University School of Medicine
New Haven, CT

Carmen Peralta, MD
University of San Francisco
San Francisco, CA

Mark Perazella, MD, FNKF
Yale University School of Medicine
New Haven, CT

Angella Perez, CCHT-A
Saint Joseph Hospital
Orange, CA

Ronald Perrone, MD, FNKF
Tufts Medical Center
Boston, MA

Glen Peterson, ACNP
University of Colorado
Boulder, CO

Gary Petingola, MSW, RSW
Health Sciences North
Sudbury, ON, Canada

Jessica Phipps, MSW, LSW
Fresenius Medical Care – North America
Plainfield, NJ

Nicole Pinkerton, MFT
Mendez National Institute
of Transplantation
S. Mark Taper Foundation
Transplant Center
Los Angeles, CA

Beth Piraino, MD, FNKF
University of Pittsburgh
School of Medicine
Pittsburgh, PA

Alan Platt, PA-C, MMSc
Emory University School of Medicine
Atlanta, GA

Tina Podymow, MD
Royal Victoria Hospital at McGill University
Montreal, QC, Canada

Lynn Poole, FNP-BC, CNN
ESRD Network Coordinating Center
McLean, VA

Friedrich Port, MD, MS, FACP
Arbor Research Collaborative for Health
Ann Arbor, MI

Michael Powe, BS

American Academy of
Physician Assistants
Alexandria, VA

Megan Prescott, LCSW, NSW-C

University of Colorado Hospital
Aurora, CO

Melissa Prest, MS, RD, LDN

Fresenius Medical Care – North America
Chicago, IL

Lynn Puma, LCSW

Levine Children's Hospital
Charlotte, NC

Wajey Qunibi, MD, FACP

University of Texas
Health Science Center
San Antonio, TX

Dena Rifkin, MD, MS, FNKF

University of California, San Diego
San Diego, CA

Janice Ritchie, RN, MSN

University Health Network
Toronto, ON, Canada

Dana Rizk, MD

University of Alabama at Birmingham
Birmingham, AL

Claudio Ronco, MD, FNKF

St. Bortolo Hospital
Vicenza, Italy

Sylvia E. Rosas, MD, MSCE, FNKF

Harvard University
Joslin Diabetes Center
Boston, MA

Brad Rovin, MD

The Ohio State University
College of Medicine
Columbus, OH

Elanderia Rowe, LMSW-IPR, NSW-C

Renal Ventures Management
Dallas, TX

Andrew Rule, MD, MSc

Mayo Clinic
Rochester, MN

Mary Rzeszut, MSW, LCSW

Winthrop University Hospital
Mineola, NY

George Saab, MD

Case Western Reserve University
Cleveland, OH

William Salzer, MD

University of Missouri Health System
Columbia, MO

Milagros Samaniego, MD, FACP, FASN

University of Michigan Health System
Ann Arbor, MI

Matt Sampson, MD, MSCE

University of Michigan Health System
Ann Arbor, MI

Mark Sarnak, MD, MS

Tufts Medical Center
Boston, MA

Heidi Schaefer, MD, FNKF

Vanderbilt University Medical Center
Nashville, TN

Jane Schell, MD

University of Pittsburgh Medical Center
Pittsburgh, PA

Brigitte Schiller, MD

Satellite Healthcare
San Jose, CA

Kathy Schiro-Harvey, MS, RD, CSR, CD

Puget Sound Kidney Centers
Mountlake Terrace, WA

Sanjeev Sethi, MD, PhD

Mayo Clinic
Rochester, MN

Amma Sewaah-Bonsu, MSN, DNP, NP-C

Nephrology Associates of Central Florida
Orlando, FL

Stuart Shankland, MD

University of Washington
Seattle, WA

Fuad Shihab, MD, FNKF

University of Utah
Salt Lake City, UT

Anushree Shirali, MD

Yale University School of Medicine
New Haven, CT

Allison Shukraft, MSW, MAT

Carolinas Healthcare System
Charlotte, NC

Jerry Simons, PA-C

East Hampton Healthcare Association
East Hampton, NY

Bhupinder Singh, MD

Southwest Clinical Research Institute
Tempe, AZ

Lonnie Smith, PharmD

University of Utah
Salt Lake City, UT

Alexis Snead, MD

Ameripath Quest Diagnostics
Oklahoma City, OK

Sandeep Soman, MD, FNKF

Henry Ford Health System
Detroit, MI

Bruce Spinowitz, MD, FACP

Nephrology Associates
Syracuse, NY

Stuart Sprague, DO, FNKF

North Shore University Health System
Evanston, IL

Wendy St. Peter, PharmD, FCCP,**FASN, FNKF**

University of Minnesota
Minneapolis, MN

Robert Stanton, MD

Harvard University Joslin Diabetes Center
Boston, MA

Paul Stevens, MBBS, BSc, FRCP

Kent and Canterbury Hospitals
Canterbury, Kent, UK

Kristin Stockard, MSW, LICSW

Seattle Children's Hospital
Seattle, WA

Matt Stricherz, EdD

DaVita, Inc.
Los Angeles, CA

Chef Duane Sunwold

Spokane Community College
Spokane, WA

Paul Szczybor, PA-C

Medstar Franklin Square Medical Center
Baltimore, MD

Manjula Kurella Tamura, MD, MPH

VA Palo Alto
Palo Alto, CA

Francesca Tentori, MD

Arbor Research Collaborative for Health
Ann Arbor, MI

Robert Terkeltaub, MD

University of California
San Diego, CA

Kirsten Thompson, MPH, RD, CSR

Seattle Children's Hospital
Seattle, WA

Robert Toto, MD
The University of Texas
Southwestern Medical Center
Dallas, TX

Raymond Townsend, MD, FAHA, FCHBPR
University of Pennsylvania
Philadelphia, PA

Mandy Trolinger, MS, RD, PA-C
Denver Nephrology
Denver, CO

Lara Tushla, MSW, LCSW, NSW-C
Rush University Medical Center
Chicago, IL

Katherine Tuttle, MD, FASN, FACP
Providence Medical Research Center
Spokane, WA

James Udelson, MD
Tufts Medical Center
Boston, MA

Katrin Uhlig, MD, MS
Tufts Medical Center
Boston, MA

Mark Unruh, MD
University of New Mexico
Albuquerque, NM

Tushar Vachharajani, MD, FASN, FACP
W. G. (Bill) Hefner VA Medical Center
Salisbury, NC

James Van Rhee, MS, PA-C
Yale University School of Medicine
New Haven, CT

Joseph Vassalotti, MD, FASN, FNKF
National Kidney Foundation
Mount Sinai School of Medicine
New York, NY

Joseph Verbalis, MD
Georgetown University
Washington, DC

Flavio Vincenti, MD
University of California
San Francisco, CA

Bradley Warady, MD, FNKF
The Children's Mercy Hospitals and Clinics
Kansas City, MO

Sarah Washburn, MS, RD, CSO
Cancer Center of Santa Barbara
with Sansum Clinic
Santa Barbara, CA

Daniel Weiner, MD, MS, FNKF
Tufts Medical Center
Boston, MA

Matthew Weir, MD
University of Maryland
School of Medicine
Baltimore, MD

Steven Weisbord, MD, FNKF
University of Pittsburgh
School of Medicine
Pittsburgh, PA

Catherine Wells, DNP, ACNP-BC, CNN-NP
University of Mississippi
Jackson, MS

Adam Whaley-Connell, DO, MSPH, FAHA, FACP, FASN, FACP, FNKF
Harry S. Truman Memorial
Veterans Hospital
Columbia, MO

Karen Wiesen, MS, RD, LDN
Geisinger Health System
Danville, PA

Aaron Wightman, MD
Seattle Children's Hospital
Seattle, WA

Katy Wilkens, MS, RD
Northwest Kidney Centers
Seattle, WA

Rebecca Wingard, RN, MSN, CNN
Fresenius Medical Care - North America
Franklin, TN

Wolfgang Winkelmayr, MD, ScD, MPH, FASN
Stanford University
School of Medicine
Palo Alto, CA

Jay Wish, MD
University Hospitals
Case Medical Center
Cleveland, OH

Beth Witten, MSW, ACSW, LSCSW
Witten and Associates, LLC
Overland Park, KS

Monica Wofford, CSP
Contagious Companies
Orlando, FL

Myles Wolf, MD, MMSc
Northwestern University
Evanston, IL

Kristine Wyatt, PA-C
The Eye Institute
Tulsa, OK

Jerry Yee, MD, FACP, FASN, FNKF
Henry Ford Health System
Detroit, MI

Bessie Young, MD, MPH
University of Washington
VA Puget Sound Care Health System
Seattle, WA

Xueqing Yu, PhD, MBBS
Sun Yat-Sen University
of Medical Sciences
Guangzhou, Guangdong, China

Camille Yuscak, LCSW-R, NSW-C
Dialysis Clinic, Inc.
Hawthorne, NY


Shaoling Zhang, PhD
University of Montreal
Montreal, QC, Canada

Deborah Zimmerman, MD, MSc
The Ottawa Hospital
Ottawa, ON, Canada


Troy Zimmerman, BA
National Kidney Foundation
Washington, DC

Kim Zuber, MS, PA-C, FNKF
Metropolitan Nephrology
Alexandria, VA


MGM GRAND HOTEL CONFERENCE CENTER



LEVEL 1



LEVEL 2



LEVEL 3



**Unlock the
potential of Acthar**
by visiting Questcor
Booth #472 to learn more



H.P. Acthar® Gel and Questcor® are registered trademarks of Questcor Pharmaceuticals, Inc.
©2014 Questcor Pharmaceuticals, Inc. PM-01-03-0852 04/14 Printed in USA.

H.P. **Acthar**® GEL
(repository corticotropin injection) 80 U/mL



National
Kidney
Foundation®

2015
SPRING
CLINICAL
MEETINGS

SAVE THE DATE!

March 25–29, 2015
Gaylord Texan
Dallas, TX

NATIONAL KIDNEY FOUNDATION
30 East 33rd Street
New York, NY 10016

Awareness. Prevention. Treatment.
www.kidney.org 800.622.9010